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Following traumatic brain injury (TBI), excess reactive oxygen species (ROS)
and other free radicals are released, inducing the cascade of secondary injury that
exacerbate the outcomes of TBI. Antioxidant nanoparticles (ANPs) have shown
promising outcomes in reducing the progression of TBI, which may be due to the higher
accumulation and retention of ANPs in the injured brain. However, there is limited
knowledge of: 1) antioxidant activities needed in TBI treatment, 2) correlation between
longer retention, bioavailability, and target engagement with antioxidant treatments, and
3) sexual dimorphism to ANP treatments.
This dissertation assesses multiple ANPs with various scavenging activities and
durations to overcome the current limitations in reducing the secondary injury of TBI.
First, an ROS scavenger NP (NP1) with thioether bonds that react within hours was
utilized, and showed reductions in oxidative stress in the acute phase of injury and
neuroinflammation in the chronic phase of injury in female mice. Next, a large size ANP

(Pro-NP™) with multiple antioxidant enzymes and scavenging activity of more than 24
hours was tested in male and female TBI mice. Pro-NP™ showed more benefit in
reducing the secondary injury in males than females in the acute phase, but exacerbate
the TBI progression in the subacute phase of injury in males. Next, a small size ANP
(NPC3) with multiple free radical scavenging capabilities that react within minutes was
tested in male and female TBI mice. We found a reduction in secondary injury at 1-day
post-injury, but the progression returned at 3-day post-injury. NPC3 also showed more
reduction in oxidative stress biomarkers in males. Finally, a ligand to target disrupted
blood-brain barrier was assessed for multiple administrations of ANPs. The results
suggested ANPs with multiple free radical scavengers were more effective in mitigating
the TBI progression than ANPs with ROS-only scavengers, minimal benefit from longer
retention and scavenging activity when antioxidants were administered immediately
following an injury, and males benefited more from ANPs treatment than females.
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CHAPTER 1: INTRODUCTION AND RATIONALE
1.1

Introduction and Rationale
Traumatic brain injury (TBI) is one of the prominent causes of death and disability

in people below 45 years old [1]. There are approximately 2.3 million emergency
department visits, hospitalizations, and deaths attributed to TBI in the United States alone
[2]. After the initial injury, numerous biochemical derangements occur that exacerbate
the injury, also called secondary injury. Two of the most significant mediators of
secondary injury are reactive oxygen species (ROS) and lipid peroxidation product
(LPOx), which readily react with protein, lipid, and DNA [3]. The oxidation of protein,
lipid, and DNA induces cell death and results in further release of ROS and LPOx.
However, no treatment for TBI has passed a multi-center Phase III trial, which might be
attributed to the poor accumulation and retention, which lead to poor target engagement,
of small molecules into the injured brain [4, 5]. The current standard of care for TBI only
aims at stabilizing the patients instead of reducing secondary injury [6, 7]. The limitations
in developing TBI treatments to reduce secondary injury include: 1) the limited
knowledge of antioxidant activities needed to reduce the secondary injury of TBI, 2) the
limited knowledge of the need for antioxidant treatments with longer retention and
reaction rate to increase the target engagement in TBI, 3) the limited knowledge of sexual
dimorphism in response to antioxidant NPs therapy, and 4) the limited treatment window
of BBB disruption following TBI.
Antioxidant NPs offer a solution to some of these current limitations as NPs are
easily adjusted to achieve the desired properties. For example, the core of the NPs can be
adjusted to scavenge ROS and LPOx, or to deliver antioxidant enzymes into the injured
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brain; the scavenging activity duration can also be adjusted from minutes to days. The
size of NPs can be easily adapted to cross the disrupted BBB, as well as to increase the
retention time in the injured brain parenchyma. The multifunctionality of NPs can be
leveraged as multiple imaging contrast agents for tracking biodistribution and interaction
of NP in the body and the brain. The surface of NPs can also be modified with coatings to
increase the blood circulation half-life, as well as ligands to extend the treatment window
following TBI when BBB is less disrupted. However, there is a need to study the effect of
various ANPs with different antioxidant activities and functional groups in both males
and females to reduce secondary injury. Therefore, various ANPs with various
scavenging activities and durations in male and female TBI mice are assessed in this
dissertation.

1.2

Dissertation Outline
This dissertation is organized as follows:
Chapter 1 provides a brief introduction and rationale for the work.
Chapter 2 reviews the current knowledge of TBI, some animal models of TBI, the

current knowledge of oxidative stress in TBI, and some of the most promising therapeutic
treatments in TBI.
Chapter 3 reviews the current knowledge of NPs for TBI treatment, some of the
limitations of NPs, and various antioxidant and imaging NPs studied for TBI.
Chapter 4 introduces the use of a thioether core-cross-linked NP (NP1) based on
considerations introduced in Chapters 2 and 3 with small hydrodynamic size and react
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with ROS within a few hours to protect the spread of neuroinflammation into the
contralateral hemisphere.
Chapter 5 assesses the treatment and therapeutic windows of SOD and catalase
encapsulated PLGA NPs (Pro-NP™), which have large hydrodynamic size and
continuously release ROS-scavenger enzymes for more than 24 hours post-administration
to reduce the oxidative stress markers.
Chapter 6 assesses the treatment and therapeutic windows of a thiol copolymer NP
(NPC3), which scavenges ROS and LPOx within minutes post-administration. Chapter 6
also assesses the reduction in oxidative stress markers with NPC3 treatment.
Chapter 7 reviews the current use of active targeting NPs for drug delivery and
their limitations.
Chapter 8 investigates a ligand that targets leaky BBB, which commonly occurs in
an aging brain and other neurodegenerative diseases. This ligand may also be useful in
improving the accumulation of NPs in minimally disrupted BBB, which occurs in
subacute phase of injury and mild TBI.
Chapter 9 summarizes and discusses the findings, and provides future directions.
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CHAPTER 2: TBI, SECONDARY INJURY, AND TREATMENTS
2.1

Introduction
Traumatic brain injury (TBI) is one of the most prominent causes of death and

disability in people less than 45 years old [8], with 69 million estimated global cases [9]
and a cost of USD 400 billion annually [10]. The initial injury to the brain from an
external force, often called the primary injury [11], can result from a blow, blast, rapid
head acceleration and deceleration, or skull penetration [12]. Following the primary
injury, numerous biochemical derangements occur and exacerbate the injury. This
secondary injury can last for more than 18 years following the initial brain injury [13].
Additionally, TBI patients have a 2-5 fold increase in risk of developing
neurodegenerative diseases later in life, such as dementia, cognitive deficits, Alzheimer’s
disease, Parkinson’s disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, and
chronic traumatic encephalopathy [8, 14].
Two of the most significant mediators of secondary injury are reactive oxygen
species (ROS) and lipid peroxidation product (LPOx), which readily react with proteins,
lipids, and DNA to form oxidized proteins, LPOx, and oxidized DNA (oxDNA) [3]. The
damaged cells then die and release more ROS and LPOx. Thus, ROS and LPOx
scavengers and inhibitors have been proposed to treat secondary injury, and have been
found to reduce neuronal cell death and improve behavioral outcomes following TBI [7,
15].
Unfortunately, despite the prevalence of TBI, the economic impact, the long-term
health risks for TBI patients, and the numerous preclinical and clinical studies, there is
currently no approved treatment for reducing secondary injury [16-19]. This failure might
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result from heterogeneity between injuries, insufficient delivery into the brain, limited
target engagement, suboptimal clinical trial design, inaccurate injury phenotyping, and
unsatisfactory assessment tools [20, 21].

2.2

Animal models of TBI
The causes of TBI can be classified into three different categories: non-impact,

diffuse, and focal. Non-impact brain damage is usually induced by a change in pressure
or acceleration/deceleration of the brain, such as during a bomb explosion [22]. In blast
damage, the sudden rise in pressure near the epicenter transmits the wave to the
surrounding air and other materials. In humans and animals, the blast wave generates
shear waves and stress waves that result in sheared axons, air emboli, air pocket
implosion, and meninges and vasculature ruptures [22-24]. In contrast, diffuse brain
injury is mainly caused by rapid acceleration and deceleration of the head, such as during
traffic incidents. The heterogeneity of the brain structures and fixation to the other parts
of the brain and the base of the skull causes different segments of the brain to move at
different velocities during rapid acceleration and deceleration, which then causes shear,
tensile, and compressive forces [25-27]. Lastly, focal brain damage can be caused by a
penetrating or severe blunt impact at a specific point on the skull, such as a gunshot, skull
fractures, or subconcussive blows [28].
In order to replicate the source and severity of the brain injuries observed in
clinical settings, animal models of TBI are designed to best replicate TBI in humans.
Thus, animal models of TBI can also be categorized into non-impact, diffuse, and focal
injuries [29-31]. Four of the most commonly used animal models in labs are blast injury
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(non-impact injury) [22], weight-drop impact acceleration injury (diffuse injury) [32],
fluid percussion injury (focal injury) [33], and controlled cortical impact injury (focal
injury) [34].
Blast injury models were designed to mimic the mechanism of brain injury
experienced during military combat, especially from bomb explosions [22]. These
models utilize compressed gas to produce energy waves [35] and can be used to induce
brain contusion, laceration, hematoma, axonal injury in the cerebellum and brainstem,
axonal degeneration, edema, hyperemia, and delayed vasospasm [36-38].
The Marmarou weight drop model was designed to mimic human diffuse TBI,
which can occur due to falls or motor vehicle accidents [32]. Marmarou’s model is useful
for producing widespread and bilateral damage to neurons, axons, dendrites, and
microvasculature [39]. Marmarou’s model also produces diffuse axonal injury in the
corpus callosum, internal capsule, optic tracts, cerebral and cerebellar peduncles, and the
long tracts in the brainstem [39].
The fluid percussion injury (FPI) models utilize a pendulum that strikes a fluid
reservoir, generating a fluid pressure pulse on the dura following craniectomy. FPI is
good at replicating intracranial hemorrhage, brain swelling, and grey matter damage [40],
but it cannot replicate damage due to skull fracture.
The controlled cortical impact (CCI) injury model is one of the most commonly
used and well-characterized models of TBI. CCI was designed to mimic human focal
injury, especially cortical tissue loss, acute subdural hematoma, axonal injury,
concussion, blood-brain barrier (BBB) disruption, and coma [34, 41-43]. CCI can also
induce widespread damage, such as acute cortical, hippocampal, and thalamic
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degeneration [44]. A metal impactor is utilized to penetrate an intact dura following
craniectomy. The impactor diameter, velocity, depth, and dwell time are highly
controlled by a pneumatic or electromagnetic impact device [45]. By controlling these
parameters, CCI is able to mimic a mild to severe brain injury [45-47]. Thus, CCI is the
most reproducible brain injury model.
In comparison to the FPI model, CCI is more useful for biomechanical studies of
TBI because of the controllable pneumatic and electromagnetic devices[48-50].
Additionally, when compared to the Marmarou weight drop model, CCI does not have a
rebound injury and has much lower mortality rate [51]. Compared to the blast injury
model, CCI only induces damage to the brain, and not to other organs [52]. CCI also
induces a more reproducible injury than the blast injury model does. However, CCI may
not be the best representation of TBI in clinical situations and may induce more severe
injuries than most clinical TBI cases [7, 53].
With these considerations, we chose the CCI model of TBI due to its ability to
induce a well-characterized and reproducible injury. The severity of the TBI modeled can
also be easily compared to other studies [46, 47]. Moreover, CCI is able to induce severe
injury, which is helpful in measuring the therapeutic effects of the treatments in TBI.

2.3

TBI cascades
The primary injury, which can cause bruising of the brain, tearing of the axons,

and physical disruptions of the brain, is followed by complex pathological processes.
Excess calcium influx induces reactive oxygen species (ROS), reactive nitrogen species
(RNS), and glutamate release, causing glutamate toxicity, mitochondrial dysfunction,
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neuroinflammation, and neurodegeneration that can last for years post-injury (Figure 2-1)
[54-58]. The biomarkers of secondary injury for oxidative stress, glutamate toxicity,
mitochondrial dysfunction, neuroinflammation, and neurodegeneration have also been
studied and reviewed in depth [15, 59-61]. ROS is one of the most studied pathways in
brain injuries because it is regarded as an important substance to initiate the cascade of
secondary injury. Indeed, various free radical scavengers and inhibitors have been studied
to reduce the progression of secondary injury (Figure 2-2). Therefore, here, we focus on
secondary injury due to oxidative stress, especially ROS, and their downstream products.

Figure 2-1. Biomarkers of secondary injury in the acute, subacute, and chronic phases of injury.
Necrosis and oxidative stress damage occur immediately following the injury, followed by lipid
peroxidation product, apoptosis, neuroinflammation, and neurodegeneration. Reprinted by
permission from John Wiley and Sons: Acute Medicine & Surgery, “Thorough overview of
ubiquitin C‐terminal hydrolase‐L1 and glial fibrillary acidic protein as tandem biomarkers
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recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries
among patients with traumatic brain injury”, (Tyndall, et al. 2021) [62].

Figure 2-2. TBI cascade pathways and possible antioxidant treatment combinations. Following
the injury, Ca2+ overload induces excess production of ROS, which induces LPOx production,
leading to neurodegeneration. Reprinted by permission from Elsevier: Biochimica et Biophysica
Acta (BBA) - Molecular Basis of Disease, “Antioxidant therapies in traumatic brain and spinal
cord injury”, (Bains, et al. 2012) [63].
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2.3.1

Oxidative stress in TBI
Free radicals, such as reactive oxygen species (ROS), are very reactive and can

quickly react with proteins, DNA, and lipids. Free radicals are the byproduct of
respiration. Under physiological conditions, free radicals are well-balanced by
endogenous antioxidant enzymes to minimize damage to the mitochondria and the cell.
Indeed, free radicals are important for physiological conditions, such as for extracellular,
cellular, and intramitochondrial signaling [64-70]. However, following primary injury,
free radicals are released in excess amounts. Oxidative stress is a phenomenon that occurs
when there are more free radicals produced than are scavenged. Oxidative stress induces
damage to DNA, proteins, and lipids. Thus, oxidative stress biomarkers include DNA
damage, lipid peroxidation products (LPOx), neuroinflammation, and neurodegeneration
[15, 55, 71]. ROS and LPOx induce mitochondrial and cellular damage and death, which
releases more ROS and LPOx into the surrounding cells and worsens the severity of the
injury. In addition, endogenous antioxidant enzymes are downregulated following the
injury [72-74].
Superoxide (O2●-) is regarded as an important substance to initiate a cascade of
oxidative stress [75]. O2●- is mainly generated from the leakage of complex I of the
mitochondrial electron transport chain. Under physiological conditions, the rate of O2●production is between 0.15–4% of O2 consumption by the mitochondria [76, 77] and
catalyzed by superoxide dismutase (SOD) into H2O2 and oxygen. In TBI, the
mitochondria is overloaded by calcium, which induces excess production of O2●- [78, 79].
Along with downregulated SOD following a TBI [72-74], O2●- is readily available to start
the cascade of oxidative stress. By itself, O2●- is not very reactive since it can also act as
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an antioxidant by donating an electron to other free radical molecules. However, O2●- can
be more hazardous when reacting with nitric oxide (NO●) to form peroxynitrite (ONOO-).
O2●- can also reduce Fe3+ into Fe2+, which catalyzes the Fenton reaction and production
of OH● and lipid peroxidation products.
Previous research has shown that oxidative stress markers peak at around 12
hours post-injury in the mitochondria [80], causing mitochondria damage and
dysfunction. Therefore, antioxidant treatment for TBI has a very limited time window
before oxidative stress causes substantial damage. Treating TBI as early as possible can
be very beneficial, before oxidative stress damages mitochondrial and cellular functions
leading to cell membrane damage and cell death which then peaks at 24 hours post-injury
[81].

2.3.2

Lipid peroxidation products in TBI
Lipid peroxidation products (LPOx) are the biomarkers of oxidative damage to

lipids by oxidative stressors such as ROS [82]. LPOx are produced when ROS react with
a polyunsaturated fatty acid of the membrane phospholipids; this process is often called
initiation. The polyunsaturated fatty acid donates one electron to the ROS and becomes a
lipid radical (L•). Following initiation of L• formation, L• reacts with oxygen to form lipid
peroxy radical (LOO•), which then reacts with another lipid and forms more L•; this
process is often called propagation of LPOx. The reaction is terminated when the
peroxidizable lipids nearby are consumed and L• reacts with another radical, yielding
highly reactive aldehydes called carbonyls, such as malondialdehyde (MDA), 4hydroxynonenal (4-HNE), and 2-propenal (acrolein). MDA is relatively stable, while 4-
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HNE and acrolein are highly reactive and covalently bind to proteins (lysine, histidine,
and arginine) through Schiff base or Michael addition reactions. Through these
mechanisms, LPOx disrupt the mitochondria and cellular membrane and function and
induce cell death [83, 84]. Following TBI, elevation of LPOx markers begin at 1 hour
post-injury and remain elevated for several days [81, 85].

2.3.3

Neurodegeneration in TBI
When a cell sustains too much damage and is beyond repair, the cell will go

through the cell death pathway, most commonly necrosis or apoptosis. Necrosis occurs
when damage to the cell is too lethal, which typically happens during the acute and
subacute phases of injury [86]. In necrosis, the cell is passively lysed through proteases,
lipid peroxidases, and phospholipases. Biomarkers of necrosis include calpain-2 and 145
kDa α-II-spectrin breakdown product (SBDP) [81]. On the other hand, apoptosis occurs
when there is enough adenosine triphosphate generation, such as in mild TBI or in the
progression of secondary injury [87, 88]. Apoptosis is usually observed in the subacute to
the chronic phases of injury [88]. In apoptosis, there are gradual membrane breakdowns,
nuclear membrane disintegration, DNA fragmentation, chromatin condensation, and
formation of apoptotic bodies [89]. Some biomarkers of apoptosis include caspases, Bax,
and 120 kDa α-II-SBDP [90-92]. Other biomarkers of neurodegeneration can include
neuron-specific enolase, ubiquitin C-terminal hydrolase-L1, tau protein, S100B,
aquaporin-4, neurofilament proteins, myelin basic protein, exosomes, and micro RNA,
which can be found in the brain, serum, and/or cerebral-spinal fluid [59].
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2.3.4

Neuroinflammation in TBI
Cytokines are small proteins that act as signaling molecules to other cells for

processes such as pro- and anti-inflammation, growth, survival, and differentiation.
Chemokines belong to the cytokine family that specializes in directing migration of white
blood cells. Cytokines and chemokines play a huge role in inflammation and
neuroinflammation as they coordinate the immune response throughout the body.
Additionally, cytokines and chemokines can be produced by cells other than leukocytes
in response to stimuli of pathological and physiological conditions.
Following a TBI, the dead cells from the primary injury release ROS and
cytokines, which signal the activation of microglia, the major innate immune cells of the
brain. The activated microglia have rounded and larger cell bodies, as compared to
resting microglia which have ramified structures and smaller cell bodies [93-97]. There
are two types of activated microglia: M1 and M2. M1 microglia are pro-inflammatory,
while M2 microglia are anti-inflammatory. M1 microglia release more ROS and proinflammatory cytokines into the surrounding tissue, activating more microglia and the
cascade of neuroinflammation. On the other hand, M2 microglia promote debris
clearance, extracellular matrix deposition, and angiogenesis [98]. At 24 hours post-injury,
the M2 microglia population is 5 times greater than the M1 microglia population [99],
which decreases to 3 times greater at 48 hours post-injury [100]. However, the M1
microglia population increases to 7.5 times the M2 microglia population at 7 days postinjury [99] and stay elevated at 28 days post-injury [101]. Indeed, one study found
chronic microgliosis lasting up to 17 years post-injury [102], thus prolonging
neuroinflammation following TBI.
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Astrocytes are one type of glial cells in the CNS. Under physiological conditions,
astrocytes regulate synaptic transmission plasticity, support CNS metabolism, and
support blood-brain barrier (BBB) integrity. Following a TBI, astrocytes are activated
(i.e., astrogliosis) due to mechanical stress and pro-inflammatory cytokines [103].
Astrogliosis can induce migration of astrocytes near the brain lesion, as well as induce
astrocyte scar formation [104]. Glial fibrillary acidic protein (GFAP) is commonly used
as the biomarker of astrogliosis. Astrocytic hypertrophy and expression of GFAP are
dependent on the injury severity [105]. Along with neurons and microglia, neuronastrocyte-microglia triads have also been used as a marker of neuroinflammation [106112]. Neuron-astrocyte-microglia triads are formed when astrocytes form scar tissue
around the neurons and microglia bisect the neurons [106]. Astrocytes are also
hypothesized to play a role in the expression of aquaporin-4 (AQP4).
AQP4 is a water channel protein that is commonly found on astrocytes processes
[113]. AQP4 expression has been associated with neuroinflammation and edema in TBI
[114-117]. Indeed, previous studies found that AQP4 deletion and silencing resulted in an
improved outcome in TBI [118, 119]. AQP4 is responsible for initiating an edema [120],
as well as for ending an edema [121]. AQP4 may also play a role in BBB disruption
following brain injury (Figure 2-3) [122].
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Figure 2-3. Colocalization of BBB and AQP4. (A) Schematic graphic of an axially sectioned
vessel and an astrocyte process. Arrowheads denote water transport direction. (B) AQP4
expression following a TBI in the human brain. In a healthy brain, AQP4 localizes exclusively
around the brain endothelial cells, which is consistent with astrocytic endfoot localization.
Whereas in a TBI brain, AQP4 is dysregulated and localizes over the entire astrocyte
plasmalemma. Adapted and Reprinted by permission from Springer Nature: Neurochemical
Research, “Mechanisms of Astrocyte-Mediated Cerebral Edema”, (Stokum, et al. 2012) [123].

2.3.5

BBB permeability in TBI
The blood-brain barrier (BBB) is a highly selective semipermeable barrier

comprised of endothelial cells in the central nervous system (CNS). The BBB prevents
the crossing of undesired solutes from the blood into the brain. Endothelial cells of the
BBB are mechanically bound together by tight junction proteins, which eliminate
paracellular space between endothelial cells. Three commonly known tight junction
protein families that constitute the BBB are occludin, zona occludin (ZO), and claudin.
It is well-known that BBB permeability is disrupted in neurological diseases [124130]. Following a TBI, the BBB is disrupted by the mechanical force as well as cellular
signaling. Previous studies found that following a TBI, BBB permeability peaked at 3
hours but the BBB stayed permeable for 3 days [4, 131, 132]. Indeed, some studies found
that tight junction proteins were reduced following TBI for up to 7 days post-injury [133135]. The permeability of the BBB has been exploited for delivery of nanoparticles (NPs)
[4, 131, 132]. At 3–4 hours post-injury (the most common treatment window in clinical
trials for TBI) the accumulation of NPs in the brain lesion was around 3–5 fold higher
than the accumulation of small molecules [4]. The retention half-life of NPs in the brain
lesion was 3.5 times longer, with the circulation half-life of NPs in the blood was 2 times
longer, compared to small molecules [5]. Higher accumulation and retention of NPs may
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increase the therapeutic benefit of NPs in reducing the secondary injury of TBI compared
to small molecule drugs.

2.4

Antioxidant therapies in preclinical and clinical trials
Due to the interconnectedness between oxidative stress and secondary injury,

there have been many studies on the development of ROS and LPOx scavengers for brain
injury. Indeed, there are many preclinical and clinical trials of oxidative stress and LPOx
scavengers for TBI and other brain injuries [7, 15, 16, 19, 63, 136, 137]. By 2018, there
were 106 clinical trials of drugs targeted to improve the outcome of TBI [19]. There are
several therapeutic treatments that showed promise in reducing oxidative stress following
a TBI and have gone through Phase II and III clinical trials, yet none has shown efficacy
in a Phase III trial to be clinically approved.
2.4.1

Cyclosporin A (CsA)
CsA is an immunosuppressant drug that impairs T-cell mediated immunity. CsA

also inhibits mitochondrial pore formation, as examined in isolated mitochondria [138,
139], thus limiting the apoptotic cascade [140] and ROS production [141] in preclinical
studies. In preclinical trials, CsA was also found to reduce LPOx and protein nitration
[142]. Since then, CsA has been studied in cerebral ischemia [143, 144] and TBI [139,
141, 142, 145, 146] in preclinical trials. However, there are mixed results of CsA in
treating TBI in clinical trials. In one of the Phase II clinical trials of CsA for TBI [147],
CsA was administered within 8 hours post-injury in severe TBI patients, at 0-10
mg/kg/day either once a day, twice a day, or continuous infusion over 72 hours. Although
CsA did not significantly improve the mortality rate, it did increase the probability of a
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favorable outcome. In two other clinical trials [148, 149], CsA did not show a positive
result; the control group showed a slightly better outcome than the CsA-treated group.
Another clinical trial with NeuroSTAT® found that NeuroSTAT® passed through the
disrupted BBB in a TBI population and provided some positive outcomes [150]. Instead
of utilizing CREMOPHOR® EL solubilizer as in previous CsA clinical trials,
NeuroSTAT® utilizes lipid emulsion of CsA, which may behave more like NPs and
therefore increase the accumulation and target engagement in the brain of TBI patients.

2.4.2

Progesterone
Progesterone is one of the endogenous steroid hormones. Previous studies

discovered that gender plays a role in the outcome of brain injuries [97, 151, 152], where
some studies found that females had a better outcome than males following TBI [97, 151,
152]. Due to sexual dimorphism, progesterone was hypothesized to play a role in
attenuating brain injury. Indeed, previous preclinical studies found that progesterone
treatment improved outcomes following TBI [153-155], stroke [156], spinal cord injury
[157], and multiple sclerosis [158]. This might be a result of the ability of progesterone to
reduce LPOx following TBI [155]. In one of the Phase II trials (ProTECT) [159],
progesterone showed a trend of fewer deaths compared to the placebo group.
Progesterone also showed a moderate to good outcome in treating moderate TBI, but not
in severe TBI. In one of the Phase III trials [160], progesterone treatment improved
neurological outcomes at 3 and 6 months post-injury, and survival rate at 6 months postinjury, in severe TBI. However, in another Phase III trial (PROTECT III) [161],
progesterone was administered within 4 hours post-injury but provided no significant
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benefit in the outcome of TBI. Thus, progesterone is not currently used as a TBI
treatment.

2.4.3

PEG-SOD
Superoxide dismutase (SOD) is an enzyme responsible for catalyzing the reaction

from O2●- to H2O2. Research investigating the use of SOD to treat TBI was started in
1986 [162, 163]. Transgenic mice overexpressing SOD were found to have better
pathophysiology and neurodegeneration outcomes following a TBI [164-166]. However,
the circulating plasma half-life of the native SOD is only 6-10 minutes due to renal
clearance [167, 168]. Therefore, SOD was conjugated to polyethylene glycol (PEG-SOD)
to increase the activity half-life to 30 hours [169]. In the Phase II clinical trial [170],
PEG-SOD was administered within 4 hours post-injury and showed stellar results in
reducing the mortality and vegetative state rates of severe TBI patients, especially at
doses of 5,000 and 10,000 U/kg PEG-SOD. In the Phase III trial [171], PEG-SOD was
administered at 10,000 and 20,000 U/kg PEG-SOD within 8 hours post-injury in 29
center studies. However, PEG-SOD did not show significant improvement in survival
rate and neurological outcome during this Phase III trial. This failure of PEG-SOD might
be contributed to the 8 hour timeframe, instead of a 4 hour treatment window. Since BBB
permeability peaked at 3 hours post-injury [4, 131, 132], the PEG-SOD treatment that
was given between 3-8 hours post-injury had reduced accumulation in the patient’s brain.
Thus, the target engagement of PEG-SOD in scavenging ROS in the brain lesions was
also reduced.
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2.4.4

Tirilazad
Tirilazad is one of LPOx inhibitors. Tirilazad works by scavenging lipid peroxy

radical (LOO•) and stabilizing membranes. Thus, tirilazad mitigates the propagation
phase of LPOx into nearby polyunsaturated fatty acids [172]. Preclinical studies of
tirilazad found improvement in the outcomes of TBI [173, 174] as well as in BBB
integrity [175]. One preclinical study of tirilazad in focal ischemia found that tirilazad
improved the outcome of strokes when administered at 6 hours post-injury [176]. In the
Phase III trial [177], the treatment window was 4 hours post-injury with 10 mg/kg
tirilazad every 6 hours for 5 days. The North American clinical trial was not published,
and the European clinical trial did not show significant improvement outcomes in
moderate and severe TBI cases [177].

2.5

Conclusions
Regardless of the prevalence of TBI, its impact on the economy, the long-term

impact on the patients’ health, and the numerous preclinical and clinical studies
performed, there has been no treatment approved for reducing the secondary injury of
TBI. Utilizing small molecule drugs might have contributed to the failures due to poor
target engagement at more than 3 h post-injury. In clinical trials, several factors
contributing to the failures might be the heterogeneity in TBI severity, treatment window,
patient care between center studies, and TBI causes. Administering multiple drugs,
rather than an individual drug, might also improve the clinical outcome. In the preclinical
trials, some factors contributing to the failures might be the lack of delayed treatment,
imperfect animal models of TBI, and bias due to conflicting interests. In Chapter 3, the
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use of NPs to improve target engagement and therapeutics efficacy for TBI treatment are
reviewed.
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CHAPTER 3: NANOPARTICLES FOR TBI TREATMENTS
Part of the work presented in this chapter has been previously published and is reprinted
with permission from Nanoparticles for Biomedical Applications, Tarudji, A.W., and
Kievit, F.M., Active targeting and transport, 2020, p.19-36, Copyright © 2020, Elsevier,
doi: https://doi.org/10.1016/B978-0-12-816662-8.00003-5 [178]

3.1

Introduction
In the biomedical field, nanoparticles (NPs) are mainly used in drug delivery,

imaging, and theranostics – the ability of NPs to act as both a therapeutic and diagnostic
tool. One of the most well-known examples of nanomaterials in medical use is Doxil, a
liposomal nanoparticle that carries doxorubicin, a standard chemotherapeutic agent used
for breast and other types of cancers. Doxil was developed to take advantage of the
leakiness of blood vessels in tumors, which allows it to permeate into the cancer tissue
before releasing the drug, as well as being retained in the tumor because of the lack of
lymphatic drainage. This so-called enhanced permeability and retention (EPR) effect that
is utilized by many developed NP systems is considered a passive targeting approach
[178].
As reviewed in Chapter 2, currently, there is no TBI treatment that has passed a
multi-center Phase III trial. We hypothesized that one of the reasons is attributed to the
poor delivery of small molecules into the injured brain [4, 5]. Our previous study found
that the accumulation and retention of NPs in the TBI, regardless of their size and surface
charge, are higher than those of small molecules [4, 5]. The promising results of NPs in
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TBI treatments led to an increasing number of investigations using NPs in improving TBI
treatments (Figure 3-1). Therefore, developing an NP with high accumulation and
retention in the brain lesion that effectively treats oxidative stress-mediated secondary
injury may improve the outcomes following TBI. In this chapter, NPs developed for TBI
treatment are reviewed to assess the different NPs sizes, functional groups, antioxidant
activities, and imaging contrasts that can affect and improve the therapeutic efficacy of
NPs in treating TBI.

Publications about NPs for TBI
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Figure 3-1. Increasing trend of journal publications about NPs for TBI treatment.

3.2

Size
The diameter of NPs plays an important role in circulation time in the body [179].

NPs with diameters larger than 100 nm and positive surface charges will mostly be
cleared out by phagocytic uptake and hepatic filtration in the liver and spleen. NPs with
diameters smaller than 10 nm will mostly be cleared out through excretion in the kidneys.
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Therefore, NPs with diameters of 10-100 nm and with negative or neutral charge are
desirable in order to increase circulation time in the body [179]. There are several studies
that support the 10-100 nm size NPs for TBI. A study showed that 100 nm Poly (lacticco-glycolic acid) (PLGA) NPs had higher accumulation rates in TBI, compared to 200
nm and 800 nm PLGA NPs [180]. However, if the particle size is too small, such as an
0.83 nm diameter Gd-DTPA, the particles will be cleared almost 2 times faster from
blood circulation and 3.5 times faster from the injured brain parenchyma, as compared to
an 8 nm NP [5]. In another study, polystyrene NPs with diameters of 20-40 nm were
found to have a higher accumulation rate in the injury site, compared to NPs with
diameters of 100 and 500 nm [132, 181]. The smaller diameter NPs also had higher
accumulation rates at 3, 6, 13, and 24 hours post-injury within the injury penumbra,
compared to the accumulation rates of larger NPs [132, 181]. Our group also tried to
define the ideal size of NPs for maximizing accumulation within the injury penumbra.
We found that NPs with a size of 80-214 nm did not show a significant difference in
accumulation within the lesion when administered intravenously [4]. We also found that
89 nm NPs accumulate better than a small molecule (0.83 nm), especially when
administered at 3 and 4 hours post-injury [4].

3.3

Ligands
In the context of NPs, ligands are molecules that bind to a specific biological

target of interest. Ligands are often used in NPs for active targeting and improve the
delivery into a specific tissue or organ. Active targeting NPs have been utilized in various
diseases (an in-depth review is provided in Chapter 7) [178]. However, almost all
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treatments for TBI, including NPs, rely on passive delivery due to the BBB disruption.
However, active targeting may be required in treating TBI when the BBB is more intact
in the subacute phase of TBI, or in mild to moderate TBI. Recent studies [182-184] have
relied on in vivo phage displays to find an ideal ligand in the acute and subacute phases of
TBI. From an in vivo phage display study [184], CAQK peptide was found to be a
promising ligand for targeting a proteoglycan complex upregulated in brain injuries [184,
185]. Another study used rabies virus glycoprotein peptide to increase binding with
acetylcholine receptors on neuronal cells [186]. All of the active targeting NPs for TBI
showed colocalization with the targeted proteins, as well as an increase in the therapeutic
efficacy of the NPs [184-186]. An in-depth review of ligands and active targeting NPs is
provided in Chapter 7.

3.4

Opsonization
This part of the chapter presented in here has been previously published and is

reprinted from Nanoparticles for Biomedical Applications, Tarudji, A.W., and Kievit,
F.M., Active targeting and transport, 2020, p.19-36, Copyright © 2020, with permission
from Elsevier under the Creative Commons CC BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/, doi: https://doi.org/10.1016/B978-012-816662-8.00003-5[178]
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Figure 3-2. Opsonization of SiO2-PEG-transferrin NP surface blocking the binding with (A) free
transferrin receptor and (B) transferrin receptor on cell surface. Adapted and Reprinted by
permission from Springer Nature: Nature Nanotechnology, “Transferrin-functionalized
nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs
on the surface”, (Salvati, et al. 2013) [187].

Blood plasma contains a large amount of proteins, biomolecules, cells, and salt,
which interact with one another and readily adsorb on the surface of NPs to form
opsonins, which are recognized by the immune system for removal. The opsonins on the
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surface of NPs form the corona, where the thickness is directly proportional to the surface
energy of the NP. The surface energy of a bare, uncoated NP is affected by
physicochemical parameters such as size, shape, surface charge, and hydrophobicity, as
summarized in Table 3-1. The surface area to volume ratio of a NP is one of the main
factors affecting corona formation on the surface of NPs because surface energy is
directly proportional with surface area. Smaller NPs have higher surface areas per mass
of NP and thus show greater corona formation as compared to larger NPs [188]. Nonspherical NPs have a higher surface area to volume ratio than spherical NPs and so show
more corona formation compared to that of spherical NPs [189]. Furthermore, NPs with a
rough surface have a greater surface area to volume ratio as compared to NPs with a
smooth surface; thus, they show more corona formation and thickness as compared to
smooth NPs. A higher degree of hydrophobicity on the surface of a NP also affects the
corona formation because of the relatively strong binding energy associated with
hydrophobic binding in aqueous solutions [188]. The surface charge of a NP also affects
corona formation through ionic interactions that attract and bind opsonins to the NP
surface [190]. Corona formation also negatively affects the physicochemical properties of
the NPs and leads to a reduction in blood circulation half-life. Furthermore, the corona
will often cover the targeting agents on the surface of the NP so they can no longer bind
with their target molecules, reducing the effectiveness of the NPs in vivo (Figure 3-2)
[191]. Polyethylene glycol (PEG) is also used to reduce opsonin binding on NPs by both
reducing the surface energy of the NP and through steric hindrance. As a result, PEG was
found to increase the half-life of circulating NPs in the blood [192].

Table 3-1. Effect of NP physicochemical properties on surface binding energy.
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Property

Effect on corona coverage and
thickness

Size

Inversely proportional

Aspect ratio

Directly proportional

Zeta potential

Directly (both + and -) proportional

Hydrophobicity

Directly proportional

Surface roughness

Directly proportional

3.5

Antioxidant as a promising therapy in TBI
As reviewed in Chapter 2, antioxidant treatments showed promising results in

reducing the progression of secondary injury of TBI in the preclinical studies. However,
lack of target engagement may cause the failure of small molecule antioxidants in the
clinical trials with delayed administration. Therefore, various antioxidant NPs (Table 3-2)
have been employed to target different therapeutic pathways in TBI.
In order to reduce the oxidative stress following TBI, some NPs with innate
properties to scavenge ROS and RNS, such as cerium oxide [74, 193-196] and carbon
NPs [197-200], have been employed. The scavenging activities of cerium oxide and
carbon NPs come from the ability to accept and donate electrons. Therefore, cerium
oxide and carbon NPs can keep regenerating and scavenging free radicals. On the other
hand, the scavenging activities of some polymeric NPs come from the chemical
functional groups that readily oxidized by ROS and RNS, such as the oxidation of the
thioether bond and thiol functional group [5, 112, 201-204]. Although polymeric NPs
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have limited scavenging activities, polymeric NPs are usually biodegradable and
nontoxic.
Currently, the most common administration pathway of NPs is through tail vein
injection (i.e., intravenous). Intravenous injection gives a faster drug delivery and a more
precise drug concentration level than other administration pathways. Thus, antioxidant
NPs with IV administration pathways are expected to give a fast response in scavenging
ROS and reducing secondary injury of TBI. Other administration pathways of NPs for
TBI treatments include transdermal [193, 195], intraperitoneal [205], retro-orbital [194],
intranasal [206], and intracerebroventricular injection [207].

Table 3-2. Various NPs with antioxidant properties for treating TBI.

Nanoparticles

Chemical

Loaded Drugs

Scavenging

Functional

Administration References

Capabilities

Groups

Pathways

N-acetyl cysteine

H2O2

Thiol

Intravenous

(NAC)

O2•–

Structures
PAMAM

Dendrimers

Sharma, A., et
al., 2018 [201]

CO3•–
•NO2
ONOO–
HOCl
LPOx
PEG-bpoly(methylstyrene)

Polymeric

4-(2,2,6,6-

H2O2

tetramethylpiperidine1- O2•–
oxyl)

Intravenous

Takahashi, T., et
al., 2020 [208]

ONOO–

aminomethylstyrene
(TEMPO)
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Divanillin + curcumin +

Curcumin

corn starch
poly(propylene sulfide)

poly(propylene sulfide) H2O2
+

Calcium-

nimodipine

channel-

Thioether

Intravenous

Sintov, A., 2020

Intranasal

[206]

Intravenous

Han, Z., 2022
[202]

blocker
2-(methylthio)ethyl

H2O2

methacrylate +

O2•–

Thioether

Intravenous

Xu, J., et al.,
2016 [5]

polyethyleneglycol
monomethylether
methacrylate +
methacrylic acid Nhydroxysuccinimide
ester
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tetrakis(3-

H2O2

mercaptopropionate)

O2•–

Thioether

Intravenous

Yoo, D., et al.,
2017 [203]
Tarudji, A.W.,

and polysorbate-80

et al., 2021
[112]
Lipoic acid 2-

H2O2

hydroxyethyl

O2•–

methacrylate +

•NO

polyethyleneglycol

•OH

monomethylether

ONOO–

methacrylate

LPOx

Cerium Oxide

Inorganic

O2•–

Thiol

Intravenous

al., 2022 [204]

Transdermal

H2O2
•NO
•OH

Priester, A., et

Yan, R., et al.,
2019 [193]

Intravenous

Bailey, Z.S., et
al., 2020 [74]
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ONOO–

Retro-orbital

Youn, D.H., et
al., 2021 [194]

Transdermal

Zhang, S., et al.,
2021 [195]

In vitro

Youn, D.H., et
al., 2022 [196]

PEG-hydrophilic carbon

Carbon

O2•–

dusters

H2O2

Carbogenic nanozyme

•NO

Intravenous

al., 2012 [197]
Intravenous

•OH
Carbon dots

ONOO–

Bitner, B.R., et

Mu, X., et al.,
2019 [198]

In vitro

Oeyang, L., et
al., 2020 [199]

Lysine quantum dots

Intravenous

Li, Q., et al.,
2021 [200]
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3.6

NPs as contrast agents in TBI
There are many unknown variables in NP delivery in TBI treatment, such as the

time-course of BBB permeability, the size and properties of NPs that promote
accumulation in TBI, and the interaction between NPs and targeted proteins. Here, we
focus on various NPs (Table 3-3) employed for different imaging modalities to
interrogate NP properties in affecting accumulation and interactions in TBI [209-212].
Fluorescence and magnetic resonance imaging (MRI) are the two most common
imaging modalities used in NPs for TBI. Similar to the antioxidant NPs, some NPs have
innate contrast agents due to the chemical structure of the core, especially inorganic NPs
such as iron oxide [213, 214], quantum dots [215, 216], and lanthanide NPs [217, 218].
Polymeric NPs usually utilize the hydrophobic core to incorporate hydrophobic dye [132,
181, 219-222] and conjugate the MRI contrast agent onto the surface [4, 5, 204].
As shown in Table 3-3, the ability of NPs to provide contrast has been exploited
to track their pharmacokinetics in TBI, especially when studying the pharmacokinetics of

Therefore, employing theranostic NPs is useful in determining the potential of the NPs
for treating TBI, as well as assessing the NP accumulation and colocalization in the
injured brain.
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a new NP [5], a new method of administration [214, 220], or a new ligand [201, 219].

Table 3-3. Various NPs with different imaging modalities for observing pharmacokinetics in TBI.

Nanoparticles

Chemical

Loaded Dyes

Structures
PAMAM

Dendrimers

Cy5

Imaging

Administration

Modalities

Pathways

Fluorescence

Intravenous

References

Sharma, A., et al,
2018 [201]

In vitro

Kannan, G., et al.,
2017 [223]

PEG-b-

Polymeric

Rhodamine

Fluorescence

Intravenous

al., 2020 [208]

poly(methylstyrene)
2-(methylthio)ethyl
methacrylate +

Takahashi, T., et

Gd

MRI

Intravenous

Xu, J., et al., 2016
[5]

polyethyleneglycol
monomethylether
methacrylate +
methacrylic acid N-
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hydroxysuccinimide
ester
tetrakis(3-

Rhodamine B

Fluorescence

Intravenous

Yoo, D., et al.,
2017 [203]

mercaptopropionate)
and polysorbate-80
Lipoic acid 2-

Gd

MRI

Intravenous

Priester, A., et al.,
2022 [204]

hydroxyethyl
methacrylate and
polyethyleneglycol
monomethylether
methacrylate
Mn(III) meso-Tri(Nethylpyridinium-2-yl)-

Gd

MRI

Intravenous

Miller, H.A., et al.,
2019 [4]

mono(N-carboxymethyl)porphyrin
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Poly(lactic-co-glycolic
acid)
Poly(lactic-co-glycolic

800CW

Fluorescence

Intravenous

Cruz, L.J., et al.,
2016 [222]

acid)
800CW

Cruz, L.J., et al.,

NIR700

Fluorescence

19

19

F

F MRI

Fluorescence

Polystyrene

2016 [219]

Intravenous

Bharadwaj, V.N.,
et al., 2016 [181]
Bharadwaj, V.N.,
et al., 2018 [132]
Bharadwaj, V.N.,
et al., 2020 [131]

Chitosan +
polyethyleneamine +

Cy5.5

Fluorescence
MRI

Intranasal

Das, M., et al.,
2014 [220]
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polylactic acid +
superparamagnetic iron
oxide nanoparticles
Mesenchymal stem cells

Inorganic

FITC

Fluorescence

Intranasal

Shahror, R.A., et
al., 2019 [214]

Superparamagnetic

MRI

iron oxide
nanoparticles
Silver sulfide (Ag2S)

A1094

Fluorescence

Intravenous

Li, C., et al., 2019
[215]

Silver selenide (Ag2Se) +

Fluorescence

Intravenous

2021 [216]

ytterbium/erbium
Sodium yttrium fluoride
+ ytterbium + erbium +

Song, D., et al.,

Fluorescence

Intravenous

Jiang, X., et al.,
2021 [217]

cerium
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Europium gadolinium

Fluorescence

Intravenous

MRI
Superparamagnetic iron

Magnetic Particle

oxide nanoparticles

Imaging

Bony, B.A., et al.,
2020 [218]

Intravenous

Orendorff, R., et
al., 2017 [213]

38

39
3.7

Conclusions
There are multiple factors considered in designing NPs for TBI as the BBB limits

the accumulation of any drugs into the brain. Fortunately, with the BBB disruption
following TBI, the accumulation and retention of NPs in the brain are better than those of
small molecules. The promising results of NPs in TBI treatments led to an increasing
number of investigations using NPs in TBI treatments (Figure 3-1). Overall, these
previous studies highlight that NPs with sizes between 10–40 nm are desirable since they
are small enough to cross the BBB, but large enough to be retained. NPs with a size of up
to 800 nm were able to accumulate in the brain following TBI. To improve the
accumulation in the injury penumbra, some NPs are equipped with active targeting (i.e.,
ligands) to bind with a specific target molecule, as well as PEG to reduce the NPs’
clearance from the body and to increase the circulation half-life. NPs with antioxidant
activities, made out of dendrimers, polymers, cerium oxides, and carbon dots, showed
promising results in reducing the progression of secondary injury due to their ability in
scavenging free radicals and lipid radicals. Polymeric NPs are preferable as they are
biodegradable and nontoxic. NPs with imaging contrast agents, such as fluorophore and
gadolinium, have been used to track the NPs’ accumulation in the brain injury, as well as
the NPs’ distribution in the body.
In the next chapter, we employed a thioether polymeric NP (NP1) with the
hydrodynamic size of 16 nm that readily scavenges ROS. The goal of the study was to
assess the NP1 treatment to reduce ROS and LPOx, as well as the spread of
neuroinflammation, following TBI.
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CHAPTER 4: ANTIOXIDANT THIOETHER CORE-CROSSLINKED
NANOPARTICLES PREVENT THE BILATERAL SPREAD OF
SECONDARY INJURY IN A CONTROLLED CORTICAL
IMPACT MOUSE MODEL OF TRAUMATIC BRAIN INJURY
The work presented in this chapter has been previously published and is reprinted with
permission from Biomaterials, 272, Tarudji, A.W., Gee, C.C., Romereim, S.M.,
Convertine, A.J., and Kievit, F.M., Antioxidant thioether core-crosslinked nanoparticles
prevent the bilateral spread of secondary injury to protect spatial learning and memory in
a controlled cortical impact mouse model of traumatic brain injury, 2021, 120766,
Copyright © 2021, Elsevier, doi: https://doi.org/10.1016/j.biomaterials.2021.120766
[112]

4.1

Abstract
The secondary phase of traumatic brain injury (TBI) is partly caused by the

release of excess reactive oxygen species (ROS) from the primary injury. However, there
are currently no therapies that have been shown to reduce the secondary spread of injury
beyond the primary insult. Nanoparticles offer the ability to rapidly accumulate and be
retained in injured brain for improved target engagement. Here, we utilized systemically
administered antioxidant thioether core-cross-linked nanoparticles (NP1) that scavenge
and inactivate ROS to reduce this secondary spread of injury in a mild controlled cortical
impact (CCI) mouse model of TBI. This protection was likely a result of NP1-mediated
reduction in oxidative stress in the ipsilateral hemisphere as determined by
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immunofluorescence imaging of markers of oxidative stress and the spread of
neuroinflammation into the contralateral hippocampus as determined by
immunofluorescence imaging of activated microglia and neuron-astrocyte-microglia triad
formation. These data suggest NP1-mediated reduction in post-traumatic oxidative stress
correlates with the reduction in the spread of injury to the contralateral hippocampus in
CCI mice. Therefore, these materials may offer an improved treatment strategy to reduce
the secondary spread of TBI.

4.2

Introduction
Of the numerous biochemical derangements that occur following a traumatic

brain injury (TBI), reactive oxygen species (ROS) are one of the most important
participants in the complex secondary pathophysiological events that manifest through
lipid peroxidation, neuroinflammation, and neurodegeneration [55, 71]. Many treatments
have been studied in an effort to protect the surrounding healthy brain from excessive
ROS release following TBI; however, there are still no treatment options that have
demonstrated an improved outcome in a large, multi-center Phase III trial [7, 15, 224].
While there are numerous reasons for the lack of success of TBI clinical trials such as
patient variability, biomarker selection, or treatment timing, a major contributor is poor
target engagement of delivered therapeutics because of low accumulation and retention in
the brain [7, 15, 224]. Thus, there is a significant unmet need to develop more effective
delivery strategies to overcome the biological barriers that would otherwise inhibit
transport of materials into the brain in order to prevent the secondary, long-term damage
associated with TBI.
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TBI is currently understood in two separate injury phases: primary and secondary.
The primary injury occurs directly at the moment of initial impact. An outside force
shears axons, disrupts the cell membrane, and causes cell death. The secondary injury,
however, is the result of biochemical reactions caused by the primary injury that begins
with the release of excitatory amino acids, an influx of calcium ions leading to
mitochondrial damage, the release of ROS, and increased expression of cytokines and
chemokines, which lead to reactive astrocytes and activated microglia. The excess ROS
also causes DNA strand damage and lipid peroxidation, which additionally increase
oxidative stress and neuronal cell death within the brain [3]. Secondary injury often
results in a positive feedback loop where further neuronal cell death causes increased
neuroinflammation leading to additional biochemical derangements and cell death, which
can spread to the contralateral hemisphere [225]. Several markers of neuroinflammation
are reactive astrocytes, activated microglia, and neuron-astrocyte-microglia triad
formation. Neuron-astrocyte-microglia triads are formed when astrocytes form scar tissue
around the neurons, and microglia bisect the neurons [106]. This secondary cascade can
continue years to decades post-injury [13, 226-228]. Several antioxidant treatments
including PEG-conjugated superoxide dismutase, PEG-conjugated catalase (PEG-cat),
tirilazad, and their combinations, have shown promise in reducing the spread of
secondary injury in pre-clinical studies but have failed to translate into an observed
clinical benefit for patients likely because of poor target engagement.
Nanoparticles (NPs) offer one promising approach to overcome the limitations of
small molecule drug delivery. Previous studies have shown enhanced permeability and
retention of NPs in the brain in mouse models of TBI resulting in improved accumulation
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and retention of NPs at the site of injury [4, 5, 132, 181, 218, 222, 229]. This is thought to
be a combined result of the relatively large size of the NP and the severely disrupted
blood-brain barrier (BBB) allowing the accumulation of blood components in the brain
[133, 230-232]. This large NP size would prevent rapid diffusion out of the brain or
removal through glymphatic clearance [233, 234]. Therefore, NPs might improve
therapeutic efficacy by increasing target engagement and reducing the spread of
secondary injury following TBI. Here, we utilized antioxidant thioether core-cross-linked
NPs (NP1), which readily scavenge high levels of ROS [203]. The thioether (i.e., sulfide)
functional group readily reacts with hydrogen peroxide and superoxide [235, 236], and
thus does not require any additional drug loading, permits scaling up, and is readily
modified with other functionality such as for imaging [5]. With the size of NP1 of 16.4
nm and molecular weight of 0.88x106 g/mol [203], we expect the accumulation in the
brain similar to previous study by Bharadwaj, et al. [181] as well as our previous work
with similar NPs [5]. We previously found our mouse models of TBI treated with NP1
showed a reduction in ROS-mediated astrocyte reactivity in vitro, reduction of
neuroinflammation in the brain, and improvement in recovery in a mouse model of severe
TBI [203]. However, it is still unclear if NP1 treatment reduces the spread of secondary
injury in the chronic phase of TBI. We hypothesized that NP1 treatment scavenged the
excess ROS released from in the acute phase of TBI, thus reducing secondary TBI
markers such as acrolein, the quantity of activated microglia, and neuron-astrocytemicroglia triad formation.
In this study, we utilized a mild controlled cortical impact (CCI) mouse model of
TBI [237] to the left cortex to test the ability of NP1 to reduce the spread of secondary
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TBI markers on the cellular level to the contralateral hippocampus. Since the right
hippocampus plays a crucial role in spatial learning and memory [238], we expected
improvement in spatial learning and memory if the spread of the secondary injury can be
slowed or reduced through NP1 treatment.

4.3
4.3.1

Methods and Materials
NP1 Synthesis
Antioxidant thioether core-crossed-linked NPs (NP1) were synthesized as

described previously [203]. Briefly, pentaerythritol tetrakis(3-mercaptopropionate) was
added to polysorbate 80 and 2,2-dimethoxy-2-phenylacetophenone mixture. The
thiol−ene reaction was conducted under UV irradiation to produce PS803SH. The
PS803SH was diluted before the addition of pentaerythritol tetraacrylate, hexylamine,
and tert-butyl acrylate or hydroxyethyl acrylate to form NP1. The NP1 were purified with
Spectra/Por regenerated cellulose dialysis membrane (6−8 kDa cutoff, Fisher Scientific)
against acetone, followed by deionized water, before being lyophilized and stored at
–20 °C until use. NP1 were dissolved to the concentration of 1 mg/mL with sterile
Dulbecco's phosphate-buffered saline (DPBS, Thermo Fisher Scientific Waltham, MA)
prior to use. The size of NP1 in PBS pH 7.4 was measured with dynamic light scattering
to be 16.4 nm, with molecular weight of 0.8x106 g/mol.

4.3.2

Controlled Cortical Impact Mouse Model of TBI
All animal procedures were performed in accordance with the approval of the

University of Nebraska−Lincoln IACUC. Six-week-old male and female C57BL/6J mice
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(Jackson Laboratory, Bar Harbor, ME, USA) were acclimated for 2 weeks prior to the
procedures. Mice were anesthetized with 3% isoflurane gas via inhalation and were
maintained at ~1.5% with a nose cone on a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA). The hair of the scalp was removed with Nair (Church and Dwight
Co., Inc., Princeton, NJ, USA), and the scalp was disinfected with a betadine scrub and
isopropanol wipes afterward. Lidocaine (0.05 mL of 5 mg/mL) and bupivacaine (0.05 mL
of 0.3 mg/mL) were applied to the scalp, and buprenorphine SR (60 µL of 0.5 mg/mL)
was given subcutaneously. An approximately 1 cm midline incision was made on the
scalp over bregma. An approximately 2 mm craniectomy was made in the skull over the
left frontoparietal cortex (2 mm anterior and 2 mm left of lambda) using a surgical drill.
A controlled cortical impactor (Hatteras Instruments, Cary, NC, USA) attached to the
stereotaxic frame with a 2 mm convex tip was used to impact the brain normal to the dura
surface at a depth of 1.5 mm and a velocity of 4 m/s with a dwell time of 80 ms. Any
bleeding was controlled and incisions were closed using tissue adhesive. NP1 (100 μL of
1 mg/mL) was injected through the tail vein immediately after the surgery for the NP1
treated group. With the average weight of 16.44 g for female mice, the average dose of
NP1 administration was 6.1 mg/kg for female mice.

4.3.3

Histological Analysis
Mouse brains were collected 32 days post-CCI. The 6 control, 7 untreated CCI,

and 8 NP1 treated CCI female mice were deeply anesthetized with 3% isoflurane until
there was no reflex movement from a paw pinch. The mice were then transcardially
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perfused with 4% paraformaldehyde in DPBS. Brain tissue was collected, trimmed to the
desired coordinates, and post-fixed in 4% buffered paraformaldehyde for 24 h followed
by 30% sucrose in DPBS for 3 days before embedded in optimal cutting temperature
(OCT, Fisher Scientific, Waltham, MA) compound, frozen on dry ice, and stored at −80
°C. The brains were sliced coronally at a thickness of 50 μm with a cryotome (Leica
Biosystems, Wetzlar, Germany). Sections were washed with DPBS to remove the OCT.
The brain slices were blocked with 3% normal donkey serum, 0.3% Triton X-100, and
0.1% sodium azide in DPBS. The primary and secondary antibody (Ab) were diluted in
the blocking buffer. The brain sections were incubated with primary Ab against NeuN
(1:1000, ABN90P, Millipore), GFAP (1:500, ab53554, Abcam), Iba1 (1:1000, 019–
19741, Wako), and acrolein (1:500, ab37110, Abcam) for 3 d at 4 °C then washed with
blocking buffer 3 times for 5 min each before being incubated with a 1:250 dilution of
donkey secondary Ab against goat AF488 (ab150129, Abcam), rabbit AF555 (ab150074,
Abcam), and guinea pig AF647 (706605148, Jackson Immunoresearch) for 2 h at room
temperature. The brain sections were again washed with the blocking buffer 3 times for 5
min each before being stained with DAPI for 5 min, washed with water, and had
ProLong™ Gold Antifade Mountant (Thermo Fisher Scientific) applied.

4.3.4

Histological quantification
Images were acquired with confocal microscopy (LSM800, Zeiss) at 40x

objective lens magnification with z-stack configuration and single stack 20x objective
lens magnification for acrolein. Quantitative fluorescence mean intensity analysis of
acrolein was performed with ImageJ software on the ipsilateral cortex, CA1, and dentate
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gyrus (DG). Quantitative image analysis of GFAP + astrocytes, Iba1+ microglia, and
triads were performed on at least two randomly selected viewing fields for each region
for each mouse. The quantification of GFAP + astrocytes, Iba1+ microglia, and triads
was counted manually in ImageJ software, and divided by the total area of the image field
(mm2) to find the density in the regions. The criteria to characterize an activated
microglia cell were defined as cells with modification in cellular structure to be
deramified, shortened, twisted, several thickened processes, spheroid shape, and/or an
enlarged cell body; as compared to the ramified microglia which have long, thin, and
radially projecting processes, as well as small cell body [97, 239, 240]. Neuron-astrocytemicroglia triad formations were only counted if astrocytes formed scar tissue around the
neurons, and microglia bisect the neurons [106]. The investigator was blinded to the
treatment throughout the quantification process. The 3D image was reconstructed with
ImageJ software and 3D viewer plugin. Using maximum intensity projections, we first
identified regions with overlap between stained neurons, astrocytes, and microglia. We
then confirmed the association of the three cell types with 3D stack confocal microscopy
to determine if the overlapping signal came from a triad or cells that were on separate
planes. Only overlapping signals that were validated as triads were counted.

4.3.5

Dihydroethidium assay
A dihydroethidium (DHE, Thermo Fisher Scientific) assay was performed as

previously described with modifications [239] on 2 control, 3 untreated CCI, and 4 NP1
treated CCI female mice. NP1 does not have any inherent fluorescent properties so
should not influence the DHE assay. Briefly, DHE was dissolved in dimethyl sulfoxide
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(DMSO) before further dilution in DPBS. DHE was injected intraperitoneally for a total
of 6 μg/g body weight into each mouse at 3 h post-CCI. The mice were perfused at 1 h
after DHE injection with ice-cold 4% buffered paraformaldehyde, fixed in 4% buffered
paraformaldehyde overnight, immersed in 30% sucrose for 48 h, embedded in OCT
compound, and sliced coronally at a 20 μm thickness with cryotome. The brain slices
were washed with DPBS three times for 5 min each, stained with DAPI for 5 min,
washed with water, and ProLong™ Gold Antifade Mountant was applied. Images were
acquired with confocal microscopy at the excitation wavelength of 488 nm, the emission
wavelength of 560–635 nm, and the 10x objective lens magnification. Quantitative
fluorescence intensity analysis was performed with ImageJ software on the perilesional
and the contralateral hemisphere.
4.3.6

Statistical analysis
All the data in this study were expressed as mean ± standard error of the mean

(SEM). A p < 0.05 was considered statistically significant. Multiple student t-tests were
employed for DHE and acrolein fluorescence mean intensity between treatment groups.
Other experiments were evaluated using a two-way analysis of variance (ANOVA) with
Tukey's multiple comparisons test. All statistics were analyzed with GraphPad Prism 7
software (GraphPad Software, CA).

4.4
4.4.1

Results
Characterizations of NP1
To determine the effects of NP1 treatment on the chronic secondary injury phase

following TBI, we utilized the CCI mouse model of TBI because it is well-characterized
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in response and recovery and its highly reproducible [42]. Following CCI, mice were
immediately injected with 100 μL of 1 mg/mL NP1 to ensure high uptake and retention
in the injury (Figure 4-1A,B) [4, 5, 203] and perfused brains collected at 4 h post-injury
for DHE and 32 d post-injury for other histology experiments (Figure 4-1C).

Figure 4-1. Characteristics of NP1s. A) Possible ROS scavenging reaction of NP1s from thioether
bond to sulfone due to oxidation by ROS. B) Table summarizing the characteristics of NP1s.

4.4.2

NP1 reduce markers of post-traumatic oxidative stress in CCI mice
In order to determine the mechanism behind the protection afforded by the NP1,

we first determined if the NP1 were able to reduce post-traumatic oxidative stress in the
ipsilateral hemisphere. Our previous work demonstrated that NP1 have high antioxidant
activity in vitro, with the ROS capacity of 9.93 µmol per mg of NP [203]. Here, we
employed a DHE assay to observe the spread of ROS in the acute phase of the injury (4 h
post-CCI). We also employed immunofluorescence to observe the presence of acrolein,
one of the products of lipid peroxidation, in the chronic phase of the injury (32 d postCCI). From the normalized DHE fluorescence mean intensity at the perilesional to the
contralateral hemisphere, there was a significant increase in the untreated CCI mice
compared to the control mice (Figure 4-2C). Likewise, there was a significant increase in
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the fluorescence mean intensity of acrolein in the ipsilateral cortex of untreated CCI mice
compared to the control mice, while there was no significant increase between the NP1
treated CCI mice and the control mice (Figure 4-2D). We also found that there was a
trending increase of the acrolein in the ipsilateral CA1 and little change in the ipsilateral
DG of untreated CCI mice compared to the control mice, which might be caused by the
depth of the DG away from the lesion as compared to CA1. Thus, this data suggests that
NP1 treatment reduced post-traumatic oxidative stress in CCI mice.
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Figure 4-2. NP1 reduced markers of oxidative stress following CCI. A) DHE staining of the
whole brain at 24 h post-injury (IP injection of DHE at 3 h post-injury) shows a marked increase
in DHE signal indicating the presence of ROS following CCI, which was reduced in mice that
received NP1 treatment immediately following impact (scale bars correspond to 500 μm). B)
Acrolein staining in the ipsilateral cortex, CA1, and DG, respectively, reveals lipid peroxidation
at 1 month following CCI, which was reduced with NP1 treatment (scale bars correspond to 50
μm). C) The DHE fluorescence mean intensity at the perilesional normalized to the contralateral
hemisphere. D-F) The acrolein fluorescence mean intensity quantification in the ipsilateral cortex,
CA1, and DG, respectively. Data are shown as mean ± SEM. * indicate a statistical difference as
compared to control (p < 0.05), as determined by multiple student t-test.

4.4.3

The density of astrocytes and microglia in CCI mice
The presence of oxidative stress markers often correlates with the reactivity and

proliferation of astrocytes and the activation of microglia [99, 241-244]. The density of
astrocytes and microglia are elevated in the subacute and the chronic phase of the injury,
and thus often used to measure neuroinflammation [245-247]. To determine if NP1
treatment reduced the density of the astrocytes and microglia, we calculated the density
of glial fibrillary acidic protein positive (GFAP+; green) and ionized calcium binding
adaptor molecule 1 positive (Iba1+; red) cells, the markers of astrocytes and microglia
respectively, in the various subfields of the hippocampus in the chronic phase of the
injury (32 d post-CCI; Figure 4-3). Compared to the control group, the density of
astrocytes in the ipsilateral CA2/3 and DG regions of untreated CCI mice was
significantly higher (p < 0.01; Figure 4-3E), while there was no different in the density of
astrocytes in the ipsilateral CA1, contralateral CA1, contralateral CA2/3, and
contralateral DG regions of untreated CCI mice (Figure 4-3B,E). The density of the
astrocytes in NP1 treated CCI mice was also similar to the control group bilaterally in the
CA1, CA2/3, and DG regions (Figure 4-3B,E). We found that, compared to the ipsilateral
CA1 (240.08 ± 12.4 microglia/mm2), CA2/3 (288.1 ± 17.05 microglia/mm2), and DG
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(270.49 ± 13.67 microglia/mm2) regions of the control group, the density of microglia in
the ipsilateral CA1, CA2/3, and DG regions of the untreated and NP1 treated CCI mice
was significantly higher (p < 0.001 and p < 0.01 in both CA1, CA2/3, and DG regions).
On the other hand, there was no significant difference in the contralateral CA1, CA2/3,
and DG regions between the control, untreated, and NP1 treated CCI mice (Figure
4-3C,F). This data suggests that NP1 did not significantly reduce the density of astrocytes
and microglia in the hippocampus at the chronic phase of the injury compared to the
untreated CCI mice.

Figure 4-3. GFAP and Iba1 immunostaining and quantification in the hippocampus at 1 month
following CCI. A and D) representative maximum projections from confocal image z-stacks of
bilateral CA1 and DG of the treatment groups (control, CCI only, and CCI+NP1); magenta is
NeuN immunostaining, green is GFAP, and red is Iba1. Scale bar corresponds to 50 µm. B, E,
and H) Quantitative analysis of GFAP+ astrocytes (cells/mm2) in bilateral CA1, CA2/3, and DG,
respectively. C, F, and I) Quantitative analysis of Iba1+ microglia/macrophage (cells/mm2) in
bilateral CA1, CA2/3, and DG, respectively. Data are shown as mean ± SEM. * indicates a
statistical difference as compared to control with two and three symbols indicating p < 0.01 and p
< 0.001, respectively, as determined by two-way ANOVA.
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4.4.4

NP1 reduce the density of activated microglia in CCI mice
To further probe the activation status of the microglia in the chronic phase of the

CCI injury (32 days post-CCI), we investigated if NP1 treatment reduced the density of
activated microglia in the hippocampus rather than total cell number. Activated microglia
change morphology from ramified to amoeboid and play a role in exacerbating the
chronic phase of the injury [99, 106, 236, 244, 245]. Therefore, we counted the density of
amoeboid microglia in the subfields of the hippocampus (Figure 4-4). Compared to the
control group, the density of activated microglia in the ipsilateral hippocampal regions of
the untreated CCI and NP1 treated CCI mice were significantly higher (p < 0.01 by twoway ANOVA). Meanwhile, the density of activated microglia in the contralateral
hippocampus of untreated and NP1-treated CCI mice was not significantly higher, except
in the ipsilateral CA1 region of the untreated CCI mice. The density of activated
microglia in the untreated CCI mice was significantly higher than the control and NP1
treated CCI mice in the CA1 region (p < 0.01). This data suggests that NP1 mitigate
microglial activation in the contralateral hippocampus, especially in the CA1 region,
which may play a role in alleviating symptoms in the chronic phase of the injury.
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Figure 4-4. Quantification of activated microglia at 1 month following CCI in the various
subfields of the hippocampus. A–C) Maximum intensity projections from z-stack confocal
images of Iba1+ microglia in A) CA1, B) CA2/3, and C) DG. Scale bar corresponds to 50 µm.
The insets are the representative image of ramified (inset in the control contralateral CA1 panel)
and amoeboid (inset in the CCI contralateral CA1 panel) morphologies of microglia, with scale
bar of 10 µm. D–F) Quantification of activated microglia (cells/mm2) as determined by
unramified and ameboid morphologies in D) CA1, E) CA2/3, and F) DG. * and # indicate a
statistical difference as compared to control and CCI, respectively, with two and three symbols
indicating p < 0.01 and p < 0.001, respectively as determined by two-way ANOVA. Data are
shown as mean ± SEM.

4.4.5

NP1 reduces neuron-astrocyte-microglia triad formation in CCI mice
To further assess any correlation between the reduction in post-oxidative stress

and microglia activation with the improved performance in MWM following NP1
treatment, we investigated if NP1 treatment reduced the markers of neuroinflammation in
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the bilateral hippocampus through counting the neuron-astrocyte-microglia triads in the
chronic phase of the injury (32 d post-CCI) [106-111]. Microglia and astrocytes are
responsible for clearing up the dead neurons and thus can be observed as neuronastrocyte-microglia triads. Compared to the ipsilateral hippocampal regions of the control
mice, the untreated CCI mice had significantly higher density of triad formation (p <
0.01), while NP1 treated CCI mice had significantly higher density of triad formation
only in the ipsilateral CA1 region (p < 0.01; Figure 4-5C). For the contralateral
hippocampus, the density of triad formation in the contralateral CA1 and DG regions of
the untreated CCI mice were significantly higher than that of the control group (p <
0.001; Figure 4-5C), while there was no difference in the density of triad between control
and NP1 treated CCI mice in the contralateral hippocampus. Compared to untreated CCI
mice, the density of triad in the ipsilateral CA2/3 and DG regions of NP1 treated CCI
mice were 2.01-fold (p < 0.01) and 1.89-fold (p < 0.001) lower, while the density of triad
in the contralateral CA1 and DG regions of NP1 treated CCI mice were 2.54-fold (p <
0.01) and 1.81-fold (p < 0.01) lower. This data suggests NP1 treatment reduced neuronastrocyte-microglia triad formation in the contralateral hippocampus of CCI mouse model
of TBI compared to the untreated CCI mice in the chronic phase of the injury, which may
correlate with less neuroinflammation and better MWM performance in the chronic phase
of the injury.
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Figure 4-5. NP1 reduced neuron-astrocyte-microglia triad formation at 1 month following CCI.
A) Representative z-stack confocal images from 50 µm sections. The white circle indicates an
identified triad. Scale bar corresponds to 50 µm. B) 3D reconstruction validation of a triad to
verify direction interactions of a microglia and an astrocyte with a neuron. C) Quantification of
triads throughout various subfields of the hippocampus showing a bilateral increase in triads in
CCI mice as compared to controls (p < 0.01 for CA1, DG, and CA2/3 Ipsi), which returns to
control levels with NP1 treatment (p > 0.6 except for CA1 ipsilateral where p < 0.05). * and #
indicate a statistical difference as compared to control and CCI, respectively, with two and three
symbols indicating p < 0.01 and p < 0.001, respectively as determined by two-way ANOVA.
Data are shown as mean ± SEM.

4.5

Discussion
In this study, we showed that NP1 treatment improved MWM performance,

reduced post-traumatic oxidative stress, reduced microglia activation, and reduced
neuron-astrocyte-microglia triads in the hippocampus in the chronic phase of the CCI
mouse model of TBI. NP1 treatment also reduced ROS in the acute phase of the injury.
Our results suggest that NP1 treatment ameliorated the spatial learning and memory of
TBI mice when administered intravenously right after the injury.
Previous studies and clinical trials demonstrated the neuroprotection of
antioxidant compounds in TBI models where most of the antioxidant compounds are
small molecules [15]. Previous data from our group has shown that, although small
molecules and NPs are distributed at the same rate in injured brain following intravenous
injection, NPs are retained up to three times longer [4, 5]. Therefore, we expect limited
target engagement from small molecules due to poor retention. The core of NP1 consists
of thioether bonds that are readily oxidized by hydrogen peroxide and superoxide [235,
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236], as demonstrated in our previous work [5, 203], as well as by the work of others
[248]. Thus, NP1 does not require any additional drug loading and production is easily
scaled up.
The CCI parameters we chose to use (2-mm-diameter impact tip with 1.5 mm
impact depth at 4 m/s) are more mild than those typically used for a mild CCI procedure
(3.4-mm-diameter impact tip with 1.5 mm impact depth at 5.25 m/s). This injury severity
was chosen to allow us to better test the ability of NP1 to prevent the spread of secondary
injury into contralateral brain.
To clarify the mechanism of improved spatial learning and memory in NP1treated mice, we assessed two markers of oxidative stress and secondary TBI: ROS and
acrolein. The DHE assay is widely used to measure ROS in vivo by fluorescing brighter
with higher concentration of superoxide and hydrogen peroxide in the tissue. Thus, we
employed a DHE assay to observe the spread and qualitative measurement of ROS in the
acute phase of the injury (4 h post-CCI). Acrolein, on the other hand, is the byproduct of
oxidation on arachidonic acid and is often used as a marker of lipid peroxidation. We
employed immunofluorescence to observe the presence of acrolein in the chronic phase
of the injury (32 d post-CCI). ROS is produced in physiological brain activity and ATP
production [249], therefore the DHE fluorescence in the control brain can be assumed as
the base ROS produced under physiological condition. In order to reduce the variation of
the base ROS in individual mice, we normalized the fluorescence from the perilesional to
the contralateral hemisphere where we do not expect the spread of secondary injury of
TBI in the acute phase. We found that, at 4 h post-CCI, NP1 treatment tended to reduce
the level of target ROS in the perilesional area compared to the untreated CCI mice
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(Figure 4-2B), showing strong evidence for high target engagement by NP1. Likewise,
NP1 treatment tended to reduce the presence of acrolein in the perilesional area in the
chronic phase of the injury compared to the untreated CCI mice (Figure 4-2D-F) further
supporting high target engagement by NP1 as formation of acrolein and other lipid
peroxidation produces is one of the secondary consequences elevated ROS. The reduction
of oxidative stress in the acute phase of the injury likely reduced the cascade of posttraumatic oxidative stress. This data, as well as our previous studies using antioxidant
NPs [5, 203], suggest that NP1 scavenged ROS and reduced the post-traumatic oxidative
stress in CCI mice when administered in the acute phase of the injury.
An elevated density of astrocytes and microglia in the brain has been widely
known as one of the markers of neuroinflammation post-TBI, which correlate with
increased neuronal cell death, impeded neurogenesis, and exacerbated behavioral deficits
following TBI [99, 241-244]. This allows density of astrocytes and microglia to be
utilized to determine the scope of neuroinflammation post-TBI. In the event of brain
injury, the dead cells from the primary injury release ROS, which signals the activation of
microglia. In return, activated microglia release more ROS and inflammatory cytokines
to the surrounding cells thereby inducing reactive astrocytes, blood-brain barrier (BBB)
permeability, edema, and increased cell death. During normal physiological conditions
microglia are mostly present in a resting state. However, even in the case of severe TBI,
not every perilesional microglia is activated. Thus, simply calculating the microglia
density post-TBI may not be representative of the density of activated microglia. Notably,
pro-inflammatory activated microglia are more prevalent than anti-inflammatory
activated microglia by three to five times at 1-month post-TBI; thus, an increase in the
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number of activated microglia is a strong indicator of neuroinflammation [101, 250, 251].
Pro-inflammatory activated microglia are also responsible for exacerbating TBI outcomes
and promoting the secondary injury cascade. To measure neuroinflammation, we utilized
the amoeboid morphology of microglia that represent the pro-inflammatory activated
microglia [93-95, 236]. In this study, there was no significant reduction in the density of
microglia in the hippocampus by NP1 treatment compared to the untreated CCI mice.
However, our results showed that NP1 treatment significantly reduced the density of
activated microglia in the contralateral CA1 region of CCI mice (Figure 4-4). We also
found that the density of astrocytes in the contralateral hippocampus of NP1 treated CCI
mice were similar to the control mice, while there was a significant increase of astrocytes
in the ipsilateral CA2/3 and DG regions of the untreated CCI mice compared to the
control mice. Thus, our results suggest that the reduction in post-traumatic oxidative
stress led to reduced neuroinflammation in the chronic phase of the injury by NP1
treatment.
Another marker of neuroinflammation is neuron-astrocyte-microglia triad
formation [106-111]. Neuron-astrocyte-microglia triad formation has been used as a
marker of neuroinflammation associated with aging, lipopolysaccharide exposure,
cerebral hypoperfusion, and mouse and rat models of Alzheimer's disease. Similar to the
other triad studies, it is well-known that neuroinflammation and neuronal cell death occur
in the CCI mouse model of TBI. Therefore, we counted neuron-astrocyte-microglia triad
formation in the hippocampal regions. Neuron-astrocyte-microglia triads are formed
when astrocytes form scar tissue around the neurons, and microglia bisect the neurons
[106]. Utilizing z-stack stack confocal microscopy, we were able to identify regions
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where both GFAP and Iba1 positive cells surrounded NeuN positive cells, as shown in
Figure 4-5B. We found that CCI mice had a significantly higher density of triads than the
control group in the hippocampus bilaterally except in the contralateral CA2/3 region. On
the other hand, there was no significant difference in the density of triads in NP1 treated
CCI mice and the control group except in the ipsilateral CA1 region, which is just below
the primary injury location. We found that NP1 treatment significantly reduced the
density of neuron-astrocyte-microglia triad formation in the contralateral CA1 region,
ipsilateral CA2/3 region, and bilateral DG region, while not significantly changing the
density of neuron-astrocyte-microglia triad formation in the ipsilateral CA1 region and
contralateral CA2/3 region compared to the untreated CCI mice. Our results strongly
suggest that NP1 treatment reduced neuroinflammation in the chronic phase of TBI in the
hippocampus bilaterally.
The present study has several limitations. First, the CCI model of TBI is not
entirely similar to the most common injury mechanism in humans. Most human TBIs that
occur are mild TBIs with no physical penetration of the cranium. However, a new study
found that the BBB is breached in the event of repeated mild TBI [252] which might
allow NP1 to accumulate in the brain and improve the outcome from the injury [253].
Second, administering treatment right after a TBI may not be possible in human patients
when medical support may not be available for hours after injury. However, our recent
work revealed that BBB permeability to one type of NP is highest at 3 h post-TBI and the
BBB is permeable to NPs up to 48 h post-TBI in this CCI mouse model of TBI [4]. These
results suggest that NP1 administration several hours post-TBI might have therapeutic
benefits in both experimental and real-world applications. Furthermore, dose-response
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studies were not performed with NP1, thus the dose of NP1 may be suboptimal to achieve
maximal antioxidant properties in the injury where there is typically a bell-shaped
response curve for antioxidant therapies [254, 255]. In addition, repeated administrations
of NP1 may also increase therapeutic efficacy beyond the single post-CCI administration
we used in this study. However, the long retention time of NPs within the injury is likely
an advantage of using these NP-based systems although the activity of NP1 over time
during its prolonged retention still needs to be determined. Furthermore, any possible
toxicity of NP1 will need to be assessed because of these prolonged retention times in the
brain. While the toxicity of NP1 has not been tested in humans, we speculate NP1 will
show good biocompatibility as it is synthesized from polysorbate 80, which has been
used successfully in a wide variety of cosmetic, food, and pharmaceutical applications,
although not without some adverse effects [256, 257]. Along with dose-response studies,
cell specific accumulation of NP1, such as in microglia or astrocytes, will need to be
measured in future studies to help determine how NP1 is reducing oxidative stress in the
injury. However, we have previously shown rhodamine B labeled NP1 passively
accumulates in the site of injury but without cell specificity [203].
Another limitation was the lack of quantitative measurement of DHE and acrolein
experiment beyond the short therapeutic window of antioxidant molecules in TBI treatment
post-TBI [258]. Since ROS has a short half-life in biological tissue, delayed treatment of
antioxidant molecules or NPs might reduce the neuroprotection efficacy. On the other
hand, carbonyl scavenger molecules or NPs might allow for a longer therapeutic window
up to the sub-acute and chronic phases of injury given during the acute phase of the injury
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[259] and should be explored in subsequent work along with additional work comparing
sex differences in relation to NP therapeutics.

4.6

Conclusion
We found that the impaired spatial learning and memory in the chronic phase of

the CCI mouse model of TBI correlated with the spread of secondary injury and
neuroinflammation in the hippocampus. We also found that NP1 reduced ROS in the
ipsilateral hemisphere at 1-day post-CCI and acrolein in the ipsilateral cortex at 1-month
post-CCI. NP1 also significantly reduced the density of activated microglia in the
contralateral CA1 region and neuron-astrocyte-microglia triad formation in the
contralateral CA1 region, ipsilateral CA2/3 region, and bilateral DG region at 1-month
post-CCI in the NP1 treated CCI-mice. This is likely the result of the high ROS
scavenging ability of NP1 combined with their high accumulation and long retention time
within the injured brain. Therefore, NP1 treatment offers a promising approach to
improve outcome following TBI by reducing the spread of secondary injury to the
contralateral hemisphere.
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CHAPTER 5: ASSESSING TIME-COURSE OF SECONDARY
INJURY MARKERS WITH ENCAPSULATED ANTIOXIDANT
ENZYME NANOPARTICLES (PRO-NP™) IN MALE AND
FEMALE MOUSE MODEL OF TBI

5.1

Abstract
Following traumatic brain injury (TBI), ROS are released in excess, inducing

oxidative stress damage, carbonyl stress damage, and cell death, which induce more
release of ROS. The use of small molecule drugs in clinical trials might limit the
accumulation and retention in the brain, thus limiting the target engagement and
therapeutic effects in reducing secondary injury of TBI. Small molecule drugs also need
to be administered every several hours to maintain the bioavailability in the brain.
Therefore, there is a need for a burst and sustained release of ROS scavenger with high
accumulation and retention in the injured brain. Here, we utilized Pro-NP™ with a size of
200 nm, which was designed to have a burst and sustained release of encapsulated
superoxide dismutase (SOD) and catalase (CAT) to scavenge ROS for more than 24 h
post-injection. We found a significant reduction in the accumulation of Pro-NP™ in the
brain lesion with delayed administration. We reported that Pro-NP™ treatment with
9,000 U/kg SOD and 9,800 U/kg CAT gave the highest reduction in oxidative stress in
male and female mice. We also studied the time-course for changes in 4-hydroxynonenal
(4-HNE), acrolein, and α-II-spectrin breakdown products (SBDPs) in the subacute phase
of injury in the untreated and Pro-NP™ treated male and female CCI mouse model of
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TBI. We found that Pro-NP™ treatment reduced oxidative stress in the acute phase of
injury, which may reduce carbonyl stress and necrosis at 1 d post-injury in the
contralateral hemisphere in male and female mice. However, Pro-NP™ treatment
increased acrolein in male and female mice, and total cell death in male mice. Thus, ProNP™ showed promising results in improving the progression of secondary injury of TBI
in the acute phase of injury, but exacerbating the progression in the subacute to the
chronic phase of injury.

5.2

Introduction
Traumatic brain injury (TBI) can be caused by either a penetrating or non-

penetrating blow to the head, which results in compression, deformation, displacement,
stretching, shearing, tearing, and crushing of brain and blood vessels [260]; this event is
also known as primary injury. The primary injury is then followed by a cascade of
biochemical derangement, also known as secondary injury, that range from the release of
calcium, excitatory amino acids, and oxidative stress to carbonyl stress, mitochondrial
dysfunction, neuroinflammation, and cell death. Secondary injury can last years to
decades post-injury [13, 226-228] and spread to the contralateral hemisphere [112, 225].
Reactive oxygen species (ROS), such as superoxide, are commonly produced by
electron transport chain in the mitochondria. Under physiological conditions, ROS are
scavenged by superoxide dismutase (SOD) and catalase (CAT) producing water and
oxygen. However, following TBI, ROS are produced at elevated rates, while endogenous
antioxidant enzymes are produced at lower rates [72-74]. Excess ROS oxidize DNA,
proteins, and lipids that result in DNA damage, lipid peroxidation products (LPOx),
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neuroinflammation, and neurodegeneration [15, 55, 71]. Therefore, antioxidant therapies,
such as PEG-conjugated SOD and PEG-conjugated CAT have been employed to improve
outcomes following TBI in preclinical studies and phase I and II trials [170, 171, 261,
262]. However, no TBI drug treatments have shown efficacy in phase III trials [7, 15,
224, 263]. The failure in TBI clinical trials might be caused by poor target engagement of
therapeutic agents because of the poor accumulation and retention in the brain. The small
molecule drugs also need to be administered every several hours to maintain the
bioavailability within the therapeutic window. Therefore, a new TBI treatment with high
accumulation and retention, as well as a prolonged release of therapy, is needed.
The properties of nanoparticles (NPs) are highly adjustable, which can be
exploited to provoke a desired response, such as higher accumulation and drug delivery
into the brain. The size of NPs is also ideal in TBI applications since the blood-brain
barrier (BBB) is disrupted following TBI [126, 127] allowing enhanced permeability and
retention of NPs in the injured brain [4, 5, 74, 132, 133, 181, 218, 222, 230-232, 264].
Higher accumulation and retention of NPs in the brain injury are expected to increase the
target engagement compared to the small molecule drugs, which may improve the
therapeutic efficacy in reducing the progression of secondary injury. Our previous ROS
scavenger nanoparticle (NP1) [112] was functionalized with thioether bond that is readily
oxidized by ROS. We found that NP1 reduced the spread of secondary TBI markers on
the cellular level to the contralateral hemisphere. Therefore, antioxidant NPs have shown
promising result for TBI treatment.
SOD and CAT are two of the endogenous antioxidant enzymes. The blood
circulation half-life of intravenously injected SOD and CAT are only 8 and 20 minutes,
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respectively, due to renal clearance since SOD and CAT have small molecular weights
[167, 168, 265]. Therefore, SOD and CAT had been conjugated with polyethylene glycol
(PEG) to increase the blood circulation half-life to 30 hours [169]. SOD and CAT had
also been encapsulated in a PLGA-based NP to be slowly released over a period of 1
week [266], which increase the target engagement in the tissue of interest. Another
advantage of employing PLGA-based NPs are the low toxicity and high biodegradability
of PLGA. PLGA also received FDA approval, which can accelerate preclinical to clinical
translation. Here, we utilized Pro-NP™, an SOD and CAT encapsulated PLGA-based
NP, with “burst” released within an hour of injection and “sustained” release for more
than 24 h post-injection [267, 268].
Combining sustained ROS scavenging activities with the accumulation and
retention of Pro-NP™ following brain injury [4], we expected Pro-NP™ to reduce the
progression of secondary injury of TBI. In this study, we utilized a severe controlled
cortical impact (CCI) mouse model of TBI [237] to the left cortex. The goals of this study
are to assess the treatment window, therapeutic window, and optimum SOD:CAT ratio of
Pro-NP™ following brain injury, as well as the reduction in oxidative stress, carbonyl
stress, and cell death in the sub-acute phases of injury.

5.3
5.3.1

Methods and Materials:
Pro-NP™ synthesis
Pro-NP™ is a proprietary composition of poly(lactic-co-glycolic acid) (PLGA)-

based biodegradable polymer NPs with superoxide dismutase (SOD) and catalase (CAT).
The original formulation was developed at the University of Nebraska Medical Center
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(Omaha, NE), then licensed by UneMed Corp., the technology transfer office, to
ProTransit Nanotherapy, LLC (Omaha, NE). Pro-NP™-SOD and Pro-NP™-CAT were
synthesized and characterized separately to allow various SOD:CAT ratio.
Pro-NP™-Gd was synthesized as previously described [4]. Briefly, 85 mg of
PLGA, 9 mg of (+)-dimethyl L-tartrate, 30 mg of bovine serum albumin, and 8.1 mg of 1,
2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)-Gd was was
dissolved In 3 mL dichloromethane (DCM). The DCM solution was then added into 18
mL of 3% w/v PVA and sonicated for 3 min. After the DCM had evaporated, the ProNP™-Gd was then centrifuged and supernatant removed for three times with distilled
water. The final pellet was resuspended in 18 mL of sucrose solution, frozen at -80 °C,
and lyophilized for 48 h. The dried powder were kept in -80 °C until further use.
Pro-NP™ and Pro-NP™-Gd were redissolved in Dulbecco’s phosphate buffered
saline (DPBS, Thermo Fisher Scientific, Waltham, MA) at desired concentrations before
injected intravenously in mice.

5.3.2

Pro-NP™ characterizations
The hydrodynamic diameter and zeta potential of Pro-NP™ were measured with

dynamic light scattering. The enzymatic activities of Pro-NP™ were measured with SOD
and CAT activity assays collected at 1 and 24 h post-incubation of Pro-NP™ in PBS
buffer (150 mM, pH 7.4) containing BSA (0.1% w/v) and Tween-80 (0.05%) at 37 °C
[269]. Gd content was measured with inductively coupled plasma mass-spectroscopy.
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5.3.3

Controlled Cortical Impact Mouse Model of TBI
All animal procedures were performed in accordance with the approval of the

University of Nebraska−Lincoln IACUC. Eight to ten-week-old male and female
C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA) were acclimated for three
days prior to the procedures. Mice were anesthetized with 3% isoflurane gas via
inhalation and were maintained at ∼1.5% with a nose cone on a stereotaxic frame (David
Kopf Instruments, Tujunga, CA, USA). The hair of the scalp was removed with Nair
(Church and Dwight Co., Inc., Princeton, NJ, USA), and the scalp was disinfected with a
betadine scrub and isopropanol wipes afterward. Lidocaine (0.05 mL of 5 mg/mL) and
bupivacaine (0.05 mL of 0.3 mg/mL) were applied to the scalp, and buprenorphine SR
(60 µL of 0.5 mg/mL) was given subcutaneously. An approximately 1 cm midline
incision was made on the scalp over bregma. An approximately 2 mm craniectomy was
made in the skull over the left frontoparietal cortex (2 mm anterior and 2 mm left of
lambda) using a surgical trephine drill. A controlled cortical impactor (Hatteras
Instruments, Cary, NC, USA) attached to the stereotaxic frame with a 2 mm convex tip
was used to impact the brain normal to the dura surface at a depth of 2.5 mm and a
velocity of 4 m/s with a dwell time of 80 ms. Any bleeding was controlled, and incisions
were closed using tissue adhesive.

5.3.4

In vivo Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)
In vivo NP assessment consisted of dynamic contrast-enhanced (DCE)-MRI using

a 9.4T MRI system (Varian) was performed to compare the Pro-NP™ accumulation at
various time-points following a TBI [4, 204, 270]. Briefly, mice were induced with about
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2% isoflurane gas and maintained at a concentration sufficient to achieve 50 to 80 breaths
per minute. Baseline T1 maps were generated using a gradient-echo sequence and the
variable flip angle method with two angles, 10° and 30° [271]. Mice were injected with
100 µL of a 0.067 mM Pro-NP™-Gd solution via tail vein catheter followed by 100 µL
PBS to flush all remaining NP solution. A flip angle of 30° was used for all post-contrast
scans, which occurred for 1 h following injection. TR was between 54 and 84 ms, TE
between 2.73 and 4.24 ms, matrix size between 128x128 and 256x256, FOV between
20x20x10 mm3 and 25x25x10 mm3, depending on the experiment. NEX varied with
matrix size to maintain temporal resolution, with 128x128, NEX = 5 for all scans, with
256x256, NEX = 4 for baseline and 1 for post-contrast scans. Following serial image
acquisition, resulting in about 100 post-contrast scans per animal, R1, concentration, and
Ktrans mapping were performed using a custom MATLAB script. R1 mapping was
performed using the variable flip angle method [272]. Concentration maps were then
generated by comparison of baseline R1 maps with post-contrast R1 maps. Ktrans, the
contrast extravasation rate constant, mapping was then performed using the Patlak model
[273, 274]. MATLAB was used to execute a least squares curve fitting routine to
calculate Ktrans for each voxel in the brain.

5.3.5

Dihydroethidium Histological Analysis
The Pro-NP™ group was treated with Pro-NP™ in DPBS IV immediately after

the surgery, while the MnTMPyP group treated with Mn(III)tetrakis(1-methyl-4pyridyl)porphyrin (MnTMPyP, 475872, Sigma-Aldrich, St. Louis, MO) in DPBS (500
μL of 1 mg/mL, IP) immediately after the surgery. The size of each treatment group was
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between 3-9 mice. A dihydroethidium (DHE, Thermo Fisher Scientific) assay was
performed as previously described with modifications [112, 204, 239]. Briefly, DHE was
dissolved in sterile dimethyl sulfoxide (DMSO) before further dilution in DPBS. DHE
(500 μL of 1.25 mg/mL, IP) into each mouse at 3 h post-CCI. Mice were transcardially
perfused at 1 hour after DHE injection with ice-cold 4% paraformaldehyde (PFA) in 0.1
M phosphate buffer pH 7.5. Brain tissue was collected, trimmed, and fixed in 4%
buffered PFA for 24 h. The brains were moved into 30% sucrose in DPBS for 3 d at 4 °C
for cryoprotection. The brains were then embedded in 2.6% carboxymethylcellulose
(CMC, C4888, Sigma-Aldrich), frozen on dry ice, and sliced coronally at a 15 μm
thickness with cryotome (Leica Biosystems CM1950, Wetzlar, Germany). The brain
slices were laid on poly-L-lysine coated microscope slide (6776215, Epredia, Kalamazoo,
MI), dried overnight at RT, and stored at -80 °C until further steps. Sections were washed
with DPBS 3 times for 5 min each to remove the CMC, followed by water, and had
ProLong™ Gold Antifade Mountant (P4981001, Thermo Fisher Scientific) applied.
Images were acquired with confocal microscopy (Zeiss LSM800, Oberkochen, Germany)
at the excitation wavelength of 488 nm, the emission wavelength of 560-635 nm, and the
5x objective lens magnification. Quantitative fluorescence intensity analysis was
performed with ImageJ software on the perilesional and the contralateral hemisphere.

5.3.6

Western blot
The Pro-NP™ group was treated with Pro-NP™ in DPBS (9:9.8 x103 U

SOD:CAT/mouse, IV) immediately after the surgery, while the CCI group did not receive
any treatment after the surgery. The control group did not receive any treatment. The
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average weight of male mice was 25 g and the average weight of female mice was 19.6 g.
Mice were transcardially perfused 1, 3, and 7 days post-CCI with ice-cold DPBS, brains
were extracted, left-right cortex and hippocampus were separated and flash-frozen in
liquid nitrogen and stored at -80 °C until further steps. Tissues were then lysed in RIPA
lysis buffer and 1 mM phenylmethylsulfonyl fluoride. Protein concentration was
measured using Pierce™ BCA protein assay (Thermo Fisher Scientific). For spectrin
breakdown products (SBDPs), 5 μg of extract protein was resolved by 5-12% SDSPAGE for spectrin breakdown products (SBDPs). They were then transferred onto PVDF
membranes (Bio-Rad). Membranes were washed with TBS and were incubated with 3%
BLOT-QuickBlocker™ (G-Biosciences, St. Louis, MO) in TBS for 1 h RT. The
membranes were incubated overnight at 4 °C with 1:1000 dilution of mouse anti-spectrin
alpha chain (MAB1622, Sigma) and 1:1000 dilution of mouse anti--actin (A5441,
Sigma) antibody in TTBS containing 3% BLOT-QuickBlocker™. Membranes were
washed with TTBS before being incubated for 1 h at room temperature with 1:5000
dilution of HRP-conjugated goat anti-mouse secondary antibody (Bio-Rad) in TTBS
containing 3% BLOT-QuickBlocker™. Membranes were then washed thrice with TTBS
and antibody binding visualized by chemiluminescence (Clarity Western ECL Substrate,
Bio-Rad) and quantified using the ChemiDoc system running the Image Lab software
package (Bio-Rad). For lipid peroxidation products (LPOx), 30 μg of extract protein was
resolved by 10% SDS-PAGE. The membranes were then blocked and incubated with
1:1000 dilution of rabbit anti-4-HNE (ab46545, Abcam, Cambridge, UK), 1:1000
dilution of mouse anti-acrolein (ab240918, Abcam), 1:5000 dilution of mouse anti-actin, and 1:3000 dilution of goat anti-rabbit or anti-mouse secondary antibody in TTBS
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containing 3% BSA. 1% sodium azide was added into the blocking buffer in between
different markers to deactivate the HRP, and the membrane was incubated in 1:500
dilution of goat anti-mouse IgG (ab6708, Abcam) to block the innate mouse IgG before
acrolein staining. ROI was drawn on the whole lane. Precision Plus Protein™ Dual Color
Standard (1610374, Bio-Rad) was used as the protein ladder.

5.3.7

Statistical analysis
All the data were displayed as mean ± standard deviation. A p < 0.05 was

considered statistically significant. The Ktrans and DHE quantification were analyzed with
one-way ANOVA and Dunnett’s post hoc test against 0 h ipsilateral for Ktrans, and
untreated CCI mice for DHE. Two-way ANOVA and Tukey’s post hoc test was utilized
for Western Blot protein quantification. All statistical analysis was performed with
GraphPad Prism 9 software (GraphPad Software, CA).

5.4
5.4.1

Results
Size, zeta potential, enzyme activities, and Gd concentration of Pro-NP™

Table 5-1. Properties of Pro-NP™s used for Ktrans imaging and antioxidant therapy.

Particle

Size
(nm)

PDI
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Initial
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Potential

Burst

Release
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(mV)
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Enzyme

(mmol/mg

Activity

Activity

Pro-NP™)

73
(U/mg

(U/mg Pro-

Pro-

NP™)

NP™)
Pro-NP™-

214

0.036

-10.3

~

~

7.56x10-6

203

0.12

-15.3

658

43

~

218

0.103

-25.7

298

37

~

Gd
Pro-NP™SOD
Pro-NP™CAT

Pro-NP™-Gd had similar characterizations to our previous study [4], with r1
relaxivity at 9.4T of 5.75 s-1 mM-1, and r2/r1 of 15. The hydrodynamic size and Zeta
potential of Pro-NP™s are in the similar range of 200–220 nm and -10–25 mV,
respectively. Thus, we did not expect difference in NPs accumulation between Pro-NP™s
in the lesion. Pro-NP™s showed “burst” and “sustained” releases, which were measured
at 1 and 24 h in the PBS containing BSA and Tween-80 at 37 °C, as expected from a
PLGA-based NP.
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5.4.2

Identifying the treatment window of Pro-NP™-Gd

Figure 5-1. Identification of treatment window of Pro-NP™-Gd. Ktrans of Pro-NP™-Gd in male
and female CCI mouse model of TBI in the lesion and contralateral hemisphere at various time
points post-injury. (a) Representative Ktrans mapping of Pro-NP™-Gd. (b) Quantification of Ktrans
mapping in the lesion. Pro-NP™-Gd accumulated in the lesion the most when administered
immediately following the injury (0 h post-injury). Data are shown as mean ± SD with n = 6 for
male mice and n = 3 for female mice. * indicates a statistical difference compared to 0 h postinjury group, with two and three symbols indicating p < 0.01 and p < 0.001, respectively, as
determined by one-way ANOVA and Dunnett’s post hoc test.

Ktrans is a permeability coefficient that describes the kinetics of NPs that cross the
BBB by taking a series of T1 images before and up to 30 min post-Pro-NP™-Gd
injection with MRI [4]. Here, Ktrans was utilized to measure the accumulation of ProNP™-Gd in the lesion at various time points in the acute phase of the injury (up to 24 h)
(Figure 5-1), which can be used to evaluate the treatment window of Pro-NP™ following
TBI. There were significant reductions of Pro-NP™s accumulation in the lesion in the
delayed administration compared to the immediate administration in male (mean ± SD =
32.46 ± 9.1 x10-3 min-1) and female (24.15 ± 12.01 x10-3 min-1) mice, even when
administered at 1 h post-injury. Although the trend of Ktrans was significantly higher in
males than females (p < 0.01), there was no significant difference between the Ktrans in
males and females at individual time points (p = 0.34, 0.37, 0.32, 0.44, and 0.09 for 0, 1,
3, 6, and 24 h, respectively), as determined by student t-test. We found significant
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accumulation in the lesion, compared to the contralateral hemisphere, at 24 h post-injury
in male mice (6.29 fold higher, p < 0.01), but not in female mice (2.77 fold higher, p =
0.12).

5.4.3

Identifying the optimum SOD:CAT-Pro-NP™ enzyme activities

Figure 5-2. Identifying the optimum SOD:CAT activities of Pro-NP™. In vivo DHE staining of
the brains at 4 h post-injury was utilized to measure the ROS level in the acute phase of injury.
Various concentrations and ratios of SOD:CAT-Pro-NP™ were administered to find the optimum
concentration in reducing ROS. (a) Representative images of confocal microscopy with of
control, MnTMPyP, and 4.5:4.9 SOD:CAT-Pro-NP™ following CCI in male mice. Scale bar is 1
mm. (b&c) Quantification of DHE fluorescence mean intensity at the perilesional normalized to
the contralateral hemisphere with various SOD:CAT-Pro-NP™ ratios in male CCI mice (b), and
various concentrations of 1:1 SOD:CAT-Pro-NP™ in male and female CCI mice (c). Data are
shown as mean ± SD with n = 3 for female mice, and n = 3-9 for male mice. * indicates a
statistical difference compared to the 0 mg/kg Pro-NP™ group, with one, two, and three symbols
indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as determined by one-way ANOVA
and Dunnett’s post hoc test.
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With immediate injection of Pro-NP™-Gd following TBI (0 h time point) having
the highest accumulation in the lesion, we evaluated the optimum SOD:CAT-Pro-NP™
enzyme activities ratio and concentration in scavenging the ROS when administered at
this time point. In vivo DHE staining was utilized to measure the reduction in oxidative
stress with Pro-NP™ treatment. We found that 4.5:4.9 and 4.5:9.8 x103 U/kg SOD:CATPro-NP™ have the highest ROS scavenging activity following TBI (50% and 64.25%
decrease, respectively). Thus, we continued with different concentrations of 4.5:4.9 x103
U/kg SOD:CAT-Pro-NP™ ratio, as used in previous study with SOD:CAT-PLGA NP
[266]. We then found that 4.5:4.9 and 9:9.8 x103 U/kg SOD:CAT-Pro-NP™ showed
significant reduction in oxidative stress in male CCI mice (50% and 56.2% decrease,
respectively). In female CCI mice, only 9:9.8 x103 U/kg SOD:CAT-Pro-NP™ showed
significant reduction in oxidative stress (54.56% decrease). MnTMPyP, a small molecule
ROS scavenger positive control, has similar efficiency in reducing ROS to the Pro-NP™
when injected immediately following the injury in male and female mice (50.66% and
65.29% decrease, respectively). Thus, we found a treatment window of 4.5:4.9 and 9:9.8
x103 U/kg SOD:CAT-Pro-NP™ in male mice and 9:9.8 x103 U/kg SOD:CAT-Pro-NP™
in female mice. Comparing between male and female CCI mice, we found that the
untreated female CCI mice had more oxidative stress level than the untreated CCI male
mice.

5.4.4

Time course of carbonyl stress progression in male and female mice following
TBI
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Figure 5-3. Analysis of carbonyl stress in the cortex. Western blot of LPOx 4-HNE and acrolein
in the ipsi- (a,b) and contralateral (c,d) cortex for male (a,c) and female (b,d) mice at 1, 3, and 7 d
post-injury. Representative blot of 4-HNE (a1,b1,c1,d1) and acrolein (a3,b3,c3,d3) in the
ipsilateral and contralateral cortex. The boxed area represents the ROI for quantification.
Quantification of 4-HNE (a2,b2,c2,d2) and acrolein (a4,b4,c4,d4) in the ipsilateral and
contralateral cortex normalized to β-actin. Data are shown as mean ± SD with n = 3 for each
treatment group. * and # indicate a significant increase compared to the control group and a
significant decrease compared to the untreated CCI group, respectively, with one, two, and three
symbols indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as determined by two-way
ANOVA and Tukey’s post hoc test.

Finding the highest accumulation at 0 h post-injury (Figure 5-1), and the optimum ROS
scavenging activities at 9:9.8 x103 U/kg SOD:CAT-Pro-NP™ in male and female mice
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(Figure 5-2), we investigated the correlation between the reduction of ROS and the
reduction of carbonyl stress following TBI by measuring 4-HNE and acrolein, two of the
most prevalent LPOx aldehyde [275]. As 4-HNE and acrolein form stable covalent bonds
with cysteine through thiol-Michael reaction, we measured the total volume of the LPOxmodified proteins with Western blot in the ipsi- and contralateral cortex (Figure 5-3) and
hippocampus (Figure 5-4). Previous study found that LPOx are elevated in the subacute
phase of injury [276]. Thus, we analyzed LPOx levels at 1, 3, and 7 d post-injury.
We found a trending reduction of 4-HNE with Pro-NP™ treatment at 1, 3, and 7 d
post-injury in the ipsilateral cortex of male and female mice, except a significant
reduction in Pro-NP™ treated male CCI mice at 7 d post-injury and Pro-NP™ treated
female CCI mice at 3 d post-injury. We observed significant and trending reductions in 4HNE with Pro-NP™ treatment at 1 d post-injury in the ipsilateral hippocampus of male
and female mice, respectively, and in the contralateral hippocampus of female mice with
Pro-NP™ treatment at 3 d post-injury. Trending reduction of acrolein with Pro-NP™
treatment at 1 d post-injury was observed in the ipsilateral hippocampus of male mice,
and at 3 d post-injury in female mice. We also observed a trending increase in 4-HNE
and acrolein in the contralateral hippocampus of the untreated male CCI mice, and a
trending reduction with Pro-NP™ treatment, at 1 d post-injury. However, we found
trending increase in acrolein with Pro-NP™ treatment at 7 d post-injury in the ipsilateral
cortex and hippocampus of male and female mice, compared to the untreated male and
female CCI mice. At 7 d post-injury, we also observed a trending increase in acrolein in
the contralateral cortex of untreated and Pro-NP™ treated male and female CCI mice.
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Figure 5-4. Analysis of carbonyl stress in the hippocampus. Western blot of 4-HNE and acrolein
in the ipsi- (a,b) and contralateral (c,d) hippocampus for male (a,c) and female (b,d) mice at 1, 3,
and 7 d post-injury. Representative blot of 4-HNE (a1,b1,c1,d1) and acrolein (a3,b3,c3,d3) in the
ipsilateral and contralateral hippocampus. The boxed area represents the ROI for quantification.
Quantification of 4-HNE (a2,b2,c2,d2) and acrolein (a4,b4,c4,d4) in the ipsilateral and
contralateral hippocampus normalized to β-actin. Data are shown as mean ± SD with n = 3 for
each treatment group. * and # indicate a significant increase compared to the control group and a
significant decrease compared to the untreated CCI group, respectively, with one, two, and three
symbols indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as determined by two-way
ANOVA and Tukey’s post hoc test.
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5.4.5

Time course of α-spectrin degradation progression in male and female mice
following TBI

Figure 5-5. Analysis of α-II-spectrin breakdown products (SBDPs) in the cortex. Western blot of
α-II-spectrin breakdown products (SBDPs) in the ipsi- (a,b) and contralateral (c,d) cortex for male
(a,c) and female (b,d) mice at 1, 3, and 7 d post-injury. (a,b,c,d) Representative blot of SBDPs in
the ipsilateral and contralateral cortex. Quantification of 150 kDa SBDP (proportional to total cell
death) (a1,b1,c1,d1), 145 kDa SBDP (proportional to necrosis) (a2,b2,c2,d2), and 120 kDa SBDP
(proportional to apoptosis) (a3,b3,c3,d3) normalized to β-actin, respectively. Data are shown as
mean ± SD with n = 3 for each treatment group. * and # indicate a significant different compared
to the control group and the untreated CCI group, respectively, with one, two, and three symbols
indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as determined by two-way ANOVA
and Tukey’s post hoc test.
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As we found reduction in DHE and some reductions in LPOx with Pro-NP™
treatment following TBI, we investigated if these reductions would correlate with the
reduction in cell death following TBI. α-II-spectrin breakdown products (SBDPs) have
been used as the marker of necrosis and apoptosis since the size of SBDPs are separated
based on the cell death pathways. SBDPs can be degraded by caspase degradation
pathway (apoptosis, 120kDa), calpain degradation pathway (necrosis, 150 kDa), and
calpain and caspase degradation pathways (total cell death, 150 kDa). Previous study
found that the highest elevation of SBDPs is in the subacute phase of injury [276]. Thus,
Western blot of SBDPs were performed at 1, 3, and 7 d post-injury for the ipsi- and
contralateral cortex and hippocampus (Figure 5-5–6).
We observed significant increases in 150 kDa at 1 and 3 d post-injury in the
ipsilateral cortex of male mice, and at 1 and 7 d post-injury in female mice. We observed
significant increase in 145 kDa at 1, 3, and 7 d post-injury in the ipsilateral cortex and
hippocampus of male mice. We also observed a significant increase in 150 and 145 kDa
at 1 d post-injury in the contralateral cortex of male mice. In the ipsilateral hippocampus,
we observed significant increase in 150 kDa at 3 d post-injury in male and female mice.
In the contralateral hippocampus, we observed a significant increase in 145 kDa at 1 and
7 d post-injury in male mice, and 150 and 145 kDa at 3 d post-injury in female mice.
We observed a significant reduction in 150 kDa with Pro-NP™ treatment at 3 d
post-injury in the ipsilateral cortex of male mice, as well as bilaterally in the
hippocampus of female mice. We also observed significant reductions in 145 kDa with
Pro-NP™ treatment at 1 d post-injury bilaterally in the cortex of male mice, as well as in
the contralateral hippocampus of male mice at 1 d post-injury. However, we did not
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observe a significant reduction in 145 kDa with Pro-NP™ treatment in female mice. We
found significant reduction in 120 kDa with Pro-NP™ treatment in the ipsilateral
hippocampus of male mice at 1 and 7 d post-injury and female mice at 3 d post-injury.
Interestingly, we observed increases in 150 kDa with Pro-NP™ treatment at 1, 3, and 7 d
post-injury bilaterally in the cortex and hippocampus of male mice.

Figure 5-6. Analysis of α-II-spectrin breakdown products (SBDPs) in the hippocampus. Western
blot of α-II-spectrin breakdown products (SBDPs) ipsi- (a,b) and contralateral (c,d) hippocampus
for male (a,c) and female (b,d) mice at 1, 3, and 7 d post-injury. (a,b,c,d) Representative blot of
SBDPs in the ipsilateral and contralateral cortex. Quantification of 150 kDa SBDP (proportional
to total cell death) (a1,b1,c1,d1), 145 kDa SBDP (proportional to necrosis) (a2,b2,c2,d2), and 120
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kDa SBDP (proportional to apoptosis) (a3,b3,c3,d3) normalized to β-actin, respectively. Data are
shown as mean ± SD with n = 3 for each treatment group. * and # indicate a significant increase
compared to the control group and the untreated CCI group, respectively, with one, two, and three
symbols indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as determined by two-way
ANOVA and Tukey’s post hoc test.

5.5

Discussion
The burst release of reactive oxygen species (ROS) occurs immediately following

TBI. The ROS oxidize DNA, lipid, and proteins, which induce more cell death and
release of ROS. Previous studies found that mitochondrial oxidative stress damage peaks
at 12 h post-injury [80], and cellular oxidative stress damage peaks around 24 h postinjury (Figure 5-3–6). Therefore, the combination of burst and sustained release was
expected to improve the ROS scavenging activity in TBI and reduce the progression of
secondary injury. In this study, we utilized Pro-NP™, an SOD and CAT encapsulated
PLGA-based NP, with burst released within an hour of administration and sustained
release for more than 24 h post-injection (Table 5-1) [267, 268].
Based on the results from clinical trials [277], the treatment window for TBI is
around 4 hours, in which the TBI treatment would give a significant benefit. However,
the lack of benefit in the clinical trial might be caused by the small molecule drugs that
were employed, in which the accumulation of small molecule drugs decreases later than 3
h post-injury [4, 278]. Previous studies showed that 10–40 nm NPs are desirable in
accumulating in the injured brain, especially when administered several hours post-injury
[5, 131, 132, 181]. However, NPs with the size of up to 800 nm were found to
accumulate in the injured brain [132, 181, 222]. Our previous study also showed the
accumulation of Pro-NP™-Gd in the brain lesion when injected at 3 h post-injury, which
was more than the accumulation of small molecules in the brain lesion [4]. Here, we
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found the highest accumulation of Pro-NP™-Gd when injected immediately following
injury, and significantly reduced with delayed administration of Pro-NP™-Gd (Figure
5-1). We also found the downward trend of accumulation with delayed administrations,
which is in agreement with the 100 nm PEGylated-polystyrene NPs in the previous study
by Bharadwaj et al. [181]. However, we observed significantly higher accumulation in
the brain lesion compared to the contralateral hemisphere at 24 h post-injury in male CCI
mice, as found by Bharadwaj et al. with 500 nm NP [181]. We found insignificantly
higher Ktrans of Pro-NP™-Gd in male mice than in female mice at any time point, which
corroborates with the finding of Bharadwaj et al. [131] with HRP and 40 nm PEGylatedpolystyrene NPs when injected immediately following the injury. However, Bharadwaj et
al. found that females have a higher accumulation of HRP and NPs when administered 24
h post-injury [131]. The difference between our findings and Bharadwaj et al. might be
caused by the 200 nm non-PEGylated NP that we employed in the study. Previous studies
showed that BBB disruption plays a huge role in the accumulation of NPs in the brain
lesion [132], and female CCI mice have less BBB disruption than male mice [279]. Thus,
less BBB disruption in female mice might lead to a significant reduction in the trend of
Ktrans of female mice although there was no significant difference between the Ktrans of
female and male mice at individual time points. Less BBB disruption in female mice
might also lead to a similar accumulation of 200 nm NPs into the brain lesion of female
mice than male mice at 24 h post-injury. On the other hand, 10–40 nm macromolecules
and NPs were small enough to pass through the disrupted BBB in female mice more than
male mice at 24 h post-injury, as found by Bharadwaj et al. [131]. Another possible
reason is that we utilized Ktrans to measure the accumulation of NPs rather than
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quantifying the NPs left behind following a perfusion, which was employed by
Bharadwaj et al. [131, 181].
Suboptimal dosing of antioxidants was found to reduce the effectiveness of
antioxidants treatment [229, 280-288]. SOD, one of the enzymes encapsulated in ProNP™, was also found to aggravate the injury when administered at higher concentrations
[254, 255, 282]. Therefore, the therapeutic window of Pro-NP™ is important and studied
here to give the best performance in reducing oxidative stress following TBI. We found
that 4.5:4.9 and 4.5:9.8 x103 U/kg SOD:CAT-Pro-NP™ treatment gave the largest
reduction in ROS, while 8,500 U/kg SOD-Pro-NP™ and 4,100 U/kg CAT-Pro-NP™
treatments did not show a significant decrease in oxidative stress compared to the
untreated CCI mice (Figure 5-2). The results suggested that the combination of SOD and
CAT was important because scavenging superoxide (O2●-) with SOD may produce excess
H2O2, which fuels the Fenton reaction. Administering CAT without SOD may also be
limited by the availability of H2O2 from O2●-. We chose 4.5:4.9 x103 U/kg SOD:CATPro-NP™ ratio as it was used in a previous study for spinal cord injury [266], and we
found a significant reduction in ROS following TBI. We then measured various
concentrations of 4.5:4.9 SOD:CAT ratio and found 9:9.8 x103 SOD:CAT-Pro-NP™
gave the greatest reduction of oxidative stress in male and female CCI mice. This
concentration of Pro-NP™ is close to 10,000 U/kg SOD and 10,000 U/kg CAT, which
are the common dosages in the preclinical studies and clinical trials [170, 261, 262, 289291]. Indeed, the phase II and III trials of PEG-SOD for TBI also employed 10,000 U/kg
[170, 262].Here, we found that the untreated female CCI mice had slightly higher
oxidative stress than the untreated male CCI mice (p = 0.18), which corroborates with a
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previous study [292]. However, 9:9.8 x103 U SOD:CAT-Pro-NP™ reduced oxidative
stress similarly in males and females, which might be caused by the compensation of the
smaller body mass of female mice than male mice.
LPOx are known as the downstream products of oxidized lipids by ROS [82]. 4HNE and acrolein are two of the most abundant and reactive LPOx aldehydes. The
alkene and aldehyde functional groups of 4-HNE and acrolein readily form covalent
bonds with cysteine and lysine of proteins, respectively [275]. Here, we found that the
LPOx in the untreated CCI mice peaked at 1–3 d post-injury. Previous studies did not
find a significant increase in LPOx in the contralateral cortex and hippocampus [293,
294]. However, we found a significant increase in acrolein at 3 d post-injury in the
contralateral hippocampus of male mice, and a trending increase in acrolein at 7 d postinjury in the contralateral cortex of male and female mice. The increase in acrolein in the
contralateral hippocampus of male mice at 1 and 3 d post-injury might suggest the spread
of excess ROS from the severe CCI injury into the contralateral hippocampus. However,
higher reduced glutathione (GSH) [295], glutathione-S-transferase [296], and catalase
[297, 298] activities in the brain of female mice might have inhibited the spread of ROS
into the contralateral hippocampus at 1 d post-injury in female mice, as was mimicked
with Pro-NP™ treatment in male mice. The increase in acrolein at 7 d post-injury in the
contralateral cortex of male and female mice might have been caused by the spread of
activated astrocytes and microglia into the contralateral hemisphere, as found in our
previous study [112].
Since the excess release of ROS followed by the production of LPOx, the
reduction in ROS with Pro-NP™ treatment in the acute phase of injury should have
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resulted in the reduction in LPOx with Pro-NP™ treatment in the subacute phase of
injury, as found in previous studies [72, 112, 229, 285, 287, 288]. At 1 d post-injury, we
observed significant reduction in 4-HNE with Pro-NP™ treatment in the ipsilateral
hippocampus of male mice, a trending reduction in 4-HNE with Pro-NP™ treatment in
the ipsilateral cortex and hippocampus of female mice, and a trending reduction in
acrolein in the ipsilateral hippocampus of male mice. The reduction of LPOx at 1 and 3 d
post-injury suggest that Pro-NP™ scavenged the ROS from the primary injury and may
give some ROS scavenging activities into several days post-injury, similar to previous
studies [229, 285, 287].
Calpain and caspase-3 are two of the drivers of necrosis and apoptosis cell death
pathways, respectively. Calpain and caspase-3 are activated by elevated intracellular
Ca2+. Calpain and caspase-3 also degraded α-II-spectrin into α-II-spectrin breakdown
products (SBDPs) with two different pathways [299-303]. Following TBI, glutamate
release, the opening of Ca2+ gating NMDA receptor, and Ca2+ voltage-dependent channels
caused an influx of Ca2+ inside the cell and mitochondria [304-307]. The elevated level of
Ca2+ has been suggested to increase ROS production [308], which in return induces more
influx of Ca2+ [308]. In the ipsilateral hemisphere of the untreated CCI mice, SBDPs
peaked at 1–3 d post-injury (Figure 5-5–6). Although previous studies did not find a
significant increase in SBDPs in the contralateral hemisphere following TBI [309-312],
we found a significant increase in SBDPs that peaked at 1 d post-injury in the
contralateral cortex and hippocampus of male mice and 3 d post-injury in the
contralateral hippocampus of female mice. The significant increase of SBDPs in the
contralateral hemisphere might be caused by a more severe CCI, as well as the use of a
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mouse model of TBI rather than a rat model of TBI that was employed in the previous
studies. We found a delay in the rising of necrosis in the contralateral cortex and
hippocampus in female CCI mice compared to male CCI mice. Higher endogenous
antioxidant enzyme activities in the brain of female than male mice [295-298] may cause
the delay of the cell death in the contralateral hemisphere in female mice, which was
mimicked by the Pro-NP™ treatment in male CCI mice. In the contralateral hemisphere
of the Pro-NP™ treated female CCI mice, we did not observe any reduction of necrosis at
3 d post-injury compared to the untreated female CCI mice. However, we found a
significant reduction in total cell death in the contralateral hippocampus and trending
reductions in apoptosis at 3 d post-injury in the contralateral cortex and hippocampus of
the Pro-NP™-treated female CCI mice compared to the untreated female CCI mice.
Thus, suggesting some protection from Pro-NP™ treatment in the female CCI mice in
reducing the spread of ROS into the contralateral hemisphere in the acute phase of injury.
However, Pro-NP™ treatment exacerbated the acrolein production at 7 d postinjury in the ipsilateral cortex and hippocampus, as well as in the contralateral cortex of
male and female CCI mice. Pro-NP™ treatment also increased the 150 kDa SBDP
bilaterally in the cortex and hippocampus in male CCI mice, but not in female mice,
compared to the untreated CCI mice. These findings were unexpected since the increase
in acrolein may indicate an increase in ROS production, which commonly occurs in the
event of neuroinflammation. However, a previous study showed that the endocytosis of
PLGA NPs did not induce pro-inflammatory responses by macrophages [313], which
may also be translatable to microglia in the brain tissue. Pro-NP™ and other PLGA NPs,
also did not show any detrimental outcome for in vitro human neuron cells [269],
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ischemia-reperfusion injury [314], phototoxicity [315], and spinal cord injury [266].
However, none of those studies looked at the neuroinflammation and carbonyl stress in
the brain in the subacute phase of injury. We suspected that the bovine serum albumin
(BSA), which was incorporated in the synthesis of Pro-NP™, may cause the increase in
acrolein and 150 kDa SBDP.
Although albumin infusion showed promising results in the preclinical studies and
clinical trials for ischemia stroke [316, 317], albumin infusion increased mortality rates in
severe TBI compared to saline infusion [318-322]. The real mechanism of albumin in
exacerbating TBI is still unclear, but there was some correlation with the albumin
extravasation in the brain parenchyma and the increase in intracranial pressure [318-320].
BSA might also have induced the activation of astrocytes and microglia [323, 324], the
senescence of astrocytes [325], the transcription of pro-inflammatory cytokines [325], the
production of ROS [324, 326], and the permeabilization of BBB [326]. Infiltrating
peripheral macrophages at 1 d post-injury into the brain [327-329] might have also been
activated by the BSA [330, 331]. Thus, activation of glial cells might have increased the
level of acrolein in the subacute to the chronic phase of injury when the burst release of
antioxidant enzymes subsided. The activation of glial cells and the permeabilization of
BBB might also have induced edema, which increased the intracranial pressure as seen in
the previous study [318-320]. The increase in intracranial pressure might have caused
some axonal damage [332], and thus caused widespread increase in 150 kDa SBDPs in
male mice (Figure 5-5–6). However, astrocytes and microglia are less activated in female
mice than male mice at 1 and 3 d post-injury [97], and thus we did not observe increase
in 150 kDa SBDP in female mice with Pro-NP™ treatment. However, in this study, we
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did not look at the activation of astrocytes, microglia, and macrophages, as well as
increase in intracranial pressure and formation of edema, since our study focused on
assessing the role Pro-NP™ treatment in reducing the oxidative stress markers following
TBI. In the future, looking at the effect of Pro-NP™ with and without BSA and dimethyl
tartrate on the activation of astrocytes and microglia might help to explain the lack of
reduction in LPOx with Pro-NP™ treatment in the subacute to the chronic phase of
injury.

5.6

Conclusion
Excess amount of ROS is released following TBI that induce the spread of ROS

and the cascade of secondary injury. The markers of oxidative damage peak at 1–3 d
post-injury. Therefore, an antioxidant NP with burst and sustained release of SOD and
CAT was utilized in this study. We established the treatment and therapeutic windows of
Pro-NP™ to determine the possibility of delayed administration and the optimum dose of
Pro-NP™ for TBI treatment. We found significant reduction in the accumulation of ProNP™ with delayed administration. Although the accumulation of Pro-NP™ in male and
female mice was similar at individual time points, we found a significantly lower trend of
Ktrans in female mice, which might be caused by less BBB disruption in female mice. The
smaller body mass of female mice might compensate for the higher oxidative stress in
female CCI mice, thus giving a similar reduction in oxidative stress compared to the male
mice. We also found that the untreated female CCI mice produce more oxidative stress
than the untreated male CCI mice. However, the endogenous antioxidant activities in
female mice might reduce the spread of LPOx into the contralateral hippocampus in the
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acute phase of injury, as well as delaying the increase in necrosis to 3 d post-injury in the
contralateral cortex and hippocampus. These findings in female mice were mimicked by
Pro-NP™ treatment in male mice. The reduction in oxidative stress in the acute phase of
injury, the protection of LPOx in the contralateral hemisphere in the subacute phase of
injury, and the delay of cell death in the contralateral hemisphere in the subacute phase of
injury showed that Pro-NP™ treatment provides protection in the spread of secondary
injury into the contralateral hemisphere. However, the components of Pro-NP™ might
need to be adjusted to reduce the elevation of LPOx and cell death in the subacute to the
chronic phase of injury.
Since the accumulation of Pro-NP™ significantly reduced when injected at later
time points, and therapeutic time window of ROS scavengers are limited, Pro-NP™ may
not be ideal for TBI treatment in the clinical situation. Moreover, we did not observe
significant improvement in reducing oxidative stress and biomarkers of secondary injury
with the burst and sustained release of antioxidant enzymes compared to the thioether
bonds of NP1 that might fully be oxidized within 1.5 hours of administration. Therefore,
in the next chapter, we investigated the use of small size NPs with thiol groups that can
scavenge both ROS and LPOx to extend the therapeutic time window.
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CHAPTER 6: ASSESSING TIME-COURSE OF SECONDARY
INJURY MARKERS WITH THERANOSTIC COPOLYMER IN
MALE AND FEMALE MOUSE MODEL OF TBI

6.1

Abstract
Following the primary brain injury, excess reactive oxygen species (ROS) and

lipid peroxidation products (LPOx) are generated and released, causing oxidative stress
damage and neurodegeneration. However, the complicated pathways of secondary injury
and limited target engagement of small molecule drugs to the brain, may have hindered
the success in treating the progression of secondary injury in the clinical trials. Here, we
utilized systemically administered theranostic neuroprotective copolymers (NPC3) that
contains thiol functional groups that rapidly bind and neutralize both ROS and LPOx
following TBI. We reported the accumulation of NPC3 in the brain lesion up to 24 h
post-injury. We also reported the treatment window of NPC3 to find the optimum
concentration of NPC3 to reduce reactive oxygen species (ROS) the most with the least
adverse effect. We found similar accumulation and percentage of ROS scavenging
activity of NPC3 in male and female mice. We also performed the time-course study in
the subacute phase of injury bilaterally in the cortex and hippocampus of male and female
mice for 4-hydroxynonenal (4-HNE), acrolein, and α-II-spectrin breakdown products
(SBDPs). We found that NPC3 treatment reduced oxidative stress following TBI, which
resulted in the reduction of carbonyl stress at 1 d and the protection of cell death in the
contralateral hemisphere in both male and female mice. Therefore, thiol-functional NPC3
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showed promising results in accumulating in the brain, scavenging ROS, and reducing
the spread of carbonyl stresses and cell death to the contralateral hemisphere.

6.2

Introduction
Traumatic brain injury (TBI) is currently divided into two separate injury phases:

primary and secondary. The primary injury occurs at the initial impact from an external
mechanical force [333] that cause axonal shearing, cell membrane disruption, and cell
death. Following the primary injury, a cascade of biochemical derangements, such as the
release of excitatory amino acids, the influx of calcium ions, and the release of oxidative
stress, lead to further cell death and progression of the injury, which is known as
secondary injury. Secondary injury often results in a positive feedback loop, which can
last years to decades post-injury [13, 226-228] and spread to the contralateral hemisphere
[112, 225].
Under physiological conditions, free radicals, such as reactive oxygen species
(ROS), are produced as the byproduct of respiration and are well-balanced by
endogenous antioxidant enzymes. However, following TBI, the elevated release of ROS
induces damage to DNA, proteins, and lipids that manifest through DNA damage, lipid
peroxidation products (LPOx), neuroinflammation, and neurodegeneration [15, 55, 71].
Moreover, endogenous antioxidant enzymes are downregulated after the injury [72-74],
leading to unabated oxidative and carbonyl stress. Thus, ROS and LPOx have become
major therapeutic targets in hopes of improving outcomes following TBI. Several
antioxidant and LPOx inhibitor treatments, including PEG-conjugated superoxide
dismutase, PEG-conjugated catalase, tirilazad, and their combinations, have shown
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promising results in reducing the secondary injury in preclinical studies and Phase I and
II trials [170, 171, 261, 262, 334]. Despite the success in preclinical studies and over 30
clinical trials, no TBI drug treatments passed Phase III trials for FDA approval [7, 15,
224, 263]. The lack of success of TBI clinical trials might be caused not only by patient
variability and biomarker selection, but also by treatment timing and poor target
engagement of therapeutic agents due to low accumulation and retention in the brain.
Nanoparticles (NPs) have emerged as a promising approach for TBI treatment
[112, 204], especially as the blood-brain barrier (BBB) is disrupted following TBI [126,
127, 132]. The size of NPs is ideal for accumulating in brain injury. NPs are small
enough that they can pass through a disrupted BBB, similar to small molecule drugs, but
NPs are large enough to be retained in the injury lesion, unlike small molecule drugs [4,
5]. Therefore, NPs show enhanced permeability and retention in the brain of mouse
models of TBI [4, 5, 74, 132, 133, 181, 218, 222, 230-232]. Higher accumulation and
retention of NPs in the brain injury are expected to increase the target engagement
compared to the small molecule drugs; thus, increasing the therapeutics efficacy to
reduce the spread of secondary injury following TBI. Indeed, we discovered that an ROS
scavenger nanoparticle (NP1) [112] reduced the spread of secondary TBI markers on the
cellular level to the contralateral hemisphere. In order to expand the scavenging beyond
ROS, we developed theranostic neuroprotective copolymers (NPC3) that can target both
ROS and LPOx [204].
NPC3 is equipped with thiol functional groups that readily react with ROS and
LPOx [204, 335, 336]. Thus, NPC3 does not require any additional drug loading, is easily
scaled up, and can be readily modified with targeting ligands or imaging agents (e.g.,
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fluorophores, Gd for MRI, etc.) [5, 203, 204]. NPC3 is also equipped with PEG to
increase biocompatibility and a favorable PK/biodistribution profile. We utilized a severe
controlled cortical impact (CCI) mouse model of TBI [237] to the left cortex to test the
treatment and therapeutic windows of NPC3 following brain injury. In addition, we also
test the ability of NPC3 to reduce ROS, LPOx, and cell death in the acute and sub-acute
phases of injury.

6.3
6.3.1

Methods and Materials:
NPC3 synthesis
20 wt% LIPOMA polymer (NPC3) were synthesized as previously described

[204]. Briefly, O950 (4.00 g, 4.21 mmol), LIPOMA (1.00 g, 3.10 mmol), 3.59 mL of a 25
mg/mL CCC stock in DMAc (90 mg, 0.293 mmol), 410 μL of a 10 mg/mL ABCVA in
DMSO (4.1 mg, 0.015 mmol), DMAc (3.5 g), and 1.15 g of NaBH4 (31 mmol, 10:1 M
ratio) were reacted under argon gas at 70 °C for 24 h. The polymers were dialyzed in
Spectrapor regenerated cellulose dialysis membrane against ethanol for one day followed
by deionized (DI) water for two days, before they were freeze-dried. Gadoliniumconjugated NPC3 (NPC3-Gd) was synthesized by adding GdMA (121 mg, 0.217 mmol)
to NPC3 (1 g, 0.058 mmol CCC), ABCVA (100 μL of a 16.09 mg/mL stock in ethanol),
O950 (0.22 g, 0.232 mmol), and DI water (4.15 mL). We found that NPC3 has a
hydrodynamic size of 9 nm and scavenges around 0.25 μmol ROS and 0.07 μmol LPOx
per mg NPC3.
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6.3.2

Controlled Cortical Impact Mouse Model of TBI
All animal procedures were performed in accordance with the approval of the

University of Nebraska−Lincoln IACUC. Eight to ten-week-old male and female
C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA) were acclimated for three
days prior to the procedures. Mice were anesthetized with 3% isoflurane gas via
inhalation and were maintained at ∼1.5% with a nose cone on a stereotaxic frame (David
Kopf Instruments, Tujunga, CA, USA). The hair of the scalp was removed with Nair
(Church and Dwight Co., Inc., Princeton, NJ, USA), and the scalp was disinfected with a
betadine scrub and isopropanol wipes afterward. Lidocaine (0.05 mL of 5 mg/mL) and
bupivacaine (0.05 mL of 0.3 mg/mL) were applied to the scalp, and buprenorphine SR
(60 µL of 0.5 mg/mL) was given subcutaneously. An approximately 1 cm midline
incision was made on the scalp over bregma. An approximately 2 mm craniectomy was
made in the skull over the left frontoparietal cortex (2 mm anterior and 2 mm left of
lambda) using a surgical trephine drill. A controlled cortical impactor (Hatteras
Instruments, Cary, NC, USA) attached to the stereotaxic frame with a 2 mm convex tip
was used to impact the brain normal to the dura surface at a depth of 2.5 mm and a
velocity of 4 m/s with a dwell time of 80 ms. Any bleeding was controlled, and incisions
were closed using tissue adhesive.

6.3.3

In vivo Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)
In vivo NP assessment consisted of dynamic contrast-enhanced (DCE)-MRI using

a 9.4T MRI system (Varian) was performed to compare accumulation of NPC3 at various
time-points following a TBI. [4, 204, 270] Briefly, mice were induced with about 2%
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isoflurane gas and maintained at a concentration sufficient to achieve 50 to 80 breaths per
minute. Baseline T1 maps were generated using a gradient-echo sequence and the
variable flip angle method with two angles, 10° and 30° [271]. Mice were injected with
100 µL of a 0.5 mM NPC3-Gd solution via tail vein catheter followed by 100 µL PBS to
flush all remaining NP solution. A flip angle of 30° was used for all post-contrast scans,
which occurred for 1 h following injection. TR was between 54 and 84 ms, TE between
2.73 and 4.24 ms, matrix size between 128x128 and 256x256, FOV between 20x20x10
mm3 and 25x25x10 mm3, depending on the experiment. NEX varied with matrix size to
maintain temporal resolution, with 128x128, NEX = 5 for all scans, with 256x256, NEX
= 4 for baseline and 1 for post-contrast scans.
Following serial image acquisition, resulting in about 100 post-contrast scans per
animal, R1, concentration, and Ktrans mapping were performed using a custom MATLAB
script. R1 mapping was performed using the variable flip angle method [272].
Concentration maps were then generated by comparison of baseline R1 maps with
post-contrast R1 maps. Ktrans, the contrast extravasation rate constant, mapping was then
performed using the Patlak model [273, 274].
MATLAB was used to execute a least squares curve fitting routine to calculate
Ktrans for each voxel in the brain.

6.3.4

Dihydroethidium Histological Analysis
The NPC3 group was treated with NPC3 in Dulbecco’s phosphate buffered saline

(DPBS, Thermo Fisher Scientific, Waltham, MA) (0, 0.4, 2, 4, 20, and 40 mg/kg, IV)
immediately after the surgery, while the MnTMPyP group treated with Mn(III)tetrakis(1-
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methyl-4-pyridyl)porphyrin (MnTMPyP, 475872, Sigma-Aldrich, St. Louis, MO) in
DPBS (500 μL of 1 mg/mL, IP) immediately after the surgery. The size of each treatment
group is three mice. A dihydroethidium (DHE, Thermo Fisher Scientific) assay was
performed as previously described with modifications [112, 204, 239]. Briefly, DHE was
dissolved in sterile dimethyl sulfoxide (DMSO) before further dilution in DPBS. DHE
(500 μL of 1.25 mg/mL, IP) into each mouse at 3 h post-CCI. Mice were transcardially
perfused at 1 hour after DHE injection with ice-cold 4% paraformaldehyde (PFA) in 0.1
M phosphate buffer pH 7.5. Brain tissue was collected, trimmed, and fixed in 4%
buffered PFA for 24 h. The brains were moved into 30% sucrose in DPBS for 3 d at 4 °C
for cryoprotection. The brains were then embedded in 2.6% carboxymethylcellulose
(CMC, C4888, Sigma-Aldrich), frozen on dry ice, and sliced coronally at a 15 μm
thickness with cryotome (Leica Biosystems CM1950, Wetzlar, Germany). The brain
slices were laid on poly-L-lysine coated microscope slide (6776215, Epredia, Kalamazoo,
MI), dried overnight at RT, and stored at -80 °C until further steps. Sections were washed
with DPBS 3 times for 5 min each to remove the CMC, followed by water, and had
ProLong™ Gold Antifade Mountant (P4981001, Thermo Fisher Scientific) applied.
Images were acquired with confocal microscopy (Zeiss LSM800, Oberkochen, Germany)
at the excitation wavelength of 488 nm, the emission wavelength of 560-635 nm, and the
5x objective lens magnification. Quantitative fluorescence intensity analysis was
performed with ImageJ software in the lesion and the contralateral hemisphere.
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6.3.5

Western blot
The NPC3 group was treated with NPC3 in DPBS (8 mg/kg, IV) immediately

after the surgery, while the CCI group did not receive any treatment after the surgery.
The control group did not receive any treatment. With the average weight of 25 g for
male mice and 19.6 g for female mice, the average dose of NPC3 administration was 8
mg/kg for male mice and 10.2 mg/kg for female mice. Mice were transcardially perfused
1, 3, and 7 days post-CCI with ice-cold DPBS, brains were extracted, left-right cortex and
hippocampus were separated and flash-frozen in liquid nitrogen and stored at -80 °C until
further steps. Tissues were then lysed in RIPA lysis buffer and 1 mM
phenylmethylsulfonyl fluoride. Protein concentration was measured using Pierce™ BCA
protein assay (Thermo Fisher Scientific). For spectrin breakdown products (SBDPs), 5 μg
of extract protein was resolved by 5-12% SDS-PAGE for spectrin breakdown products
(SBDPs). They were then transferred onto PVDF membranes (Bio-Rad). Membranes
were washed with TBS and were incubated with 3% BLOT-QuickBlocker™ (GBiosciences, St. Louis, MO) in TBS for 1 h RT. The membranes were incubated
overnight at 4 °C with 1:1000 dilution of mouse anti-spectrin alpha chain (MAB1622,
Sigma) and 1:1000 dilution of mouse anti--actin (A5441, Sigma) antibody in TTBS
containing 3% BLOT-QuickBlocker™. Membranes were washed with TTBS before being
incubated for 1 h at room temperature with 1:5000 dilution of HRP-conjugated goat antimouse secondary antibody (Bio-Rad) in TTBS containing 3% BLOT-QuickBlocker™.
Membranes were then washed thrice with TTBS and antibody binding visualized by
chemiluminescence (Clarity Western ECL Substrate, Bio-Rad) and quantified using the
ChemiDoc system running the Image Lab software package (Bio-Rad). For lipid
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peroxidation products (LPOx), 30 μg of extract protein was resolved by 10% SDSPAGE. The membranes were then blocked and incubated with 1:1000 dilution of rabbit
anti-4-HNE (ab46545, Abcam, Cambridge, UK), 1:1000 dilution of mouse anti-acrolein
(ab240918, Abcam), 1:5000 dilution of mouse anti--actin, and 1:3000 dilution of goat
anti-rabbit or anti-mouse secondary antibody in TTBS containing 3% BSA. 1% sodium
azide was added into the blocking buffer in between different markers to deactivate the
HRP, and the membrane was incubated in 1:500 dilution of goat anti-mouse IgG
(ab6708, Abcam) to block the innate mouse IgG before acrolein staining. ROI was drawn
on the whole lane.

6.3.6

Statistical analysis
All the data were displayed as mean ± standard deviation. A p < 0.05 was

considered statistically significant. The Ktrans and DHE quantification were analyzed with
one-way ANOVA and Dunnett’s post hoc test against 0 h ipsilateral for Ktrans, and
untreated CCI mice for DHE. One-way ANOVA and Tukey’s post hoc test was utilized
for Western Blot protein quantification. All statistical analysis was performed with
GraphPad Prism 9 software (GraphPad Software, CA).

6.4

Results
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6.4.1

Identifying the treatment window of NPC3

Figure 6-1. Identifying the treatment window of NPC3. Ktrans of NPC3-Gd in male and female
CCI mouse model of TBI in the lesion and contralateral hemisphere at various time points postinjury. (a) Representative Ktrans maps overlaid on structural images of NPC3-Gd administered at
various time points following CCI in male and female mice. (b) Quantification of Ktrans mapping
in the lesion. NPC3-Gd accumulated in the lesion the most when administered immediately
following the injury (0 h post-injury). Data are shown as mean ± SD with n = 3 for each treatment
group. * indicates a statistical difference compared to 0 h post-injury group, with two and three
symbols indicating p < 0.01 and p < 0.001, respectively, as determined by one-way ANOVA and
Dunnett’s post hoc test.

To evaluate the accumulation and treatment window of the NPC3 in the lesion,
we injected CCI mice with Gd-labeled NPC3 NPs (NPC3-Gd) at various time points in
the acute phase of the injury (up to 24 h) (Figure 6-1). We then took a series of T1 images
before and up to 30 min post-NPC3-Gd injection with MRI and measured Ktrans, a
permeability coefficient that describes the kinetics of the NPs entering the brain from
circulation [4]. We observed the highest accumulation of NPC3-Gd in the lesion when
injected immediately following the injury in both male (mean ± SD = 18.35 ± 4.5 x10-3
min-1) and female (29.29 ± 16.36 x10-3 min-1) mice, followed by 1 and 3 h post-injury
(male: 14.75 ± 4.51 x10-3 min-1 and 13.13 ± 1.05 x10-3 min-1; female: 28.14 ± 15.69 x10-3
min-1 and 13.95 ± 2.12 x10-3 min-1). Although there was a significant reduction in the
accumulation of NPC3-Gd in the lesion at 6 and 24 h post-injury (male: 6.01 ± 0.33 x10-3
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min-1 and 5.62 ± 1.78 x10-3 min-1; female: 5.99 ± 0.33 x10-3 min-1 and 5.46 ± 0.55 x10-3
min-1), we observed that the NPC3-Gd accumulation in the lesion was significantly
higher, even at 24 h post-injury, than the accumulation of NPC3-Gd in the contralateral
hemisphere in female mice (3.77 fold higher, p = 0.0032), but not in male mice (6.23 fold
higher, p = 0.0056) as determined by student t-test.

6.4.2

Identifying the therapeutic window of NPC3

Figure 6-2. Identifying therapeutic window of NPC3 in male and female CCI mouse model of
TBI. In vivo DHE staining of the brains at 4 h post-injury was utilized to measure the ROS level
in the acute phase of injury. (a) Representative images of confocal microscopy with various
concentrations of NPC3 and MnTMPyP following CCI. Scale bar is 1 mm. (b) Quantification of
DHE fluorescence mean intensity in the lesion normalized to the contralateral hemisphere. Data
are shown as mean ± SD with n = 3 for female mice treatment groups, and n = 5 for male mice
treatment groups. * indicates a statistical difference compared to the 0 mg/kg NPC3 group, with
two and three symbols indicating p < 0.01 and p < 0.001, respectively, as determined by one-way
ANOVA and Dunnett’s post hoc test.

Finding the highest accumulation of NPC3 in the lesion when injected
immediately following the injury (0 h time point), we evaluated the treatment window of
NPC3 in scavenging ROS when administered at this time point. We utilized in vivo DHE
staining to measure the ROS level in the lesion and determine ROS reduction following
NPC3 treatment. We injected a series of NPC3 concentrations (0, 0.4, 2, 4, 20, and 40
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mg/kg; 100 µL of 0-10 mg/mL NPC3 in DPBS) through tail vein for both male and
female mice. We measured the DHE fluorescence mean intensity using confocal
microscopy in the lesion and normalized it to the DHE fluorescence mean intensity in the
contralateral hemisphere (Figure 6-2). We observed the highest increase in DHE mean
intensity in the untreated CCI mice (0 mg/kg NPC3) in both male (mean ± SD = 61.7 ±
7.96 % increase) and female (121.9 ± 11.93 % increase) mice. DHE mean intensity was
significantly reduced with 2, 4, and 20 mg/kg NPC3 in male mice (46.44%, 68.02%, and
68.64% decrease, respectively), and 4 and 20 mg/kg NPC3 in female mice (58.04% and
57.19% decrease, respectively) compared to the 0 mg/kg NPC3 group. We observed no
significant reduction in the DHE mean intensity at 40 mg/kg of NPC3 in both males
(30.11% decrease, p = 0.1027) and females (30.39% decrease, p = 0.1374) compared to
the 0 mg/kg NPC3 group. We found that MnTMPyP, a small molecule ROS scavenger
positive control, has similar efficiency in reducing ROS to the NPC3 when injected
immediately following the injury in male and female mice (59% and 64% decrease,
respectively). Thus, we found a treatment window of 2–20 mg/kg in male mice and 4–20
mg/kg in female mice.
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6.4.3

Time course of carbonyl stress in male and female mice following TBI

Figure 6-3. Analysis of carbonyl stress in the cortex. Western blot of LPOx 4-HNE and acrolein
in the ipsi- (a,b) and contralateral (c,d) cortex for male (a,c) and female (b,d) mice at 1, 3, and 7 d
post-injury. (a1,b1,c1,d1) Representative blot of 4-HNE in the ipsilateral and contralateral cortex.
The boxed area represents the ROI used for quantification. (a3,b3,c3,d3) Representative blot of
acrolein in the ipsilateral and contralateral cortex. The boxed area represents the ROI for
quantification. (a2,b2,c2,d2) Quantification of 4-HNE in the ipsilateral and contralateral cortex
normalized to β-actin. (a4,b4,c4,d4) Quantification of acrolein in the ipsilateral and contralateral
cortex normalized to β-actin. Data are shown as mean ± SD with n = 3 for each treatment group.
* and # indicate a significant increase compared to the control group and a significant decrease
compared to the untreated CCI group, respectively, with one, two, and three symbols indicating p
< 0.05, p < 0.01, and p < 0.001, respectively, as determined by one-way ANOVA and Tukey’s
post hoc test.
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As we found the maximum accumulation at 0 h post-injury (Figure 6-1), and the
maximum ROS reduction in between 4-20 mg/kg NPC3 (Figure 6-2), we investigated if
the reduction of ROS would correlate with reduced carbonyl stress following the injury
by measuring two of the most prevalent LPOx following TBI, 4-HNE and acrolein [275].
Thus, we measured the total volume of the 4-HNE-modified proteins, and 25 and 50 kDa
bands for acrolein-modified proteins, with Western blot (Figure 6-3–4). We analyzed
LPOx levels 1, 3, and 7 d post-injury since carbonyl stress has been shown to peak in the
subacute phase of the injury [276].
At 1 d post-injury, we found a significant increase in 4-HNE and acrolein in the
ipsilateral cortex and hippocampus of male CCI mice, as well as a trending increase in
female CCI mice. At 1 d post-injury, we also found a trending increase in acrolein in the
contralateral cortex and hippocampus of male CCI mice. At 3 d post-injury, we found a
significant increase in acrolein and 4-HNE in the ipsilateral cortex and hippocampus of
male CCI mice, as well as 4-HNE in the ipsilateral cortex and hippocampus of female
CCI mice. At 3 d post-injury, we also observed a trending increase in 4-HNE and
acrolein in the ipsilateral cortex and hippocampus of male CCI mice, and acrolein in the
ipsilateral cortex and hippocampus of female CCI mice. At 7 d post-injury, we found a
significant increase in acrolein in the ipsilateral cortex and hippocampus of male CCI
mice, and ipsilateral cortex of female CCI mice. At 7 d post-injury, we also found a
trending and significant increase in acrolein in the contralateral cortex of male and female
CCI mice, respectively, as well as a trending increase in acrolein in the contralateral
hippocampus of female CCI mice.
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We observed a significant and trending reduction in 4-HNE with NPC3 treatment
at 1 d post-injury in male and female mice, respectively, in the ipsilateral cortex and
hippocampus. We observed a trending and significant reduction in 4-HNE with NPC3
treatment at 3 d post-injury in male and female mice, respectively, in the ipsilateral
hippocampus. We also observed trending reduction in acrolein with NPC3 treatment at 7
d post-injury in the contralateral cortex of male mice and contralateral cortex and
hippocampus of female mice, as well as a significant reduction in acrolein in the
ipsilateral cortex of female mice.
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Figure 6-4. Analysis of carbonyl stress in the hippocampus. Western blot of 4-HNE and acrolein
in the ipsi- (a,b) and contralateral (c,d) hippocampus for male (a,c) and female (b,d) mice at 1, 3,
and 7 d post-injury. (a1,b1,c1,d1) Representative blot of 4-HNE in the ipsilateral and contralateral
hippocampus. The boxed area represents the ROI for quantification. (a3,b3,c3,d3) Representative
blot of acrolein in the ipsilateral and contralateral hippocampus. The boxed area represents the
ROI for quantification. (a2,b2,c2,d2) Quantification of 4-HNE in the ipsilateral and contralateral
hippocampus normalized to β-actin. (a4,b4,c4,d4) Quantification of acrolein in the ipsilateral and
contralateral hippocampus normalized to β-actin. Data are shown as mean ± SD with n = 3 for
each treatment group. * and # indicate a significant increase compared to the control group and a
significant decrease compared to the untreated CCI group, respectively, with one, two, and three
symbols indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as determined by one-way
ANOVA and Tukey’s post hoc test.
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6.4.4

Time course of α-spectrin degradation in male and female mice following TBI

Figure 6-5. Analysis of α-II-spectrin breakdown products (SBDPs) in the cortex. Western blot of
α-II-spectrin breakdown products (SBDPs) in the ipsi- (a,b) and contralateral (c,d) cortex for male
(a,c) and female (b,d) mice at 1, 3, and 7 d post-injury. (a,b,c,d) Representative blot of SBDPs in
the ipsilateral and contralateral cortex. Quantification of 150 kDa SBDP (proportional to total cell
death) (a1,b1,c1,d1), 145 kDa SBDP (proportional to necrosis) (a2,b2,c2,d2), and 120 kDa SBDP
(proportional to apoptosis) (a3,b3,c3,d3) normalized to β-actin, respectively. Data are shown as
mean ± SD with n = 3 for each treatment group. * and # indicate a significant increase compared
to the control group and a significant decrease compared to the untreated CCI group, respectively,
with one, two, and three symbols indicating p < 0.05, p < 0.01, and p < 0.001, respectively, as
determined by one-way ANOVA and Tukey’s post hoc test.

Finding that NPC3 treatment significantly reduced ROS that tended to reduce
LPOx following brain injury, we investigated if these reductions correlated with reduced
cell death following brain injury. We analyzed cell death through the necrosis and
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apoptosis pathways using Western blot of α-II-spectrin breakdown products (SBDPs) to
separate SBDPs based on size that corresponds to apoptosis (caspase degradation
pathway, 120 kDa), necrosis (calpain degradation pathway, 145 kDa), and total cell death
(caspase and calpain degradation pathways, 150 kDa). We chose 1, 3, and 7 d post-injury
to measure SBDPs as SBDPs are most elevated in the subacute phase of the injury [276].
In the ipsilateral cortex (Figure 6-5A&B), we observed a significant reduction in total cell
death with NPC3 treatment at 3 d post-injury and necrosis at 1 and 3 d post-injury in
male mice.
We found significant and trending increases in 150 and 145 kDa at 1, 3, and 7 d
post-injury in the ipsilateral cortex and hippocampus of male and female CCI mice,
except the 145 kDa in the ipsilateral cortex and 150 and 145 kDa in the ipsilateral cortex
and hippocampus of female CCI mice at 7 d post-injury. We also observed a significant
increase in 150 and 145 kDa in the contralateral cortex, as well as a trending increase in
145 kDa in the contralateral hippocampus, in male CCI mice at 1 d post-injury. We
observed a significant increase in 145 kDa in the contralateral cortex and hippocampus of
female CCI mice at 1 and 3 d post-injury. We found a significant increase in 145 kDa in
the contralateral hippocampus of female CCI mice at 3 and 7 d post-injury.
We did not observe any significant reduction in cell death with NPC3 treatment in
the ipsilateral cortex and hippocampus of female mice, except in the ipsilateral
hippocampus at 3 d post-injury. We observed a significant decrease in 150 kDa with
NPC3 treatment in the ipsilateral cortex and hippocampus of male CCI mice at 3 d postinjury, and in the ipsilateral hippocampus at 7 d post-injury. We also observed a
significant decrease in 145 kDa with NPC3 treatment in the ipsilateral cortex at 1 d post-
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injury. In the contralateral cortex, we observed a significant reduction in 150 and 145
kDa with NPC3 treatment at 1 d post-injury in male mice, and 145 kDa at 1 d post-injury
in female mice. We also observed a trending and significant decrease in 145 kDa with
NPC3 treatment at 1 and 7 d post-injury, respectively, in the contralateral hippocampus
of male mice. At 3 d post-injury, a slight reduction in 145 kDa with NPC3 treatment was
observed in the contralateral cortex and hippocampus of female mice.

Figure 6-6. Analysis of α-II-spectrin breakdown products (SBDPs) in the hippocampus. Western
blot of α-II-spectrin breakdown products (SBDPs) in ipsi- (a,b) and contralateral (c,d)
hippocampus for male (a,c) and female (b,d) mice at 1, 3, and 7 d post-injury. (a,b,c,d)
Representative blot of SBDPs in the ipsilateral and contralateral cortex. Quantification of 150
kDa SBDP (proportional to total cell death) (a1,b1,c1,d1), 145 kDa SBDP (proportional to
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necrosis) (a2,b2,c2,d2), and 120 kDa SBDP (proportional to apoptosis) (a3,b3,c3,d3) normalized
to β-actin, respectively. Data are shown as mean ± SD with n = 3 for each treatment group. * and
#
indicate a significant increase compared to the control group and a significant decrease
compared to the untreated CCI group, respectively, with one, two, and three symbols indicating p
< 0.05, p < 0.01, and p < 0.001, respectively, as determined by one-way ANOVA and Tukey’s
post hoc test.

6.5

Discussion
Theranostic neuroprotective copolymers (NPC3) with thiol functional groups

showed scavenging activity of H2O2 and alkene group of LPOx [204]. Thiol functional
groups are also known to react with peroxynitrite and nitric oxide [201, 337, 338]. Thus,
NPC3 expands the scavenging activity compared to the NP1 and Pro-NP™, which only
scavenges ROS through thioether bonds [112, 203] and antioxidant enzyme [267, 268],
respectively.
Treatment window, also known as therapeutic time window, is defined as a period
of time that a treatment would give a significant benefit. The treatment window for TBI is
around 4 h post-injury, based on the results from clinical trials [277]. However, the
treatment window in the clinical trials might be limited due to the low accumulation and
target engagement of small molecule drugs in the injured brain when administered later
than 4 h post-injury [4, 278]. Here, treatment window is performed to study the drug dose
and bioavailability of NPC3 in the brain lesion at various time points post-injury. Our
Ktrans findings corroborate with previous studies, in which the accumulation of NPs is the
highest when administered immediately following the injury [181], and less accumulation
of NPs in the lesion when administered later than 3 h post-injury [4, 131, 132]. We found
similar accumulation of 9 nm NPC3 when administered at 0, 1, and 3 h post-injury,
compared to the decrease in the accumulation of 20, 40, 100, and 500 nm PEGylated-NPs
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in the previous study [181] and 200 nm non-PEGylated Pro-NP™ (Figure 5-1).
Therefore, the small size of NPC3 might give a similar scavenging capability in the
lesion when injected immediately and 3 h post-injury. However, NPC3 might need to be
functionalized with targeting ligands, such as CAQK peptide to improve the
accumulation in the lesion at 6 and 24 h post-injury [184]. 6 and 24 h time-points are
important in delivering antioxidant NP, as almost 50% of TBI patients arrived at the
hospital more than 4 h post-injury [339] and oxidative stress damage peaked at 24 h postinjury, as shown by LPOx and SBDPs in Figure 6-3–6.
We did not observe a noticeable difference in the accumulation of NPs in the
lesion between males and females at 24 h post-injury, as supported by a previous study
with Evans Blue dye [278]. However, Bharadwaj et al. [131] found significantly less
HRP and 40 nm PEGylated-polystyrene NP accumulation in the ipsilateral cortex of male
mice compared to the female mice. The discrepancy between our results and those of
Bharadwaj et al. may be caused by how we assessed the NP accumulation. In this study,
we utilized Ktrans, which measures the changes of NPC3-Gd from the blood into the lesion
over a period of 30 minutes, rather than measuring the HRP and NPs left behind after the
perfusion as Bharadwaj et al. did. Another possible cause was that Bharadwaj et al.
employed a more severe CCI than we did. Since we have a similar Ktrans value of NPC3
between male and female mice, any discrepancy in the NPC3 treatment between males
and females was not due to a difference in the accumulation of NPs in the brain.
However, in this study we did not perform delayed administration of NPC3 as we are
focusing on the effect of NPC3 in the progression of secondary injury in TBI.
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The therapeutic window is essential in the antioxidant treatment since previous
studies found the bell-shaped response curve of antioxidant treatment in TBI, in which
suboptimal dosing of antioxidants would give a suboptimal reduction in oxidative stress
or even exacerbate the injury progression [229, 280-288]. Therefore, the therapeutic
window of NPC3 was studied here to find the optimum dose of NPC3 in scavenging
ROS, which we found to lie in between 4–20 mg/kg NPC3 in both male and female mice.
We found a greater reduction in oxidative stress in male mice (68%) compared to female
mice (58%) with NPC3 treatment. The higher reduced glutathione (GSH)- in the brain
mitochondria of female mice compared to male mice [295] might compete with the
reaction rate between free radicals and NPC3 in female mice since GSH has the same
functional group as NPC3. However, we found a negative return in ROS scavenging
above 20 mg/kg NPC3. This might be caused by the cytotoxicity of NPC3, as shown in
vitro with SH-SY5Y neuron cells [204]. We found that NPC3 concentrations greater than
1 mg/mL decreased cell viability of SH-SY5Y neuron cells, while NPC3 concentrations
greater than 2.5 mg/mL resulted in nearly complete cell death. We chose 8 mg/kg NPC3
for male and female mice as the middle point for measuring LPOx and SBDPs reduction
with NPC3 treatment. Compared to our previous study with NP1 [112], 8 mg/kg NPC3
only scavenges around 1/20 ROS that was scavenged by 4 mg/kg NP1, but we observed a
similar reduction in oxidative stress with NPC3 treatment compared to NP1 treatment
(68% reduction in females). The multiple scavenging activities of thiol groups, such as
ROS, reactive nitrogen species, and lipid radicals, might be more effective in mitigating
the secondary injury cascade compared to ROS-only scavenger with thioether bonds of
NP1. Similarly, NPC3 treatment also reduced more oxidative stress in male mice
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compared to Pro-NP™ although the accumulation of Pro-NP™ into the brain lesion was
higher than NPC3. Oxidized thiol groups on NPC3 may also be reduced by glutathione
and glutathione reductase. Thus, NPC3 may be able to reuse the thiol groups, which
translate to higher scavenging capacity of NPC3 in vivo than in vitro. In the future,
administering NPC3 a few hours following the injury and measuring the reduction of
LPOx following NPC3 administration might allow us to measure the LPOx scavenging
capability of NPC3 in TBI, which is more commonly available in the acute phase of
injury [55].
Following a TBI, excess ROS oxidize lipids and form lipid radicals, which are
degraded into lipid peroxidation products (LPOx). 4-HNE and acrolein are two of the
most abundant and reactive LPOx aldehydes, and readily form covalent bonds with
cysteine and lysine of proteins [275]. In the untreated CCI mice, we observed LPOx
peaked at 1–3 d post-injury (Figure 6-3–4). Similar to previous studies [293, 294], we did
not find a significant increase in LPOx in the contralateral cortex and hippocampus of the
untreated CCI male and female mice at 1 and 3 d post-injury, except at 3 d post-injury in
the contralateral hippocampus of male mice. We also found a trending increase in
acrolein at 1 d post-injury in the contralateral cortex and hippocampus of male mice. The
difference between our study and previous studies was that we employed a mouse model
of TBI than a rat model of TBI. We also employed a more severe CCI injury compared to
the previous studies. Therefore, our results suggested that LPOx were more likely to
spread into the contralateral hemisphere in a severe CCI mouse model of TBI. At 7 d
post-injury, we found a trending and significant increase in acrolein in the contralateral
cortex of male and female mice, respectively, that have not been studied. The increase in
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M1 microglia and astrocytes population at 7 d post-injury [97, 99], which release free
radicals and pro-inflammatory markers, might induce the increase in acrolein in the
contralateral cortex at 7 d post-injury.
Since we found a reduction in ROS with NPC3 treatment in the acute phase of
injury, we expected to see the reduction in LPOx in the subacute phase of injury, as found
in the previous studies [72, 112, 229, 285, 287, 288]. Here, we found reductions of 4HNE with NPC3 treatment at 1 d post-injury in the ipsilateral cortex and hippocampus of
male and female mice, similar to the previous study with antioxidant treatments [229,
285, 287]. However, there was a minimal reduction of LPOx-modified proteins with
NPC3 treatment at 3 d post-injury in the ipsilateral cortex and hippocampus, except in the
ipsilateral hippocampus of female mice, which might be caused by NPC3 treatment did
not completely scavenge all of the excess ROS (Figure 6-2). Therefore, the remaining
ROS continued the secondary injury cascade, especially as we observed some delays in
the elevation of 4-HNE from 1 d to 3 d post-injury in the ipsilateral cortex and
hippocampus of male and female mice, similar to the elevation of LPOx in a milder CCI
injury [83, 276]. The minimal reduction of LPOx with NPC3 treatment at 3 d post-injury
might also be contributed to the absence of NPC3 at more than 1 d post-injury. The
reaction between NPC3 with ROS and LPOx occurs within minutes following the NPC3
administration as the thiol group is reactive [204]. In addition, we expect a brain retention
half-life of around 14 hours, similar to that of ORP with the size of 8 nm [5]. Therefore,
we do not expect NPC3 to scavenge and reduce LPOx in the subacute phase of injury.
Multiple administration of NPC3, such as at 0, 6, 12, and 24 hours post-injury, might be
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an ideal future study as studied in Cyclosporine A, LPOx inhibitors, and LPOx
scavengers [83, 147, 177, 283, 340].
Interestingly, we found a trending reduction in acrolein with NPC3 treatment at 1
and 7 d post-injury in the contralateral cortex and hippocampus of male and female mice,
while we saw increase in acrolein at 7 d post-injury with Pro-NP™ treatment (Figure
5-3–4). The trending reductions in acrolein and 4-HNE with NPC3 treatment at 1 d postinjury in the contralateral hippocampus of male mice suggest that the ROS scavenging
activity of NPC3 mitigated the spread of ROS to the contralateral hippocampus. On the
other hand, higher GSH [295], glutathione-S-transferase [296], and catalase [297, 298]
activities in the brain of females than males might have mitigated the spread of the ROS
into the contralateral hippocampus at 1 d post-injury, even though untreated female CCI
mice had a higher oxidative stress level than the male CCI mice (Figure 6-2). At 7 d postinjury, the trending reductions in acrolein with NPC3 treatment in the contralateral cortex
of male and female mice might suggest that NPC3 treatment reduced the spread of
activated astrocytes and microglia, as well as neuroinflammation, into the contralateral
hemisphere in the chronic phase of injury, which corroborate with our previous study at 1
month post-injury with NP1 treatment [112].
Ca2+ influx into brain cells is a well-known phenomenon following brain injuries,
which can be caused by the glutamate release, as well as the opening of Ca2+ gating
NMDA receptor and Ca2+ voltage-dependent channels [304-307]. ROS may increase the
Ca2+ intake into the mitochondria following a TBI [308]. The elevated level of Ca2+ has
also been suggested to increase ROS production [308], as well as activation of calpain
and caspase-3. Calpain and caspase-3 drive necrosis and apoptosis cell death pathways,
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respectively, which also degraded α-II-spectrin in two different pathways [299-303]. In
the ipsilateral hemisphere of untreated CCI mice, SBDPs peaked at 1–3 d post-injury
(Figure 6-5–6), similar to previous studies [44, 309-312, 341]. Previous studies [309-312]
found no significant increase in SBDPs in the contralateral cortex and hippocampus
following TBI. However, here, we found a significant increase in total cell death and
necrosis in the contralateral hemisphere of the untreated CCI mice, which peaked at 1 d
post-injury in male mice and 3 d post-injury in female mice. The difference between our
study and previous studies were that we used a mice model of TBI, instead of a rat model
of TBI, and a faster and deeper CCI than the previous studies. The delay in the rise of
necrosis in the contralateral hemisphere of female mice to 3 d post-injury compared to 1
d post-injury in male mice may be caused by the higher endogenous antioxidant enzyme
activities in the brain of female mice [295-298]. The delay in the elevation of necrosis to
3 d post-injury in the contralateral hemisphere was also observed in the NPC3 treated
male CCI mice, which suggest a protection of cell death by NPC3 treatment in the
contralateral hemisphere of male CCI mice. NPC3 treatment also reduced necrosis in the
contralateral cortex of female CCI mice. Unlike Pro-NP™ treatment, we did not see
increase in 150 kDa SBDP in the NPC3-treated male CCI mice compared to the untreated
male CCI mice. Therefore, NPC3 treatment may not induce intracranial pressure as ProNP™.
However, NPC3 treatment did not significantly reduce SBDPs in the ipsilateral
cortex and hippocampus of the female CCI mice, and the ipsilateral hippocampus of the
male CCI mice. The failure to reduce the SBDPs may suggest that NPC3 did not reduce
enough oxidative stress to reduce the Ca2+ overload, which induced more ROS and

118
cytoskeletal degradation. Ca2+ released from the endoplasmic reticulum in the event of
matrix deprivation and cytoskeletal changes due to detachment may also limit the
effectiveness of NPC3 in reducing cell death in the ipsilateral cortex and hippocampus
[342, 343]. The increase in SBDPs due to mechanical disruption was also supported by
lack of correlation between the reduction in 4-HNE and SBDPs with NPC3 treatment in
the ipsilateral cortex and hippocampus of the male and female CCI mice at 1 d postinjury. On the other hand, minimum matrix disruption from CCI in the contralateral
cortex and hippocampus, and enough ROS scavenging by NPC3 treatment, may reduce
the necrosis at 1 d post-injury in male mice and 3 d post-injury in female mice. In the
future, a milder CCI mouse model of TBI with less necrosis and cavity [45] may provide
a better result in looking at SBDPs in the ipsilateral hemisphere.
Another limitation of this study was that we did not synchronize and check for the
estrous cycle in female mice since some studies showed minimal correlation between
estrous cycle and TBI outcomes [278, 344]. Indeed, our results also showed similar
individual variabilities in males and females, especially in the subacute phase of injury.
However, progesterone and estrogen play roles in neuroprotection and antioxidant
activities [345-349]. All of the 0 mg/kg female mice and two of the 4 mg/kg female mice
came from the same cohort and confinement, and there is a possibility that 5 out of 6
unsynchronized female mice were in the same stage of estrous cycle [350]. Therefore,
there is a possibility that they were all in the estrus stage at the time of the injury, when
progesterone and estrogen were at the lowest, which may lead to higher increase in
oxidative stress compared to the untreated female CCI mice in the Pro-NP™ study
(Figure 5-2). In the future, synchronizing and examining the estrous cycle may be
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important in determining the oxidative stress in the acute phase of injury, but may not be
important when measuring the biomarkers in the subacute phase of injury.

6.6

Conclusion
TBI has been associated with elevated free radicals, LPOx, and cell death. To

reduce secondary injury progression following TBI, an ROS and LPOx scavenger NP
was developed. In this study, we established the treatment and therapeutic windows of
NPC3 to determine the possible time and dose of administrations of NPC3, as shown by
the Ktrans and in vivo DHE assay. From Ktrans, there is no significant reduction in NPC3’s
accumulation in the brain lesion up to 3 h post-injury, and there is no significant
difference in the BBB permeability between male and female mice up to 24 h post-injury.
Female CCI mice produced more oxidative stress than male CCI mice. However, there
was a delayed increase in necrosis in the contralateral cortex and hippocampus of female
CCI mice, which is mimicked by NPC3 treatment in male CCI mice. The reduction in
oxidative stress in the acute phase of injury, the delay of LPOx elevation in the ipsilateral
hemisphere in the subacute phase of injury, and the reduction of LPOx and cell death in
the contralateral hemisphere in the subacute phase of injury showed that NPC3 provides
some protection in TBI. Although NPC3 may need multiple injections to reduce more
oxidative stress, carbonyl stress, and cell death, NPs with thiol groups are great
candidates for TBI treatment. Thus, active targeting might be needed to improve the
accumulation of NPC3 in the brain lesion at 6 and 24 h post-injury.
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CHAPTER 7: ACTIVE TARGETING AND TRANSPORT
Part of the work presented in this chapter has been previously published and is reprinted
with permission from Nanoparticles for Biomedical Applications, Tarudji, A.W., and
Kievit, F.M., Active targeting and transport, 2020, p.19-36, Copyright © 2020, Elsevier,
doi: https://doi.org/10.1016/B978-0-12-816662-8.00003-5 [178]

7.1

Abstract
Actively targeted nanoparticles (NPs) are founded on the ability of ligands to bind

with a surface marker of a target cell or tissue. Unlike passively targeted NPs that depend
solely on the leakiness of blood vessels and passive diffusion, actively targeted NPs bind
to target cells, allowing better distribution in target tissue, higher internalization into
target cells, accumulation on circulating neoplastic cells, and passage across
semipermeable barriers. Despite the many potential advantages of actively targeted NPs,
there are no currently approved actively targeted NPs used clinically. This chapter
focuses on the chemical interactions of actively targeted NPs with their target, the
differences between commonly used ligands for actively targeted NPs and associated
challenges, and the various diseases that have been studied using actively targeted NPs.

7.2

Introduction
Active targeting is often used to increase the delivery rate, accumulation, and

retention of the NPs inside the targeted tissue, which allows better drug release and more
effective drug delivery. However, active targeting should not be thought of as actively
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seeking out target tissue as with a heat-seeking missile. Rather, actively targeted NPs still
fully distribute throughout the body but only accumulate and are retained more efficiently
in target tissues as with walking along a beach scattered with landmines where the
landmine only goes off when contacted. More importantly, active targeting increases the
selectivity of internalization and endocytosis by specific cells, improves target tissue
distribution, and increases the permeability of biological membranes by targeting an
active transporter of the barrier (e.g., blood–brain barrier [BBB] and blood–testes barrier)
[351-357]. This has been shown in various elegant studies with tumor targeting where
total tumor accumulation was not affected by the presence of a targeting agent on the
surface of the NP, but the targeting agent did enhance distribution throughout the tumor
as well as intracellular delivery [358-361]. Moreover, since actively targeted NPs do not
solely depend on EPR, actively targeted NPs allow targeting of hematological
malignancies [362, 363], small metastatic tumors [364], neurodegenerative disorders
[365-367], and other diseases that do not show the EPR effect.
The nanosize of NPs (typically 5–200 nm) results in an extraordinarily high surfacearea-to-volume ratio, which can lead to upward of a square meter of surface area per
milligram of NP. The high surface-area-to-volume ratio allows for relatively large
quantities of active targeting ligands to be conjugated or adsorbed onto the NP surface.
Targeting ligands in close proximity to one another on the NPs surface can lead to a
higher binding affinity to target cells through the multivalent effect, where the binding
strength between NPs and targeted tissue is stronger than individual ligands to the tissue
[368, 369]. The concentration of ligands mounted on the NPs affects the total affinity
binding of ligands. For example, Poon et al. showed that there is a decrease in the
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dissociation constant, KD, indicating an increase in binding affinity, when there are more
folates on the surface of the NPs [369]. Additionally, Hong et al., found a similar
multivalent effect using generation-5 dendrimers conjugated with folic acid, where an
increase of up to 15,200-fold was observed when compared to the KD of free folic acid
binding [370]. However, there appears to be a limit to this multivalent effect. As ligand
concentration on the surface of the NP is too concentrated, steric binding interference
begins to prevent binding of targeting ligand to antigen resulting in reduced binding
affinities [369].
Despite extensive research with actively targeted NPs, there has not been any active
targeting NP system used clinically. Some have shown safety and efficacy in Phase I and
Phase II trials, but none have passed large, multi-center Phase III trials [371]. In this
chapter, we describe the physical phenomena behind active targeting mechanisms and
place them within the context of actively targeted NPs. We provide examples of how
these different strategies are used for active targeting of NPs to various diseases.

Table 7-1. Various types of binding energy between two molecules in a solution.

Bond

Energy

Length of

(kJ/mol) interaction
(nm)
Ion-dipole

20

10

Hydrogen

20

0.15-0.5

Hydrophobic

<40

10

Van der Waals

4

0.4-0.6
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Average

2.6

molecular kinetic
energy in solution
Nanoparticle

7.6–454

surface energy

7.3

The strength of molecular interactions
Binding affinity is the strength of a molecule to bind with a targeted counterpart

molecule. Every molecule has a binding affinity with other molecules as can be observed
with many docking simulation studies in a two-molecule system. However, in the real
world, these two molecules are surrounded by other large and small molecules and a high
concentration of water (~55 M). Therefore, the binding affinity of an active targeting
agent to a targeted molecule must be stronger than the binding affinity with nonspecific
molecules. The interaction between active targeting and targeted molecules can be
through various chemical forces, including the hydrophobic effect, ionic bond, hydrogen
bond, and van der Waals interactions (Table 7-1). Van der Waals forces are the weakest
among the chemical interactions, having a binding energy of 4 kJ/mol, just above the 2.6
kJ/mol of average kinetic energy of a molecule in solution at 37 °C [372]. Even though
the cumulative strength of van der Waals forces increases when there are more atoms to
interact, the van der Waals forces are easily overcome by the other forces and bonds.
Moreover, the small interacting surface area between a targeting and targeted molecule
reduces the van der Waals forces significantly. For example, the binding site of an
antibody is usually only over several amino acids, or 0.4–8 nm2. Van der Waals forces
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also work across a short range of approximately 0.5 nm because of the exponential decay
as the distance increases. Furthermore, van der Waals forces become repulsive closer
than 0.4 nm apart. The second weakest bond energy is the hydrogen bond. Hydrogen
bonds occur in an interaction between an oxygen or nitrogen atom with a hydrogen atom,
which is formed by the polarity difference between oxygen or nitrogen and hydrogen.
The hydrogen bond usually occurs at a distance of 0.15–0.5 nm [373]. However, in
aqueous solutions, the hydrogen bond between targeting and targeted molecules
issignificantly weakened as both form hydrogen bonds with the surrounding solvent. The
ionic bond, on the other hand, is stronger in the ability to interact and attract an
oppositely charged atom. An ionic bond works across a much larger distance and can
reach up to 10 nm apart. The hydrophobic effect significantly helps the targeting ability
as water molecules in aqueous solutions interact with hydrophobic molecules less than
with water or other hydrophilic molecules. The interaction range of hydrophobic
molecules is less than 10 nm and decays exponentially with distance. The high surfacearea-to-volume ratio of NPs also generates a high surface energy, around 7.6–454 J/m2
depending on the size, shape, and material of the NP, which can lead to nonspecific
binding to nontarget molecules. Therefore, any targeting agent must have a binding
energy that is greater than the surface energy of the NP to provide successful active
targeting. Depending on the NP, the surface energy can be substantial, so the NP must be
adequately coated with a biocompatible polymer such as polyethylene glycol (PEG) to
reduce this surface energy and allow for active targeting.
The binding between the targeting and the targeted molecules is initialized when
the molecules are around 10 nm apart. The ionic interaction brings the molecules closer
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until the secondary bonds, which act in the shorter range, such as hydrophobic
interactions, hydrogen bonds, and van der Waals forces, pull them together. Even though
the primary ionic bond is strong at long-range interactions, both primary and secondary
bonds are essential in keeping both molecules together because the total binding energy
of primary and secondary bonds is usually much higher than the binding energy of the
primary bond alone [373]. On the other hand, the same attraction mechanisms are also
formed with other molecules, which often cause nonspecific binding and NP surface
energy–generated protein corona around the NPs that can potentially overwhelm specific
ligand–antigen interactions (Table 7-1) [191]. Therefore, the combined specificity of
targeting agents and the ability of NPs to prevent corona formation are both crucial.Blood
plasma contains a large amount of proteins, biomolecules, cells, and salt, which interact
with one another and readily adsorb on the surface of NPs to form opsonins, which are
recognized by the immune system for removal. The opsonins on the surface of NPs form
the corona, where the thickness is directly proportional to the surface energy of the NP.
The surface energy of a bare, uncoated NP is affected by physicochemical parameters
such as size, shape, surface charge, and hydrophobicity, as summarized in Table 3-1. The
surface area to volume ratio of a NP is one of the main factors affecting corona formation
on the surface of NPs because surface energy is directly proportional with surface area.
Smaller NPs have higher surface areas per mass of NP and thus show greater corona
formation as compared to larger NPs [188]. Non-spherical NPs have a higher surface area
to volume ratio than spherical NPs and so show more corona formation compared to that
of spherical NPs [189]. Furthermore, NPs with a rough surface have a greater surface
area to volume ratio as compared to NPs with a smooth surface; thus, they show more
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corona formation and thickness as compared to smooth NPs. A higher degree of
hydrophobicity on the surface of a NP also affects the corona formation because of the
relatively strong binding energy associated with hydrophobic binding in aqueous
solutions [188]. The surface charge of a NP also affects corona formation through ionic
interactions that attract and bind opsonins to the NP surface [190]. Corona formation also
negatively affects the physicochemical properties of the NPs and leads to a reduction in
blood circulation half-life. Furthermore, the corona will often cover the targeting agents
on the surface of the NP so they can no longer bind with their target molecules, reducing
the effectiveness of the NPs in vivo (Figure 3-2) [191]. Polyethylene glycol (PEG) is also
used to reduce opsonin binding on NPs by both reducing the surface energy of the NP
and through steric hindrance. As a result, PEG was found to increase the half-life of
circulating NPs in the blood [192].

Table 3-1
7.4

Targeting agents
Targeting agents are one of the main components in actively targeted NPs. Most

ligands utilize 3D structure, charge, and hydrophobicity, which complement its targeted
molecules to increase the binding specificity. Various ligands are utilized in actively
targeted NPs with a wide range of molecular weights, targeting specificities, and
manufacturing costs (Table 7-2). Each ligand has its own advantages and disadvantages
for their use in actively targeted NPs.
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Table 7-2. Comparison of molecular weight, binding affinity between ligands and targeted
molecules, half-life in blood circulation, targeting specificity, and manufacturing cost between
different targeting agents that are commonly used in actively targeted NPs.

Targeting

Molecular

Binding

Blood

agents

weight

affinity

half-life

(kDa)

range (KD)

150

10-7-10-13

15-30

M

days

10-5-10-11

Several

M

days

10-5-10-11

Antibody
(IgG)
F(ab’)2

F(ab)

110

50

Specificity

Cost

USD/g

+++

$$$

50-60
300

+++

$$$$

30 min

+++

$$

10-5-10-11

10-30

+++

$$

M

min

10-7-10-11

5-10 min

+++

$$

50

4-15 min

+++

$$

600

10-7-10-15

10-20

++

$$

400-

M

days

10-3-10-5 M

Minutes

100

M
scFV

Aptamers

28

5-50

M
Peptides

1.5-50

10-9-10-12
M

Protein

Carbohydrate

80

0.2-100

to hours

700
++

$$

489539
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Vitamin

0.3-1.4

10-9-10-11

Hours to

M

days

++

$

4-54

+ : the targeting specificity of ligands relative to one another (+= not specific, ++=
moderately specific, +++= very specific).
$ : the production cost of ligands relative to one another ($= <USD0.25/µmol, $$=
USD0.25-5/µmol, $$$= USD5-10/µmol, $$$$= > USD10/µmol).

7.4.1

Antibody/Antibody fragment

Figure 7-1. An illustration showing the shape and dimension of Ab and Ab fragments from both
front and side views.
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Antibodies (Abs) are one of the earliest and most commonly used ligands for actively
targeted NPs. Abs are a specific type of protein produced in B cells that bind to target
antigens as part of the body's adaptive immune system. Here, we consider Abs separate
from proteins since Abs are widely used in NP targeting studies because of their high
specificity, strong affinity, and a wide variety of available targets.
There are five major classes of antibodies or immunoglobulins (Ig) that are produced
in mammals: IgA, IgD, IgE, IgG, and IgM, all made up of combinations of heavy chains
(50 kDa or 440 amino acids each) and light chains (25 kDa or 220 amino acids each)
[374-378]. The most common Ig used in active targeting is IgG [376, 377]. IgG is the
dominant class of human Ig and consists of two identical light chains and two identical
heavy chains that are held together by several disulfide bonds between cysteines to form
a 150 kDa molecule (Table 7-2). The heavy and light chains each contain three
complementary-determining regions, located at the N-termini of Abs. These
complementary-determining regions have the most variable amino acid combinations to
complement the specific target antigen and also provide a very strong avidity in the range
of 10-7-10-13 M (Table 7-2) [379]. The C-termini of Abs contain a fragment crystallizable
region (Fc), which has a high affinity toward leukocytes. The structure of Abs allows the
Abs to recognize and bind to the antigen of pathogen or cell, whereas the Fc region
remains accessible for leukocyte binding and subsequent phagocytosis of the target
pathogen or cell. Therefore, the orientation of Ab attachment to NPs is important to
ensure functionality.
NPs with Fc regions facing outward can be recognized and phagocytosed by
leukocytes. One possibility to overcome this limitation is by removing the Fc region from
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the Ab. Whole Ab can be cleaved with pepsin and papain to produce F(ab’)2 (110 kDa)
and Fab (50 kDa), respectively. F(ab’)2 can also be cleaved by dithiothreitol to generate
Fab’ (55 kDa). Since the variable region is the most crucial part in binding with an
antigen, the cleaving of Ab does not eliminate the binding ability of Ab fragments.
Moreover, work has been done with a single chain of the variable fragment (scFv,
25 kDa) to only keep the variable region while having much smaller molecules than the
whole Ab or Ab fragments (Figure 7-1) [378, 380, 381].
F(ab’)2 and full Abs (KD = 6.9 × 10−9 M) have binding affinities up to 100 times
stronger than the binding affinities of Fab and scFv (KD = 6 × 10−7 M and 5.9 × 10−7 M,
respectively).37 F(ab’)2 and Abs have two binding regions, whereas Fab and scFv only
have one binding region; thus, the lack of a multivalent effect may account for some of
this loss in binding affinity or increase in KD. This was shown empirically by utilizing
high-speed atomic force microscopy. Preiner et al.38 found that whole Abs showed
bipedal stochastic walking on a surface of regularly spaced epitopes until the Abs found
two antigens, within a 6–12 nm range, which perfectly aligned with both binding regions
of the Ab. Conversely, monovalent Fab fragments might rotate on the same antigen until
it found the same orientation and stand still. The multivalent effect might need to be
considered when designing the density of Abs and Ab fragments on the NP surface
because suboptimal distance and geometric constraint destabilize multiple binding [382385].
The specificity and high affinity of Abs to bind with antigens combined with the
ability of NPs as a delivery vehicle and imaging agent have brought many opportunities
and breakthroughs in biomedicine. Therefore, the conjugation of Abs onto the surface of
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NPs has been widely studied, such as Ab-NP conjugation strategy, the density of Ab on
NPs surface [383-385], and controlled orientation of Ab on the surface [386],
Abs possess a large number of functional groups that can be conjugated to NPs.
These include carboxylic acid groups (glutamic and aspartic acids), amine groups (lysine,
asparagine, and glutamine), and thiol groups (cysteine). However, the spread of these
amino acids along the Abs results in an uncontrollable orientation of conjugated Ab on
NP. NPs containing a random orientation of Abs resulted in a 10-fold reduction in
antigen-binding affinity compared with NPs where the Ab-binding regions all faced
outward [387]. Therefore, various conjugation strategies for Ab attachment on NPs
results in different abilities to control orientation as outlined below.

7.4.1.1 Several common covalent binding reactions
7.4.1.1.1 Carboxylic acid and primary amine reaction:
An amide bond is a stable linkage formed by the condensation reaction of a
carboxylic acid and a primary amine, usually through a carbodiimide reaction (Table
7-3). Carbodiimide reactions often utilize 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) to form an intermediate ester bond before
being substituted by a primary amine group. An amide bond can also be formed by
activating primary alcohol groups on Abs (serine, threonine) or NPs with ptoluenesulfonyl chloride to become amine reactive. An advantage of the amide bond is
that no modification on the Ab is required, reducing the risk of loss in reactivity and
denaturation. One of the limitations is the inability to control the orientation of the Ab on
NP because of the distribution of carboxylic acid and amine groups throughout the Ab.
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The Ab might link to more than one NP, to more than one site of the same NP, or even
linkage to NP on the variable region, which can block Ab binding to targeted molecules.
Therefore, the ratio of reactants must be carefully controlled.

7.4.1.1.2 Schiff base reaction
A reaction between an aldehyde and primary amine forms an imine bond, a Schiff
base. Typically, NPs are activated with aldehyde groups such as by reaction with excess
glutaraldehyde. Another way of binding Ab to NP with Schiff base is to utilize hydrazide
or hydrazine functional group (R–NH–NH2) with aldehyde or ketone to form a
hydrazone bond (Table 7-3).
While these conjugation reactions do not ensure a well-oriented Ab, the mild
oxidation of vicinal hydroxyl groups with sodium periodate on carbohydrate residues to
become aldehyde groups can result in oriented Ab conjugation [388]. This takes
advantage of the fact that carbohydrate residues on Abs are specifically located on the Fc
region. As an example, an oxidized Ab was conjugated to a hydrazide group of a
bifunctional PEG that also contains a dithiolaromatic group. The dithiolaromatic group
was then used to bind to the surface of a gold NP through a covalent bond between sulfur
and gold atom [388].

7.4.1.1.3 Thiol reaction
Although thiols are present on Abs, they are involved in intramolecular disulfide
bridges within the native Ab. Hence, these disulfide bridges must first be reduced to
make thiols available for reaction. Conversely, free thiols can be introduced onto Abs by
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reaction with amine groups, such as with using Traut's reagent. Free thiols on Abs can be
used to conjugate to NPs through disulfide or thioether bonds (Table 7-3). Typically,
disulfide bonds are not used because they are difficult to control and often lead to crosslinking between NPs. On the other hand, thioethers can be formed with maleimideactivated NPs as well as through Michael addition reactions with aldehydes on the NP,
with efficiency up to 95%–99% [389]. Abs with activated thiol groups can also create a
covalent bond to metal NPs (e.g., gold NPs), which is often called a dative bond where
the bond was formed through electron from the metal atom shared to the thiol group
(Table 7-3). F or example, Abs were reduced with tris(2-carboxyethyl)phosphine, a weak
reducing agent that allows more specific disulfide bond reduction on Ab, which are then
available for dative binding to the gold NPs [390]. However, the reduction method might
be too harsh to the Ab that it might damage the Ab tertiary structure and reduce the
binding activity of Ab significantly when compared withthe carbodiimide reaction and
ionic interaction [390]. Similar to the formation of an amide bond or a Schiff base, Abs
orientation on the NPs are also hard to be controlled using these thiol reactions.

7.4.1.1.4 Click chemistries
Click chemistries are a set of reactions that are highly specific, stereospecific,
efficient, easily performed, reactive in easily removed solvents and eliminate the need for
chromatography to remove byproducts. These reactions might require a catalyst, a
substance involved in a chemical reaction that increases the reaction rate but is not
consumed in the overall reaction. Copper is a typical catalyst used in click chemistry
between an azide functional group (N3) and an alkyne functional group (Table 7-3).
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Click reactions to conjugate Abs to NPs have been shown to be fivefold to eightfold more
efficient than amide reactions [391, 392]. Nevertheless, Ab orientation on the NPs is still
difficult to control.

7.4.1.2 Several common non-covalent bindings
7.4.1.2.1 Avidin-Biotin
The specific binding between avidin and biotin is one of the strongest known noncovalent bonds (KD ~ 10-15 M) (Table 7-3). Avidin is a glycoprotein with four subunits,
which can bind to up to four biotins. An advantage of this reaction is that avidin can be
introduced directly into the Ab backbone in the Fc region through genetic engineering of
hybridomas, in vitro cell cultures that produce Abs. The resulting fusion protein can then
be attached to biotinylated NPs with well-controlled orientation and stoichiometry.

7.4.1.2.2 Protein A and G
Protein A and protein G are proteins utilized by Staphylococcus aureus and
Streptococcus C40, respectively. Both protein A and protein G are able to bind and
neutralize Ab from immune recognition, as they specifically bind to the Fc region of IgG.
This has provided the opportunity to utilize these proteins to control Ab orientation on
NPs (Table 7-3). Up to 95% of protein A on the surface of cyanoacrylic NPs was found
to bind with Ab during the conjugation reaction [393]. However, in vivo studies were
disappointing where Ab conjugated NPs accumulated mostly in the liver and spleen. The
adsorption of excess protein in blood serum might compete with protein A, which can
break the binding between Ab and protein A [394].
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7.4.1.2.3 Physioadsorption
Adsorption of Abs on the NP surface was one of the earliest studied attachment
techniques. Ab-bound phospholipid-based NPs were prepared by merely adding the
ligand to the NPs solution. If the phospholipid charge was neutral, 4%–40% of the IgG
bound to the liposomal NP. When anionic phospholipids were used, the binding of Ab to
NP was about 50% higher than that of neutral phospholipids [395]. These results suggest
that Ab adsorption on liposomal NPs depends on the hydrophobicity, as well as the ionic
charge of the liposome NP (Table 7-3). Ab-bound liposomal NPs increased the antigen
binding by 30–50% compared to free Ab [395]. However, Abs might be exchanged by
stronger binding opsonin in the blood, potentially decreasing the effectiveness of the AbNP.

7.4.1.2.4 Others
A small indole molecule can be entrapped into the nucleotide-binding site of Ab
(KD = 1–8 μM) with the help of ultraviolet light (Table 7-3). The nucleotide-binding site
allows specific site and orientation of Ab on the NP surface [396]. Utilizing the
nucleotide-binding site of Ab increased NP binding and sensitivity toward antigen
significantly as compared with a carbodiimide reaction, ionic interaction, and thiol bond
[390].
Despite the advantages of Abs as a targeting ligand, its large size can significantly
increase the hydrodynamic size of small NPs. For example, 12.5 nm NPs increase in size
to 25 nm after being conjugated with Abs [390]. The production cost of Ab is also very
expensive because of the need for live animal hosts to produce titers. Mammalian cell
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culture can be used as a potentially cheaper method but requires significant numbers of
cells to generate useable quantities of Ab. F(ab’)2 is derived from whole Ab with further
purification, which makes the production cost of F(ab’)2 even more expensive than the
production cost of the whole Ab. Even though Fab can be derived from whole Ab, similar
to F(ab)’2 production, Fab and scFv can also be produced from bacteria, which grow
much faster and in higher densities than mammalian cell culture and can reduce the
production cost of Fab and scFv.

Table 7-3. Commonly used linkage, functional group, and chemical reactions to bind Abs with NPs, as well as the binding stability and Abs
orientation on the surface of the NPs.

Type of

Linkage

Bond
Covalent

Conjugated functional

Commonly used reaction

Linkage stability

Abs Orientation

Carbodiimide reaction

Stable

Uncontrolled

Schiff base reaction

Labile under acid

Can be controlled

group
Amide bond

Primary amine –
carboxylic acid

Imine bond

Hydrazide/hydrazine –
aldehyde/ketone

Thioether bond

Thiol – maleimide

Disulfide bond

Thiol – thiol

condition
Michael reaction

Stable

Uncontrolled

Labile under

Uncontrolled

reducing conditions

Noncovalent

Dative bond

Thiol – metal

Triazole ring

Azide – alkyne

Biotin – avidin

Biotin – avidin

Click chemistry

Stable

Uncontrolled

Stable

Uncontrolled

Stable

Can be controlled

Biotin – streptavidin
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Protein A and G

Protein A/G – Ab Fc

Labile under

region

competing Abs

Ionic bond

Labile under

(physioadsorption)

competing opsonins

Nucleotide binding Nucleotide binding site
site – indole

Ultraviolet free radical

Controlled

Uncontrolled

Controlled

– indole
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7.4.2

Aptamers

Figure 7-2. (A) Size comparison between Ab and thrombin aptamer [397] and (B) Chemical
structure of Thrombin binding aptamer [398]. Reprinted by permission from Elsevier: Current
Opinion in Chemical Biology, “Aptamer therapeutics advance”, (Lee, et al. 2006) [397].
Reprinted by permission from Royal Society of Chemistry: Organic & Biomolecular Chemistry,
“Stability and bioactivity of thrombin binding aptamers modified with D-/L-isothymidine in the
loop regions”, (Cai, et al. 2014) [398].

Beyond their use for storing and expressing the genetic code, nucleic acids (DNA and
RNA) form two- and three-dimensional structures, which are more stable than linear
oligonucleotides. Oligonucleotides are well-known for their double-stranded helical
structures and their single-stranded hairpin structures. However, these are not the only
three-dimensional structures of oligonucleotides. For example, a thrombin-binding
aptamer is a G-quadruplex structure formed by the stacks of planar guanine tetrads
(Figure 7-2), where molecular structure of the thrombin-binding aptamer was determined
by NMR spectroscopy and X-ray crystallography [399]. The natural use of
oligonucleotides to bind with other molecules is very limited; however, random
arrangements and panning of oligonucleotides have led to the evolution of
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oligonucleotide-based targeting ligands. The randomly arranged oligonucleotide
sequences are called aptamers, which means: to fit [400].
An early and widely used method to produce aptamers is through SELEX (Systematic
Evolution of Ligands by Exponential enrichment), which was developed in 1990 [401].
In the same year, an independent study found a specific three-dimensional structure of
RNA that was able to bind with a small molecule [400]. SELEX produces aptamers of
20–100 oligonucleotides, with molecular weights of 5-50 kDa (Table 7-2). The process of
SELEX usually goes through 8–20 panning steps from a large pool of aptamers (1013–
1015 aptamer sequences) until only several high-affinity aptamers toward targeted
molecule are obtained at the end of the cycles.
Similar to Abs, aptamers can bind to various antigens, such as inorganic molecules,
small organic molecules, proteins, peptides, carbohydrates, antibiotics, whole cells, and
even organisms, with high specificity and selectivity. The interactions between aptamers
and antigens are usually based on electrostatic interactions, hydrophilic interactions, and
complementary shapes. The multivalent effect can also be exploited with aptamermodified NPs to increase binding affinity. This was shown using a dimer aptamer
composed of two aptamers (15-mer and 29-mer thrombin aptamers linked by a flexible
linker), which bind two different sites on thrombin. The dimer aptamer decreased the
KD 10-fold when compared with the KD of the 15-mer thrombin aptamer itself [402]. A
similar effect was found with multiple different aptamer sequences on a single NP.
Multitargeted NPs were able to accumulate on the targeted molecule at a higher level
than NPs modified with a single aptamer sequence [403].
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Another advantage of aptamers is that they can be engineered to have multiple
regions with different functions such as to promote entrapment inside an NP. For
example, phosphorothioate-modified DNA bases were used to give a hydrophobic
characteristic to the aptamers while a tumor targeting sequence was kept hydrophilic
[404]. This allowed the active targeting domain to be exposed on the surface of the NP
while entrapping the hydrophobic domain inside the NP during NP synthesis. The
entrapped aptamer was able to improve accumulation of the targeted NPs on lung cancer
cells grown subcutaneously in nude mice.
One of the limitations of aptamers is the high serum nuclease activity in blood that
can quickly degrade nucleotides or aptamers—unmodified nucleotides have stability halflives of as short as 2 min in blood serum (Table 7-2) [405]. These very short half-lives
can be overcome by chemical modifications of the aptamer backbone such as capping the
3′-terminus to prevent 3′-exonuclease activity, which is much higher than 5′-exonuclease
activity in serum. Another strategy is to create enantiomer nucleotide backbones (l-ribose
and l-deoxyribose), which also reduces nuclease degradation [406]. Despite the
adaptability of aptamers, their binding is typically limited toward hydrophobic and
negativelycharged antigens. Aptamers are very hydrophilic, and the phosphate backbone
is negatively charged; therefore, the difference between hydrophobicity–hydrophilicity
characteristics of antigen and aptamers weakens the binding because of the hydrophobic
force preventing hydrogen bonding to occur. Likewise, if the antigen is negatively
charged, there will be a repulsive ionic interaction between the antigen and aptamer.
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7.4.3

Proteins

Similar to Abs, proteins also contain functional groups on their N- and C-termini, as
well as the amino acid building blocks. Transferrin has been extensively used as a
targeting protein on the surface of NPs because of its ability to target the transferrin
receptor, which is upregulated in many types of cancer cells. One of the advantages using
proteins is the higher molecular weight compared withthe other ligands (e.g., MW of
transferrin is 80 kDa), which significantly increase the circulation time of the protein in
the blood (Table 7-2). One of the most common conjugations of transferrin to NPs is
through carbodiimides reaction to form an amide bond. For example, transferrin
conjugated to PEG–liposomal NPs wasused to target disseminated gastric cancer cells
through an intraperitoneal injection [407]. The transferrin-targeted NPs had higher uptake
and penetration into solid tumor tissue, which resulted in a higher survival rate in a
human xenograft mouse model as compared with control NPs without transferrin [407].
In another study, transferrin-targeted NPs were found to penetrate hepatic and cervical
tumor spheroids much more than the free drug and non-targeted NPs [408].
However, the competition between proteins on NPs and the excess protein in the
blood plasma might reduce the targeting ability of protein targeting NPs toward the
protein receptors [408, 409].
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7.4.4

Peptides

Figure 7-3. Two binding sites of a polypeptides chain of GRGDSP and PSHRN increase the
binding specificity and avidity toward Fibronectin III on the repeats 9 and 10, compared to the
individual binding sites. Inspired by Kokkoli E. Engineering Biomimetic Peptides for Targeted
Drug Delivery. Washington, DC: The National Academies Press; 2011 [410].

Peptides can be thought of as very small proteins, as they consist of a short chain of
amino acids and can be conjugated to NP in a similar conjugation technique as Ab
conjugation to NP. The conjugation site and the availability of the active site for binding
with antigen are also important when considering peptide conjugation strategies. On the
other hand, peptides are similar to nucleic acid aptamers as most peptides are easily
synthesized in the lab and bind with a specific target. Peptide sequences can be
discovered through multiround panning processes using phage display technology [411].
Peptides can also be engineered to have similar active binding sites with antibodies and
proteins. The binding affinities of peptides are comparable with the binding affinities of
antibody fragments, which are in the nanomolar range. Peptides can be designed with
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multiple binding sites to take advantage of the multivalent effect, which increases the
binding affinity of the peptides to the antigens (Figure 7-3) [410].
Arginine–glycine–aspartate (RGD) tripeptide and its derivatives are well-known for
their ability to bind to integrins, the binding proteins of cells with the extracellular matrix.
Integrins are often upregulated in solid tumors; hence many tumor-targeted NPs have
relied on RGD-based peptides as a targeting agent [412-416]. To increase binding affinity
and specificity to α5β1 integrin, which is overexpressed on breast, prostate, rectal, and
colon cancers, a multivalent peptide containing GRGDSP and PHSRN subunits was
developed [417, 418]. From the crystal structure, GRGDSP and PHSRN peptides are able
to bind on the same face of fibronectin 3.5 nm apart [419]. RGD domain of the GRGDSP
is a well-known component to interact with fibronectin, whereas PHSRN peptides are the
synergy region that increases the avidity between targeting peptides and fibronectin. This
multivalent peptide was attached to the surface of a liposomal/micellar NP carrying
doxorubicin to improve delivery into colon cancer cells. As a result, the multivalent
peptide sequence was able to improve the delivery rate as compared with the NPs
targeted with GRGDSP alone [418].
However, peptides have several disadvantages such as cleaving and degradation of
peptides exposed on the surface of NPs by serum protease in the blood plasma, which
reduce the effectiveness of peptide targeting. Fortunately, the stability of peptides in
blood plasma can be improved by adding cysteines to form disulfide bonds generating a
more stable cyclic peptide, blocking the C- and N-terminus, utilizing d-amino acids
backbones, or using synthetic amino acids that are incompatible with proteases [420-
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422]. The small size of peptides also prone to kidney clearance (MW = 1.5-50 kDa)
(Table 7-2), which can be overcome by conjugating peptides to NPs.

7.4.5

Carbohydrates

Carbohydrates consist of carbon, hydrogen, and oxygen, and sometimes phosphorus,
sulfur, and nitrogen atoms. There are three types of carbohydrates: monosaccharides,
disaccharides, and polysaccharides. Monosaccharides are the simplest form of
carbohydrates, such as glucose, fructose, and galactose, and are usually the building
blocks of the more complex carbohydrates. Disaccharides comprise two
monosaccharides, such as sucrose (glucose and fructose), lactose (glucose and galactose),
and maltose (glucose and glucose). Polysaccharides and oligosaccharides are a chain of
sugars with three or more monosaccharides and can be linear (such as with amylose) or
branched (such as with glycogen). Therefore, the molecular weight and blood circulation
half-life of carbohydrates widely varied, with molecular weights of 0.2–100 kDa and
blood circulation half-lives of minutes to hours (Table 7-2).
Many cancer cells overexpress the CD44 cellsurface marker, which binds
to hyaluronic acid (HA), a glycosaminoglycan component of the extracellular matrix. HA
has garnered significant attention as it can be conjugated to the NP surface as a targeting
agent similar with other ligands [423-425], and it can also be utilized as the HA-based NP
building block reducing the need for secondary conjugations [361, 426-430]. HA-based
NPs have been used for targeting various tumor types in mouse models for intraoperative
imaging [361, 427, 428] as well as drug delivery [426, 429, 430].
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Many cancer cells overexpress the CD44 cellsurface marker, which binds
to hyaluronic acid (HA), a glycosaminoglycan component of the extracellular matrix. HA
has garnered significant attention as it can be conjugated to the NP surface as a targeting
agent similar with other ligands.

7.4.6

Vitamins

Vitamins are molecules, which are essential for the body but are not part of minerals,
essential fatty acids, and essential amino acids. Vitamins can be hydrophobic (vitamin A,
D, E, and K) or hydrophilic (vitamin B and C). Almost every tissue has vitamin
receptors, but some tumors and specific tissues often overexpressed vitamin receptors,
which allows for vitamins to be used in actively targeted NPs.
Two of the most utilized vitamins in actively targeted NPs are folate (vitamin B9) and
vitamin B12. Folate is required for biosynthesis of purines and pyrimidines. Even though
the folate receptor availability on the normal cells is limited, folate receptors are
commonly overexpressed on the surface of activated myeloid cells and tumor cells, such
as ovarian, lung, breast, and brain cancers [431, 432]. On the other hand, vitamin B12 is
often used in active targeting for intestine absorption as vitamin B12 promotes receptormediated endocytosis to go through the intestine endothelial cells into the blood vessel
[433-436].
Vitamin B12 is much larger (1355 Da) than other vitamins (e.g., folate is 441 Da)
(Table 7-2). Therefore, vitamin B12 needs a specific pathway to be absorbed in the
intestine. In the small intestine, vitamin B12 interacts with intrinsic factor protein, which
helps to bind to intrinsic factor receptor and is absorbed through the intestinal wall.
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Folate, on the other hand, has a carboxylic acid group that is readily conjugated with
an amine group and other functional groups. The conjugation of folate on the carboxylic
acid also does not affect the KD of folate to the folate receptor, as the terminal carboxylic
group is more reactive for conjugation. There are two folate receptors, FR-α (KD ~ 10-11)
and FR-β (KD ~ 10-9) (Table 7-2) [437]. FR-α is overexpressed on 40% of human cancers
and has limited expression in normal cells. On the other hand, FR-β is upregulated in
activated myeloid cells, such as 70% of acute myeloid leukemia cells [438, 439]. Folate
is also stable, is inexpensive, promotes rapid internalization into tumor cells, is readily
conjugated, and is nonimmunogenic.
Vitamins as targeting agents offer high specificity to their respective receptors (KD =
10-9-10-11 M) [437], non-immunogenicity, as well as ease of production leading to very
low costs (Table 7-2). However, vitamin-modified NPs have similar disadvantages as
protein-targeting NPs, in which excess vitamins in the body might compete with vitaminmodified NPs to bind with the specific receptor [440-443], reducing the targeting ability.
Moreover, the expression of vitamin receptors (e.g., folate receptor) on the surface of
multiple cell types, such as activated myeloid cells and tumor cells, might cause offtargeting using vitamin-targeting NPs.

7.5

Active targeting strategies for various diseases
NPs have been widely studied over the past few decades in the biomedical field.

However, most studies have focused on cancer, which has led to the formation of a
substantial body of literature on understanding the effects of physicochemical, molecular,
and active targeting properties of NPs in tumor tissues and the body. Fortunately, much
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of this literature, such as ligand conjugation techniques, physicochemical properties of
NPs that increase blood circulation half-life, and strategies that improve tissue
penetration, can be translated to use in other diseases. Even though cancer is still one of
the most focused research areas of NPs, the utility of NPs in non-neoplastic diseases has
begun to gain attention. This includes the use of the active targeting ability of NPs to
increase transmembrane penetration, accumulation in non-EPR diseases, and more
selective and specific therapeutics delivery and imaging. Here, focus is given to studies
that have preclinical mechanistic data.

7.5.1

Cancer

Cancer is an unregulated cell growth usually caused by mutations in cell growth
signaling and receptor regulatory proteins. Cancer is well-known for its EPR effect
compared with healthy tissues because of uncontrolled angiogenesis and lack of
lymphatic drainage. Therefore, passive targeting NPs are able to show a significant result
in cancer therapy. However, active targeting can still improve NP delivery in EPR
cancers. A series of studies found that active targeting did not increase the accumulation
of NPs in EPR tumors, which was dominated by the EPR effect, but distribution
throughout the tumor and delivery into cells was increased with active targeting [358,
359, 444-446]. These results showed the importance of active targeting in improving NP
delivery even in tumors where the EPR effect allows for passive NP targeting. Active
targeting is even more critical in cancers that do not have an EPR effect such as some
hematological malignancies [447-451], small metastatic tumors [452-455], and
circulating tumor cells [456]. In these cases, active targeting is required for specific
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binding to these cells. For example, Ab-modified iron oxide NPs targeted to the
HER2/neu receptor were able to bind to breast cancer metastases to the liver, lungs,
brain, and bone marrow in a transgenic mouse model, whereas IgG control-modified NPs
showed no uptake into these cells [364]. Active Ab-mediated targeting of NPs to tumors
can be further enhanced when NPs are loaded with chemotherapeutic agents.
Chemotherapy loading into the active targeted NPs reduced the immune response against
these PEG-coated NPs, allowing for increased tumor delivery compared with the active
targeted NPs without chemotherapy loading [457]. The reduction in the immune response
was a result of the cytotoxicity of the chemotherapy agent to both adaptive and innate
immune cells, which blocked any subsequent immune response [457].
Leukemia is a hematological malignancy that does not form a solid tumor despite
some evidence of EPR observed in bone marrow [458]; hence, there is no EPR effect that
NPs can exploit. Therefore, actively targeted NPs might be ideal in targeting leukemia
cells to reduce the toxicity of systemic therapies. On acute myeloid leukemia, epidermal
growth factor receptor (EGFR) is often overexpressed, which can readily be targeted by
an anti-EGFR Ab, aptamer, or peptide. In one study, anti-EGFR Ab was biotinylated to
allow for attachment to NeutrAvidin-modified mesoporous silica NPs (MSNs) [363].
Active targeted NPs were able to specifically bind to and be internalized by EGFRexpressing leukemia cell both in vitro and in an ex ovo model. Following this,
chemotherapy-loaded, anti-EGFR Ab-targeted MSNs showed active targeting-mediated
cell kill in leukemia cells both in vitro and in a mouse model, which improved survival
[459].
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The GE11 peptide, an EGF mimetic, has been conjugated to various NPs for active
targeting of EGFR-overexpressing tumors [460-463]. However, the internalization
mechanism for NPs modified with the artificial GE11 peptide is different from that of
those modified with natural EGF [464]. Single particle tracking revealed EGF-modified
NPs were rapidly internalized into EGFR-expressing cells in vitro, showing 80%
internalization within 10 min. On the other hand, GE11-modified NPs took 4 h to reach
the same level of internalization as EGF-modified NPs, while non-targeted NPs reached
only 31% internalization. The difference in internalization between NPs targeted with
EGF and GE11 was found to be a result of EGFR activation with native EGF, which
promoted rapid internalization, whereas EGFR was not activated by GE11 [464]. This is
one example of how the choice of active targeting agent on the surface of an NP can alter
target cell uptake.

7.5.2

Atherosclerosis

Atherosclerosis is the leading cause of cardiovascular disease, in which chronic,
inflammatory lipid-rich plaques and cholesterol particles accumulate within the artery
wall. The inflamed endothelial cells are also prone to leakiness, which can result in an
EPR-like effect. Therefore, NPs are suitable to be used in passive drug delivery and
diagnosis of atherosclerosis [465-468]. While passive targeting of atherosclerotic plaques
can be achieved with NPs depending on the permeability of the vessel wall [469], active
targeting is expected to achieve higher penetration into the plaque and internalization into
target cells. Several ligands have been used in active targeting of atherosclerosis, such as
vascular cell adhesion molecule-1 (VCAM-1) [470, 471], monocyte chemoattractant
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protein-1 (MCP-1) [472], interleukin-10 (IL-10) [473], and E-selectin [474], in hopes of
improving therapeutic delivery and retention to reduce plaque size and inflammation.
These active targeted NPs showed higher accumulation rates within the plaques and
significantly longer retention times to potentially improve therapeutic delivery. HA NPs
have also been used for active targeting of inflammatory cells in plaques since the
inflammatory process requires HA-immune cell interactions [475]. HA also acts as a
therapeutic as nanoformulated HA has been shown to act as an anti-inflammatory [476].
Thus, the HA provided the building blocks to achieve the NP size needed for passive
accumulation, active targeting to promote target cell-specific interactions, and therapy by
providing atheroprotective effects [475].

7.5.3

Kidney Disease

Chronic kidney disease is a state of reduced kidney function that can lead to various
other health complications such as stroke, hypertension, and liver dysfunction. Small
molecule therapeutics have been hindered by poor circulation times, which requires high
doses to be delivered leading to off-target side effects and even lethality. Thus, active
targeted NPs have been developed using a kidney-targeting peptide (KKEEE)3K to
specifically bind to megalin, a cell surface receptor on renal tubule cells, through
multivalent display [477]. NPs slightly larger than the 10 nm cutoff of glomerular
filtration were used and showed selective accumulation on renal proximal tubule
cells in vitro. In healthy mice, active targeted NPs showed significantly higher kidney
accumulation than non-targeted NPs, suggesting the use of active targeting for kidney
disease [477].
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7.5.4

Neurological disorders
Neurological disorders encompass various diseases, including brain cancer,

traumatic brain injury (TBI), stroke, neuroinflammation, and progressive
neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The treatment of
neurological disorders is especially challenging because of the sensitivity and importance
of the brain to survival as well as the BBB, which prevents the passive accumulation of
delivered therapies into the brain. Whereas passive targeting of NPs is possible for
disorders where the BBB is significantly disrupted such as in brain cancer [478] and TBI
[5, 132, 181, 203, 479, 480], active targeting is required in disorders where BBB integrity
is intact. Targets typically include transmembrane ligands to act as a Trojan horse to gain
access into the brain through receptor-mediated transcytosis across the BBB. These
include receptors for transferrin [481-484], lactoferrin [485-487], and possibly RAGE
(receptor for advanced glycation end products), which is overexpressed on diseased brain
microvascular cells [488], or tight junction proteins.
The rabies virus glycoprotein peptide (RVG29,
TYIWMPENPRPGTPCDIFTNSRGKRASNG) was developed to cross the BBB by
taking advantage of the pathway exploited by the neurotropic rabies virus, either through
nicotinic acetylcholine receptor (nAchR) or GABA receptor binding. RVG29 conjugated
to generation-5 PAMAM dendrimers through bifunctional PEG accumulated in all
regions of the mouse brain significantly higher than the nontargeting NPs [489]. Similar
results have been found in other RVG29 active-targeting NPs where receptor-mediated
transcytosis across the BBB increased brain delivery of various therapeutics to improve
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treatment in mouse models of Alzheimer's disease and Parkinson's disease [367, 490492].
RVG29-conjugated NPs have been utilized for active targeting toward TBI [365].
TBI is an injury that results from a primary impact to the brain followed by the secondary
release of biochemicals such as reactive oxygen species (ROS), glutamate, calcium, and
lipid peroxidation products that can cause long-term neuroinflammation and
neurodegeneration for years following the injury. A transportan–RVG29 peptide complex
was developed to form a micelle, where anti-caspase-3 siRNA was entrapped inside the
cationic micelle. As a result, RVG29 significantly increased the micelle accumulation in
a mouse model of TBI compared withcontrol peptide and resulted in decreased caspase-3
production in target neurons [365].
Neuroinflammation increases expression of vascular cell adhesion molecule-1
(VCAM-1) on brain endothelial cells, which is an ideal target of active NP targeting. NPs
targeted to VCAM-1 with Abs or peptides have been used for imaging specific regions of
neuroinflammation [493, 494]. Similar strategies have been used with the platelet–
endothelial cell adhesion molecule (PECAM-1), which is also overexpressed on brain
endothelial cells as a result of neuroinflammation. NPs actively targeted to PECAM-1
show improved brain delivery as compared with control NPs [495]. This could improve
diagnostic information and provide a platform for therapeutic delivery.

7.5.5

Rheumatic Inflammation

Rheumatoid arthritis (RA) is a chronic inflammatory disease where macrophages are
chronically activated and degrade bone and cartilage around joints. While methotrexate
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(MTX) is one of the most common and effective therapeutics for RA treatment, its
prolonged use is accompanied by drug resistance and adverse side effects. Therefore,
active targeted NPs could help improve the site-specific delivery of MTX. Activated
macrophages express the folate receptor [496], FR-β, which opens the opportunity for
folate surface modification of NPs. As an example, an MTX-encapsulated folate–PEG–
lipid NP was developed where folate was covalently conjugated to the PEG on the
surface of the NP to achieve higher uptake into lipopolysaccharide-activated RAW264.7
cells as compared with non-targeted NPs showing the specificity toward activated cells.
Similarly, folate and MTX surface-decorated dendrimers have been used for improved
active in vivo delivery to inflamed joints [497, 498].
As another target, synovial fibroblasts in RA highly activate nuclear factor-kappa B
(NF-κB), leading to inflammation. The HAP-1 peptide is able to specifically bind to
synovial fibroblasts offering the ability for active NP targeting. Encapsulated NEMObinding domain peptide, which inactivates NF-kB, within a HAP-1-coated NP, showed
accumulation enhancement on SF compared with non-targeted NP, as well as a reduction
in both histological score and pro-inflammatory signaling compared with control NPs
[499].

7.5.6

Diabetes

Diabetes is a condition where the body cannot regulate blood glucose level, which
can be a result of either the pancreas producing little to no insulin (type I diabetes) or the
body not responding to insulin (type II diabetes). Insulin monitoring and injection remain
the most effective treatment for diabetes patients to regulate the level of blood glucose.
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Therefore, more patient-friendly approaches for insulin delivery are desirable for a better
control glucose levels and improve patient compliance. NPs offer a means for active
transport out of the gastrointestinal tract to allow for oral delivery of therapeutics [500502].
Vitamin B12 is absorbed in the ileum of the small intestine for active transcytosis
across the epithelial barrier into the blood. Therefore, attaching vitamin B12 to the
surface of NPs can provide an active targeting mechanism to gain access to systemic
circulation across the epithelial barrier [503]. In one study, insulin-entrapped calcium
phosphate NPs were coated with chitosan conjugated to vitamin B12 to allow for active
transcytosis across the epithelium [433]. In diabetic rats, active targeted NPs increased
the oral bioavailability of insulin 4.3-fold as compared with non-targeted NPs, which
extended the therapeutic response to insulin as compared with standard subcutaneous
injection of insulin [433]. Transferrin can also be used for active targeting in the
intestines to promote NP uptake, transcytosis across the epithelial barrier, and insulin
absorption to achieve a therapeutic response [504]. To target goblet cells, which are
responsible for mucus production in the intestines and transcytosis into the blood, NPs
have been modified with the CSK (CSKSSDYQC) targeting peptide and were found to
enhance absorption of delivered insulin [505-507].

7.6

Conclusions and future outlook
Various actively targeted NPs have been developed using various NP materials,

NP sizes, ligands, conjugation techniques, antigens, and targeted tissues. Actively
targeted NPs have also shown promising results in in vitro and in vivo studies for
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improving the selectivity and specificity of accumulation and drug efficacy in targeted
tissues compared with those of passive targeting NPs. Some actively targeted NPs have
also been found to increase permeation across biological barriers such as the BBB and
intestinal barrier. Active targeting is crucial for NP delivery to diseases that do not show
an EPR effect. However, despite the growing interest and the prospect of actively
targeted NPs in the biomedical field, as well as numerous clinical trials, there is currently
no approved actively targeted NP used clinically. The diversity in the surface marker
expressed by targeted tissue between individuals, complicated synthesis of actively
targeted NPs, and difficulty in upscaling production hinder the translation of actively
targeted NPs into widespread clinical use. On the other hand, the exponential
improvement in technologies, such as better diagnostic tools for preselection of patients
who would respond to the therapies, might be helpful in pushing actively targeted NPs
into the market in the future.

157

CHAPTER 8: CLAUDIN-1-TARGETED NANOPARTICLES FOR
SITE-SPECIFIC DELIVERY TO AGING-INDUCED
ALTERATIONS IN THE BLOOD-BRAIN BARRIER
The work presented in this chapter has been previously published and is reprinted with
permission from ACS Nano, 15, Bony, B.A., Tarudji, A.W., Miller, H.A., Gowrikumar,
S., Curtis, E.T., Gee, C.C., Vecchio, A., Dhawan, P., and Kievit, F.M., Claudin-1targeted nanoparticles for site-specific delivery to aging-induced alterations in the bloodbrain barrier, 2021, p.18520–18531, Copyright © 2021, American Chemical Society. doi:
https://doi.org/10.1021/acsnano.1c08432 [270]

8.1

Abstract
Aging-induced alterations to the blood–brain barrier (BBB) are increasingly being

seen as a primary event in chronic progressive neurological disorders that lead to
cognitive decline. With the goal of increasing delivery into the brain in hopes of
effectively treating these diseases, a large focus has been placed on developing BBB
permeable materials. However, these strategies have suffered from a lack of specificity
toward regions of disease progression. Here, we report on the development of a
nanoparticle (C1C2-NP) that targets regions of increased claudin-1 expression that
reduces BBB integrity. Using dynamic contrast enhanced magnetic resonance imaging,
we find that C1C2-NP accumulation and retention is significantly increased in brains
from 12 month-old mice as compared to nontargeted NPs and brains from 2 month-old
mice. Furthermore, we find C1C2-NP accumulation in brain endothelial cells with high
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claudin-1 expression, suggesting target-specific binding of the NPs, which was validated
through fluorescence imaging, in vitro testing, and biophysical analyses. Our results
further suggest a role of claudin-1 in reducing BBB integrity during aging and show
altered expression of claudin-1 can be actively targeted with NPs. These findings could
help develop strategies for longitudinal monitoring of tight junction protein expression
changes during aging as well as be used as a delivery strategy for site-specific delivery of
therapeutics at these early stages of disease development.

8.2

Introductions
The blood–brain barrier (BBB) plays a crucial role in the central nervous system

(CNS) by creating a barrier between the neural tissue and the blood to prevent
contamination from foreign substances. Aging is linked with decreased BBB integrity as
well as functional impairment of transporters and can aggravate BBB responses to any
CNS injury and systemic inflammatory stimuli [508, 509] across multiple different brain
regions including the cortex [510], hippocampus [510, 511], and corpus callosum [512].
This is a result of age-induced alterations in gene expression, mitochondrial dysfunction,
or abnormal protein accumulation in the CNS [513, 514]. Moreover, these alterations
have been implicated in promoting neurodegeneration, declined cognitive function,
reduced cerebral blood flow, and vasculopathies [515-517]; thus, BBB disruption can
initiate during normal aging and lead to mild cognitive impairment and progression to
Alzheimer’s Disease and other dementias [511, 518]. In fact, BBB breakdown has
recently been proposed as an early biomarker of neurocognitive decline.
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The function of the BBB is controlled through a complex and not completely
understood interaction with the neurovascular unit (NVU), but BBB function relies on
adequate assembly of tight junction (TJ) proteins on the surface of brain endothelial cells.
[519]. These transmembrane proteins play a vital role in the formation and maintenance
of TJ function [519-522]. Among TJ transmembrane protein members, claudin-5 and
occludin constitute TJs at the BBB [520]. Claudins and occludin have four membranespanning helices and two extracellular segments that facilitate interactions between other
TJ proteins to ultimately form TJ barriers [521, 522]. TJ protein expression is altered
during aging and leads to the observed age-related leakiness of the BBB [523-525].
Indeed, claudin-5 expression decreases during aging and disease [526]. In addition to
claudin-5, brain endothelial cell surface expression of claudin-1 has been found to
increase in response to injury, resulting in increased leakiness of the BBB [527].
Furthermore, claudin-1 is transcriptionally regulated by Sirt1 [528], where age-associated
reductions in expression are observed [529], which would be expected to increase
expression of claudin-1, and may play a causative role in BBB hyperpermeability in
aging and disease [530-532]. In addition, inflammatory stimuli such as those observed
during normal aging [533, 534], have been shown to increase expression of claudin-1 in
astrocytes, which play a major protective role in the BBB [535]. This increased
presentation of claudin-1 may impair claudin-5′s BBB function through disruption to
claudin-5 interactions with other TJ proteins. Therefore, claudin-1 represents a strong cell
surface receptor candidate for specific targeting of the early stages of BBB breakdown
prior to neurocognitive decline.
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Nanoparticles (NPs) offer the advantage of multifunctionality, whereby they can
be engineered to display a targeting agent on their surface to promote binding to specific
cells, provide contrast in various imaging modalities, and carry a therapeutic payload to
increase target engagement. There has been significant effort placed on developing NPs
that can cross the BBB to improve brain delivery for various neurological disorders [536538]. Strategies typically involve passive strategies that rely on increased leakiness of the
BBB such as with a brain tumor [539] or following trauma [5, 131, 132, 181, 203, 218,
365, 480, 540, 541], or through active strategies with the so-called “trojan horse” method
that exploits transporters expressed on brain endothelial cells to hijack the native
transport mechanism into the brain [357, 542-545]. These include targets such as the
transferrin transporters, amino acid transporters, glucose transporters, etc. However, this
strategy suffers from the lack of specificity to target diseased brain regions, as these
transporters are typically ubiquitously expressed. Furthermore, the transporters can
become downregulated during the disease process, thus reducing uptake in regions where
delivery is desired. Therefore, our goal has been to identify brain endothelial cell targets
that become overexpressed on the luminal side of the BBB to provide active targeting at
the earliest stages of the disease process specifically where these alterations in the brain
are occurring.
Here, we report our development of a claudin-1 targeted NP that directly binds
purified claudin-1 and has the ability to accumulate and be retained in regions of the
brain vasculature with aging-induced increases in claudin-1 expression. We utilize a Gd
NP core that provides contrast in magnetic resonance imaging (MRI) to observe NP
accumulation and retention in the brain as well as fluorophore modification for
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fluorescence imaging of NP binding to regions of high claudin-1 expression. We find that
12 month-old mice (corresponding to middle age in humans) have a higher claudin-1
expression in brain endothelial cells than their 2 month-old (corresponding to
adolescence in humans) counterparts and that this higher claudin-1 expression correlates
with higher NP accumulation and retention as measured by MRI.

8.3
8.3.1

Methods
Materials
Gadolinium chloride hydrate (GdCl3·xH2O, 99.9%), europium(III) nitrate

hydrate (Eu(NO3)3·5H2O, 99.9%), triethylene glycol (TEG, 99%), sodium hydroxide
(NaOH), poly(ethylene glycol) diacid (Mn, 600), ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (EDC, ≥98%), and N-hydroxysuccinimide (NHS, 98%),
molecular weight cutoff dialysis membranes (Flot-A-Lyzer, 20 kDa) were purchased
from Sigma-Aldrich. Alexa Fluor 647 cadaverine (AF647, Mn, ∼1000) was purchased
from Thermo Fisher Scientific. Cldn1–146, [546], cldn1-53 [546], occludin-207 [547]
and C1C2 [527] were purchased from Genscript Corporation, and they are all amidated at
the C-terminal and acetylated at the N-terminal. Deionized water in the experiments was
obtained by using a Millipore water purification system. All other chemicals and solvents
used in this work were high-performance liquid chromatography (HPLC) grade.

8.3.2

Synthesis of Gd NPs
One mmol of GdCl3·xH2O was added into 30 mL of triethylene glycol contained

in a 100 mL three-necked flask. The mixture was heated to 80 °C and magnetically
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stirred until the precursors were completely dissolved in the solvent. Then, 3 mmol
NaOH was added and continued stirring for 4 h at 180 °C. To coat the hydrophobic NPs,
2 mmol PEG-diacid was added, and the reaction was continued with stirring for 12 h at
150 °C. After completely cooling, the synthesized NPs were washed 3 times using
deionized water.

8.3.3

Conjugation of NPs
To conjugate NPs to the peptide, 1 mL of 0.1 mg/mL NPs was taken in 0.9 mL

PBS. To the NPs, 4 mg of EDC and 2 mg of NHS were added in a stepwise fashion with
continuous stirring. Peptide (0.1 mg/mL) was then added and continuously stirred for 2 h.
A float-a-lyzer dialysis kit was used to remove unconjugated peptides. The whole
experiment was conducted in the dark.
To make the NPs fluorescent for microscale thermophoresis measurements,
AF647 was attached to the Gd NPs using the EDC-NHS coupling reaction. Briefly, 0.1
mL of 1 mg/mL Gd NPs was taken into 0.9 mL PBS. Then 2 mg of EDC and 1 mg of
NHS were added in a stepwise fashion with continuous stirring. Alexa Fluor 647 (0.1
mg/mL) was then added, and the mixture was continuously stirred for 2 h. Unconjugated
fluorophore was removed with a Float-a-lyzer dialysis kit. The whole experiment was
conducted in the dark.

8.3.4

Characterization
A high-voltage transmission electron microscope (TEM) (Tecnai Osiris TM, 200

kV) was used to measure particle diameters of PEG diacid-coated Gd NPs. A copper grid
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(PELCO mesh size 400, TED PELLA, INC.) covered with an amorphous carbon
membrane was placed onto a filter paper. Then, a sample solution diluted in triply
distilled water was dropped over the copper grid by using a micropipette (Eppendorf, 2–
20 μL). Dynamic light scattering (DLS) studies of the NPs were conducted using a
Malvern Instruments Zetasizer Nano series instrument. Solutions of the NPs were
prepared in DPBS (pH 7.4) at a concentration of 0.05 mM. The resulting solutions were
filtered with 0.22 μm filters before the measurement. The NP concentration was
determined by using an inductively coupled plasma mass spectrometer (Agilent 7500 cx).
To determine this, ∼0.5 mL of the NP solution was taken out and treated with HNO3 to
dissolve NPs in the solution completely. A Fourier transform-infrared (FT-IR) (Nicolet
AVATAR 380 FT-IR) was used to verify the surface coating. To record the FT-IR
absorption spectrum (400–4000 cm–1), the powder sample was prepared. Peptide
attachment to NPs was confirmed using BCA assay. Attaching efficiency was confirmed
using the equation: conjugation efficiency of peptide (%) = amount of peptide in
NPs/initial amount of peptide × 100.
To calculate the number of peptides per NP, we determined the ratio of molarities
of peptides to NP cores. Molarity of the peptides was determined from the conjugation
efficiency and molecular weight of the peptides (cldn146, cldn53, ocldn207, and C1C2
are 1897.06, 3027.4, 1978.22, and 2891.12 g/mol, respectively). To calculate the molarity
of the NP, we calculated the mass of a NP, where m = ρ × V, where ρ is the density of the
NP (7.4 g/cm3 for Gd oxide) and V is the calculated volume of the NP (V = 4/3πr3,
where r is the radius of the NP). The number of NP in colloidal solution is N = C/m,
where C is the concentration of metal in NP solution (0.08 mg/mL) measured by ICP-MS
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and m is the mass of a NP calculated above. The molarity of NP is MNP = N/V × 1/NA,
where N is the number of particles calculated before, V is the volume of NP solution,
and NA is Avogadro’s number.

8.3.5

R1 and R2 Relaxivity and R1 and R2 Map Image Measurements
Both R1 and R2 map images, as well as both T1 and T2 relaxation times, were

measured by using a 9.4 T MRI instrument (Varian 9.4 T) equipped with a 4 cm
Millipede RF imaging probe with triple-axis gradients (100 G/cm max). A series of five
aqueous solutions of different concentrations (1.0, 0.5, 0.25, 0.125, 0.0625, and 0.03125
mM Gd) were prepared by diluting each MRI solution with PBS. Then, both map images
and relaxation times were measured by using these solutions. The R1 and R2 relaxivities
were then estimated from the slopes in the plots of 1/T1 and 1/T2 versus NPs
concentration, respectively. The measurement parameters for the fast spin–echo T1
mapping sequence were as follows: the external MR field (H) = 9.4 T, the temperature =
22 °C, the number of acquisition (NEX) = 1, the field of view (FOV) = 25 × 25 mm2, the
matrix size = 128 × 128 voxels, echo train length = 16, echo spacing = 8.1 ms, slice
thickness = 2 mm, seven different repetition times (TRs) were used in linear increments
from 200 to 2000 ms, and the echo time (TE) = 32.42 ms. Signal was fit to the following
equation using MATLAB to find T1:
𝑇𝑅

𝑆 = 𝑆0 (1 − 𝑒 − 𝑇1 )
where S is the signal for a given voxel, and S0 is the signal of that voxel at
saturation. T2 mapping was carried out using a multiecho scan with the same parameters
as the T1 scan with the following exceptions: the number of echoes = 10, 10 TEs linearly
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spaced from 10 to 100 ms, and TR = 3000 ms. T2 mapping was performed using Osirix
and linear fitting followed in MATLAB.

8.3.6

Animals
Both male and female 2 month-old C57BL/6J mice (Jackson Laboratory, Bar

Harbor, ME) and 12 month-old C57BL/6J and CX3CR1-GFP (Jackson Laboratory, Bar
Harbor, ME) from a C57BL/6J background mice were used. Mice were housed in a 12
h/12 h day/night cycle with ad libitum access to standard mouse chow and water. All
animal work was approved by and performed under the guidance of the University of
Nebraska-Lincoln IACUC. The animal experiments were run in two separate experiments
using two independent preparations of C1C2-NPs. An initial experiment with n = 3–4
mice in each group (control, Cldn146, Cldn53, Ocldn, and C1C2 all in 12 month-old
mice) was followed by a second experiment with n = 4–5 mice in each group (C1C2 in
12 month-old mice and 2 month-old mice) to verify our results.

8.3.7

Ktrans MRI
In vivo NP assessment consisted of dynamic contrast-enhanced (DCE)-MRI using

a 9.4T MRI system (Varian) to compare the targeting agent effect on the uptake as
previously described [540]. Briefly, mice were induced with about 2% isoflurane gas and
maintained at a concentration sufficient to achieve 50 to 80 breaths per minute. Baseline
T1 maps were generated using a gradient-echo sequence and the variable flip angle
method with two angles, 10° and 30° [271]. Mice were injected with 100 μL of a 0.5 mM
NP solution via tail vein catheter followed by 100 μL PBS to flush all remaining NP

166
solution. A flip angle of 30° was used for all postcontrast scans, which occurred for 1 h
following injection. TR was between 54 and 84 ms, TE between 2.73 and 4.24 ms, matrix
size between 128 × 128 and 256 × 256, and FOV between 20 × 20 × 10 mm3 and 25 × 25
× 10 mm3 depending on the experiment. NEX varied with matrix size to maintain
temporal resolution, with 128 × 128, NEX = 5 for all scans, with 256 × 256, NEX = 4 for
baseline and 1 for postcontrast scans.
Following serial image acquisition, resulting in about 100 postcontrast scans per
animal, R1, concentration, and Ktrans mapping were performed using custom MATLAB
script. R1 mapping was performed using the variable flip angle method based on the
following equation [272]:
𝑆𝑆𝑃𝐺𝑅
𝑆𝑆𝑃𝐺𝑅
=
𝐸1 + M0 (1 − 𝐸1)
𝑠𝑖𝑛 (α) 𝑡𝑎𝑛 (α)
where SSPGR is signal intensity, α is FA, E1 is exp(TR/T1), and M0 is a
proportionality factor related to longitudinal magnetization. E1 describes the linear
relationship between the two signal intensity ratios, taking the slope, m, of that line
enables calculation of T1 as:
𝑇1 =

−𝑇𝑅
𝑙𝑛(𝑚)

Concentration maps were then generated by comparison of baseline R1 maps with
post-contrast R1 maps using the following equation:
𝐶(𝑡) =

𝑅1(t)– R1(t 0 )
r1

where C(t) is the concentration at time t, R1(t) is the post contrast R1-value at t,
R1(t0) is baseline R1, and r1 is relaxivity of the contrast agent. Ktrans, the contrast
extravasation rate constant, mapping was then performed using the Patlak model:
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𝐶(𝑡) = 𝑣𝑝 𝐶𝑎 (𝑡) + 𝐾𝑡𝑟𝑎𝑛𝑠 ⨂ 𝐶𝑎 (𝑡)
where C is the tissue concentration, Ca is the arterial plasma concentration, vp is
the plasma volume fraction, and ⨂ is convolution. The Patlak model was chosen based
on its previous use to assess subtle changes in BBB permeability associated with aging
[548, 549]. MATLAB was used to execute a least squares curve fitting routine to
calculate Ktrans for each voxel in the brain.

8.3.8

Microscale thermophoresis (MST)
Human claudin-1 was expressed and purified as reported previously [550]. MST

measurements were performed using a Monolith instrument (NanoTemper
Technologies). For experiments with human claudin-1, the assay buffer contained 10 mM
Tris HCl, pH 8.0, 100 mM NaCl, 4% glycerol, and 0.04% n-dodecyl-β-Dmaltopyranoside (β-DDM). NPs and peptides were labeled with AF647 prior to MST
analysis as described above. For the binding experiments, the concentration of human
claudin-1 was varied from 0.2 to 74000 nM, and the AF647 labeled C1C2-NP was fixed
at 70 nM, while the AF647 labeled NPs and AF647 labeled C1C2 peptide were fixed at 1
μM and 0.3 μM, respectively. Binding of the AF647 labeled C1C2-NP to human claudin3, -4, and -9 were tested using 0.4–14000 nM, 0.8–28000 nM, and 0.6–20000 nM,
respectively, with the AF647 labeled C1C2-NP fixed at 70 nM. This assay buffer was
similar, except β-DDM was replaced with 0.1% n-undecyl-β-D-maltopyranoside. In order
to check nonspecific binding of β-DDM micelle to the AF647 labeled C1C2-NP, the
concentration of ß-DDM was varied from 0.97 mM to 0.2 μM and the concentration of
the AF647-labeled C1C2-NP was fixed at 1 μM. A similar experiment was performed
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wherein the concentration of UDM was varied from 10 mM to 0.7 μM and the
concentration of AF647-labeled control NP was fixed at 1 μM. The nonspecific binding
of human claudins -4 and -9 to the NP was examined by varying the concentrations of
human claudins -4 and -9 from 0.1 nM to 20.1 μM and 0.09 nM to 31.1 μM, respectively.
The human claudin subdilutions were mixed with the NPs or peptides and loaded in
standard monolith NT.115 capillary tubes for measurement. All experiments were
conducted at 23 °C using the nanored channel of the Monolith instrument, and the data
were analyzed by using either Monolith analysis software or Graph Pad Prism, version 9
(Graph Pad Software, San Diego, California).

8.3.9

In-vitro analysis over C1C2-NP binding towards Claudin-1
bEnd.3 cells were cultured according to the ATCC culture conditions in DMEM.

These cells were subjected to ethanol (50mM) treatment to induce claudin-1 expression
and incubated with C1C2-NP for 4 hrs. For determining attachment of the C1C2-NP to
human claudin-1, human claudin-1 encoded PCMV script plasmid was overexpressed in
bEnd.3 cells and then incubated with C1C2-NP for 4 hrs.

8.3.10 Fluorescence imaging
A fluorescence microscope (LSM800, Zeiss) was used to take the fluorescence
image of mice brain. Mice were transcardially perfused after 2 h of MRI with 4%
paraformaldehyde (PFA) in Dulbecco’s phosphate-buffered saline (DPBS, Thermo Fisher
Scientific, Waltham, MA). We did not perform a PBS perfusion prior to PFA because of
the likelihood of washing out materials weakly bound to the vasculature or within the
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leaky BBB. While this experimental design does increase the chance of a false positive
caused by NP uptake by peripheral macrophages that become fixed in circulation in the
brain, the timeline for our imaging session and subsequent brain collection (∼2 h
postinjection) is much shorter than the timeline for this peripheral macrophage uptake
and trafficking to occur (e.g., it takes 24–48 h following a traumatic brain injury for the
first circulating immune cells to arrive) [551-553]. Brain tissue was collected, trimmed,
and fixed in 4% buffered PFA for 24 h. The brains were moved into 30% sucrose in
DPBS for 3 d at 4 °C for cryoprotection. The brains were then embedded in 2.6%
carboxymethylcellulose (CMC, C4888, Sigma-Aldrich, St. Louis, MO), frozen on dry
ice, and sliced coronally at a 15 μm thickness with cryotome (Leica Biosystems, Wetzlar,
Germany). The brain slices were laid on poly-l-lysine-coated microscope slides
(6776215, Epredia, Kalamazoo, MI) and dried overnight at RT. Sections were washed
with DPBS three times for 5 min each to remove the CMC. The brain slices were blocked
with 3% normal donkey serum, 0.3% triton X-100, and 0.1% sodium azide in DPBS for 1
h at RT. The primary and secondary antibody (Ab) were diluted in the blocking buffer.
The brain sections were incubated with 1:250 dilution of rat anti-CD31 (ab56299,
Abcam, Cambridge, UK) and 1:100 dilution of rabbit anticlaudin-1 (51-9000, Invitrogen,
Carlsbad, CA) overnight at 4 °C and then washed three times for 5 min each with
blocking buffer before the sections were incubated with a 1:250 dilution of an AF488
labeled goat antirat secondary Ab (ab150157, Abcam) and AF555 labeled donkey
antirabbit secondary Ab (ab150074, Abcam) for 2 h at RT. The brain sections were again
washed three times for 5 min each with the blocking buffer before being stained with
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DAPI for 5 min, washed with DPBS followed by water, and mounted with ProLong Gold
Antifade Mountant (Thermo Fisher Scientific).
Images were acquired with confocal microscopy at 40x objective lens
magnification. Quantitative image analysis of claudin-1 and CD31 colocalization was
performed with JACoP and ImageJ software on at least three randomly selected viewing
fields for each region for each mouse.

8.3.11 Western blot
Mice were transcardially perfused with ice-cold DPBS. The brains were extracted, and the
cortex and hippocampus were separated. Cortex and hippocampus were then lyzed in RIPA
lysis buffer and 1 mM phenylmethylsulfonyl fluoride. Protein concentration was measured
using Pierce BCA protein assay (Thermo Fisher Scientific). Thirty μg of extract protein
was resolved by 12% SDS-PAGE and transferred onto PVDF membranes (Bio-Rad).
Membranes were washed with TBS and were incubated with 3% QuickBlocker (GBiosciences, St. Louis, MO) in TBS for 1 h RT. The membranes were incubated overnight
at 4 °C with 1:500 dilution of rabbit anticlaudin-1 (51-9000, Invitrogen), 1:500 dilution of
mouse anticlaudin-5 (35–2500, Invitrogen), or 1:1000 dilution of mouse anti-β-actin
(A5441, Sigma) antibody in TTBS containing 3% QuickBlocker. Membranes were washed
with TTBS before being incubated for 1 h at room temperature with 1:3000 dilution of
HRP-conjugated goat antirabbit or antimouse secondary antibody (Bio-Rad) in TTBS
containing 3% QuickBlocker. Membranes were then washed three times with TTBS and
antibody binding visualized by chemiluminescence (Clarity Western ECL Substrate, Bio-
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Rad) and quantified using the ChemiDoc system running the Image Lab software package
(Bio-Rad).

8.3.12 Biodistribution
Mice were transcardially perfused with ice-cold DPBS 1 h following injection of
control or C1C2 conjugated NPs (100 μL of 0.5 mM NPs) and heart, lungs, liver,
kidneys, spleen, colon, and intestines were collected and weighed. Three 2 month-old and
three 12 month-old mice were used for this experiment. Gd concentrations were
determined by digesting tissues with 600 μL of HNO3 at 100 °C for 120 min prior to
filtering and dilution for measurement using inductively coupled plasma mass
spectrometry (ICP-MS).

8.3.13 Statistical analysis
All the data in this study were expressed as mean ± standard error of the mean
(SEM). A p < 0.05 was considered statistically significant. Data fitting for MST
measurements were performed with GraphPad Prism 9.

8.4
8.4.1

Results
Nanoparticle synthesis and characterization
BBB dysfunction has been shown with aging and age-related neurodegenerative

conditions such as Alzheimer’s disease [511]. This BBB dysfunction represents a
possible target for site specific delivery using multifunctional NPs. Here, we utilized
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ultrasmall 3.5 nm Gd NPs labeled with AF647 to provide multimodal imaging through
MRI and fluorescence. PEG diacid was used to coat the synthesized NPs. The addition of
PEG to NP surfaces can reduce clearance by the reticuloendothelial system (RES) and
increase circulation time [554-556]. Not only can the PEG coating prevent aggregation,
but it can also increase solubility in serum because of repeating the hydrophilic ethylene
glycol units [557, 558]. The high-resolution TEM images of PEG diacid coated Gd NP
cores revealed the average NP diameter is around 3.5 nm verifying their ultrasmall size
(Figure 8-1A). From DLS measurements, the average hydrodynamic size of the
nanoparticle was 10.5 nm (Figure 8-1B), and the ζ potential was -16.1 mV (Figure 8-1C).
The PEG diacid coating was confirmed using FTIR. We compared PEG diacid-coated Gd
NPs with free PEG diacid and observed that the C═O stretch was red-shifted by ∼ 165
cm–1 from that (= 1740 cm–1) of a free PEG diacid (Figure 8-1D), confirming the
attachment of −COOH group to the NPs as commonly observed in metal oxide NPs
coated with −COOH group containing ligands [559, 560].
To determine the MRI enhancing properties of the NPs, both R1 and R2 were
measured at 9.4 T and plotted as a function of Gd concentration. Longitudinal (r1) water
proton relaxivities were estimated from the corresponding slopes, giving a value of 4.05
s–1 mM–1, and transverse (r2) water proton relaxivities were estimated from the
corresponding slopes, giving a value of 3.35 s–1 mM–1 for PEG-Gd NPs. T1 and T2 map
images (Figure 8-1E and 1F) show apparent dose-dependent contrast enhancement.
Peptides were conjugated to PEG on the surface of the NPs through EDC-NHS chemistry.
Peptide density on the surface of the NP was between 15 and 19 peptides per NP (
Table 8-1) depending on the peptides, indicating similar peptide densities of around 2.02, 2.14,
2.56, and 2.02 nm2/ peptide, respectively. The hydrodynamic sizes and ζ potentials of all peptide
conjugated NPs were similar (
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Table 8-1), reducing the chances of confounding cell binding and uptake effects
caused by different physicochemical properties of the NPs [561-563].

Figure 8-1. NP characterizations. (A) HRTEM images of the PEG diacid-coated ultrasmall Gd
NPs. The corresponding circle shows the diameter of the NP, which is 3.5 nm. (B) From DLS, the
average size of the NP is 10.5 nm. (C) The ζ potential value is −16.1 mV for Gd NPs. (D) FT-IR
absorption spectra of (I) free PEG diacid (red line), (II) PEG diacid-coated ultrasmall Gd NPs
(black line). (E) R1 relaxivity and T1 map images and (F) R2 and T2 map images of Gd NPs.

Table 8-1. Properties of NPs and peptides

Zeta

Name

Hydrodynamic

No. of peptides Potential

size (nm)

Per NP

Sequence of peptides
(mV)
(with NPs)

Cldn146QEFYDPLTPINARYE
NP

13.94±0.08

19

1.62±0.13

174
Cldn53-

SCVSQSTGQIQCKVF

NP

DSLLNLNSTLQAT

13.8±0.11

18

2.24±0.18

14.23±0.11

15

3.65±0.19

14.5±0.13

19

7.81±0.38

Ocldn207- GSQIYMICNQFYTPG
NP

GTG

C1C2-NP

SSVSQSTGQIQSKVD
SLLNLNSTQATR

8.4.2

MRI assessment of brain accumulation and retention
BBB permeability is typically investigated utilizing small-molecule Gd-based

contrast agents for dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
We have recently extended the use of this DCE-MRI method for use with contrastenhancing NPs to compare the permeabilities of different NPs [218].DCE-MRI
represents a robust method for assessing NP accumulation and retention in the brain as
compared to more static, noninvasive methods such as concentration mapping or
fluorescence imaging at single time points, which cannot distinguish between NP in the
blood or that which has been transferred to the tissue compartment. While DCE-MRI has
typically been used to measure permeability of tissues, we have recently reported a
method for comparing the permeabilities of NPs within a tissue using MRI to identify the
permeability coefficient Ktrans [218, 540]. The spatial resolution of this method does not
enable direct observation of NP escaping from the vasculature into the parenchyma, but
the observation of accumulation over time in a region may suggest this extravasation is
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occurring. NPs may, alternatively, be retained on the luminal side of the BBB, but in that
case, their accumulation may suggest engagement with cellular receptors such that local
concentrations at the BBB are higher than those in the general circulation. The effect of
peptide targeting on NP accumulation and retention in the brains of 12 month-old mice
was assessed in brain regions known to be affected by BBB breakdown during aging (i.e.,
corpus callosum [512], hippocampus [511], hypothalamus [564], cortex [565, 566]) and
in regions thought to be minimally affected by aging (i.e., muscle). In the corpus
callosum (Figure 8-2), NPs targeted with the C1C2 peptide against claudin-1 (C1C2-NPs)
showed a significant increase in Ktrans in 12 month-old mice as compared to other peptide
modified and control NPs as well as compared to 2 month-old mice suggesting
preferential binding to upregulated surface claudin-1 induced by aging. Similarly in the
hippocampus (Figure 8-3), C1C2-NPs had a trending increase in Ktrans that was not
significant because of high variability of Ktrans values in these 12-month old mice that
could be a result of differential claudin-1 expression between mice. A summary of Ktrans
results for each brain region is shown in Table 8-2. In the corpus callosum of 12 monthold mice, the mean Ktrans value for control NPs was 0.0017 min-1, similar to that observed
in 12–16 month old mice using Magnevist as the contrast agent [512]. The mean Ktrans
value for C1C2-NPs was significantly greater at 0.0058 min-1, suggesting active binding
to increased claudin-1 expression. In the hippocampus of 12 month-old mice, the mean
Ktrans value for control NPs was 0.0018 min-1, similar to a Ktrans of ~0.001 min-1 observed
for middle aged humans of around 40 years of age using MultiHance as the contrast agent
[511]. For C1C2-NPs, a Ktrans value of 0.0040 min-1 was observed in the hippocampus.
The highest Ktrans value in the cortex and hypothalamus of 2 month old or/and 12 month
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old mice was 0.0148 min-1 and 0.0102 min-1 for C1C2-NPs. On the other hand, the
highest Ktrans value in the muscle was observed for control mice as 0.0079 min-1.

Figure 8-2. NP accumulation in the corpus callosum. (A) Ktrans maps showing NPs uptake in
corpus callosum, (B) Mean Ktrans values of different peptide conjugated NPs in corpus callosum.
Data are presented as an average of mice (3-8 mice) experiments with standard deviations,
*p < 0.05. Significance as compared to all other treatments was determined using two-way
ANOVA with Dunnett’s post-hoc test.

Figure 8-3. NP accumulation in the hippocampus. (A) Ktrans maps showing NPs uptake in
hippocampus, (B) Mean Ktrans values of different peptide conjugated NPs in hippocampus. Data
are presented as an average of mice (3-8 mice) experiments. Significance as compared to all other
treatments was determined using two-way ANOVA with Dunnett’s post-hoc test.

Table 8-2. Brain region specific accumulation and retention of NPs targeted with various peptides
as measured using the permeability coefficient, Ktrans (min-1), with MRI. CC, corpus callosum;
HC, hippocampus; CTX, cortex; HT, hypothalamus.
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NP Type
C1C2NP
Cldn146-

Cldn53-

Ocldn207-

C1C2-

Control

(in 2
NP

NP

NP

NP

(x 10-4)

month
-4

(x 10 )

-4

(x 10 )

-4

(x 10 )

-4

(x 10 )
old)

Brain Region

(x 10-4)
CC

17±14

14±12

22±12

25±14

58±30

19±19

HC

18±12

12±5

18±85

19±14

40±30

19±17

CTX

16±10

3±3

26±9

20±21

148±67

22±15

HT

12±15

8±2

26±13

37±13

102±56

26±17

16±13

9±13

33±7

57±22

28±29

Muscle 79±22

8.4.3

Specific binding and affinity of C1C2-NP to claudin-1
To determine whether C1C2-NPs bind claudin-1 specifically, mouse brain

microvascular endothelial (bEnd.3) cells were exposed to the AF-647 modified NPs in
vitro. Control cells showed no binding to C1C2-NPs as expected, as claudin-1 expression
is low under normal culture (Figure 8-4A–C). We found claudin-1 expression was
induced by exposure to ethanol (the mechanism of which needs further study), and C1C2NPs showed much higher binding to cells, suggesting specific binding to mouse claudin1. To determine if C1C2-NPs could also bind to human claudin-1, bEnd.3 cells were
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transfected to express human claudin-1 and exposed to C1C2-NPs. High NP binding was
observed in this condition, suggesting C1C2-NPs can bind to both human and mouse
claudin-1.
To assess the binding affinity of C1C2-NPs to human claudin-1, we labeled
C1C2-NPs with AF647 and quantified binding to recombinant human claudin-1 using
MST. The dissociation constant (KD) of C1C2-NPs to human claudin-1 was 21 ± 14 µM
(Figure 8-4D). Measuring the binding of empty NPs to human claudin-1, we found
a KD of >300 μM, while for C1C2 peptides alone, no binding to human claudin-1 was
detected. The lack of C1C2 binding to human claudin-1 observed in this assay could be
caused by the conformational freedom of the peptide free in buffer, which could disrupt
specific C1C2-claudin-1 interactions. Anchoring the peptide to the surface of a NP would
reduce the conformational freedom of the peptide and increase specific C1C2-claudin-1
interactions. In addition, the lower KD of C1C2-NPs could be caused by a multivalent
effect where multiple peptides on the surface of a NP are involved in claudin-1
interactions. In order to rule out nonspecific binding of the AF-C1C2-NP to the β-DDM
micelle, the concentration of β-DDM was varied, and the concentration of AF-C1C2-NP
was fixed at 1 μM. No significant binding could be observed within the range of β-DDM
concentration used for the measurement with human claudin 1 (data not shown). The
specificity of the binding of AF647-C1C2-NP was verified by measuring its binding to
the human claudins -3, -4, and -9. Human claudin-3 does not show any binding. While
there is evidence for claudin-1/claudin-3 cis compatibility as determined by
colocalization in vivo using fluorescence microscopy [567], our MST results indicate
C1C2-NP does not bind to claudin-3 in vitro. This difference may be a result of
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weakened interactions in vitro when there is an absence of larger claudin assemblies, or a
result of the only 69% sequential similarity between claudin-1 and claudin-3 within the
C1C2 binding region. The data points for human claudins -4 and -9 could not be fit to the
sigmoidal dose response curve, suggesting that the binding of AF647-C1C2-NP to human
claudins -4 and -9 is quite weak (Figure 8-5A, B). However, both human claudins -4 and
-9 bind to AF647-NP (Figure 8-5C, D), and this does not represent nonspecific binding of
the NPs to the detergent micelles. These data indicate that the presence of C1C2 peptide
makes the NP-peptide conjugate specific for binding to human claudin-1 as well as
mouse claudin-1 from our in vitro experiment.
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Figure 8-4. C1C2-NP specifically binds to both mouse and human Claudin-1. (A–C) In
vitro immunofluorescence of NPs binding claudin-1 in mouse brain endothelial (bEnd.3) cells.
(A) Western blot analysis of claudin-1 in bEnd.3 cells and those induced to express claudin-1
through ethanol exposure or exogenous expression through plasmid transfection. (B)
Quantification of claudin-1 expression relative to β-actin. *** indicates a statistical difference
(p < 0.0001) in claudin-1 expression as compared to control cells. (C) C1C2-NP (magenta)
binding to ethanol induced mouse claudin-1 and exogenously expressed human claudin-1. Scale
bar represents 10 μm. (D) Dissociation constants (KD) for C1C2, C1C2-NP, and NP complex
formation with human claudin-1. Binding curves for the complex formation between human
claudin-1 and C1C2-NP (green), NP (red), and C1C2 peptide (blue) using microscale
thermophoresis. The concentration of human claudin-1 was varied from 74 μM to 0.2 nM in all
three experiments. The concentrations of C1C2-NP, NP, and peptide were fixed at 70 nM, 2 μM,
and 1 μM, respectively. The buffer used for the measurements contained 10 mM Tris HCl, pH
8.0, 100 mM NaCl, 4% glycerol, and 0.04% b-DDM. The experimental data points with human
claudin-1 and C1C2-NP are reported as standard deviations from two independent measurements.
The estimated value of the dissociation constant is 21 ± 14 μM. Human claudin-1 does not show
significant binding to the nontargeted NP, as the dissociation constant is very high >300 μM. The
data with the peptide alone does not fit at all, indicating little binding with free peptide in
solution.
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Figure 8-5. C1C2-NP shows little specific binding to other claudins. (A) Binding of human
claudins 3, 4 and 9 to C1C2-NPs using microscale thermophoresis. (B) Fitting of the data points
in the case of human claudins 3 and 4 resulted in undefined 95% confidence intervals and in the
case of human claudin 9 the data did not fit even after the maximum number of iterations with the
sigmoidal dose response curve. (C) Binding of human claudins 4 and 9 to control NPs monitored
using microscale thermophoresis (D) Fitting of the data points in case of human claudin 4
resulted in undefined 95% confidence intervals, while in the case of human claudin 9 the
estimated binding constant with control NPs is ~3 µM. Data fitting for human claudins 3, 4 and 9
were performed using Graph Pad Prism.

8.4.4

NPs were observed in regions of high claudin-1 expression
As we found higher Ktrans values of NPs in the 12 month-old as compared to the 2

month-old mice, we performed immunofluorescence staining of claudin-1 and CD31 to
observe the coexpression of claudin-1 in brain endothelial cells and the localization of
C1C2-NPs with respect to these regions (Figure 8-6). We found colocalization of
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claudin-1, CD31, and NPs in the 12 month-old mice, but this was not observed in the 2
month-old mice. To support this observation, we quantify the colocalization of CD31 and
claudin-1 using the JACoP extension in ImageJ (Figure 8-7C and D). Mander’s
colocalization coefficient showed a significant increase of CD31 and claudin-1
colocalization in the brains of 12 month-old mice as compared to 2 month-old mice. This
strongly supports the idea that the C1C2-NPs are able to bind to regions of increased
claudin-1 on the aging BBB. Furthermore, ICP-MS analysis of peripheral organs 1 h
post-injection showed increased C1C2-NP accumulation in the kidneys (Figure 8-8),
further supporting the claim of C1C2-NP binding to claudin-1. In addition, claudin-1,
which is expressed on Bowman’s capsule in the kidneys [568], has higher expression
levels during aging [525], and we observed higher C1C2-NP accumulation in kidneys
from 12 month-old mice as compared to 2 month-old mice.

Figure 8-6. Representative images of in vivo C1C2-NP (red) accumulation in the corpus callosum and hippocampus colocalize with the
immunofluorescence staining for claudin-1 (green) and CD31 (purple). Blue DAPI staining indicates nuclei. Scale bar is 20 µm. NP accumulation
can be observed in the 12 month old mice, but not in the 2 month old mice.
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Figure 8-7. Quantification of claudin-1 expression and localization in mice brains. A–B) Western
blot analysis of A) claudin-5 and B) claudin-1 expression normalized to β-actin. There was no
significant difference in claudin-5 and claudin-1 expression between 2- and 12- month-old mice.
C–D) Mander’s overlap coefficient of claudin-1 and CD31 colocalization from confocal
microscopy images. There was a significant increase in claudin-1 and CD31 colocalization in the
brains of 12-month-old mice as compared to 2-month-old mice in corpus callosum (CC), CA2/3,
and dentate gyrus (DG) regions, but not in CA1. Data are presented as an average (3-5 mice) with
standard error of the mean as determined by two-way ANOVA with Sidak’s multiple comparison
test. ** and *** indicate p < 0.01 and 0.001, respectively.
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Figure 8-8. Biodistribution analysis of control and C1C2-NPs in 2-month-old and 12-month-old
mice. Significant differences were only observed in the kidney indicating increased accumulation
of C1C2-NPs in 12-month-old mice as compared to 2-month-old mice and control NPs (p < 0.01
for control NP vs C1C2-NP in 12-month-old mice, 2-month-old mice vs 12-month-old mice
injected with C1C2-NP by one-way ANOVA followed by Tukey's multiple comparisons test)

8.5

Discussion
The significantly higher Ktrans observed in the corpus callosum using C1C2 NPs

compared with the control non-targeted NPs (Figure 8-2) indicates significantly higher
accumulation and retention when claudin-1 is targeted with the C1C2 peptide as
compared to other peptides and peptides against occludin. This result is in accordance
with previous work that found following BBB disruption, occludin and claudin-5 in the
brain endothelium are no longer present and instead move away and colocalize with
astrocytes [569]. There are trending differences in the hippocampus but without
significance (Figure 8-3), but NP accumulation in the hippocampus is observed with
higher claudin-1 expression on brain endothelial cells in 12 month-old mice (Figure 8-6,
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Figure 8-7C and D) which might suggest higher biological variability in claudin-1
expression in the hippocampus as compared to the corpus callosum. Our findings of
limited accumulation in 2 month-old mice support the previous investigation from
Montagne et al. [511] where BBB leakiness is lower in younger adults. The differences
between corpus callosum and hippocampus may be reflective of characteristic differences
between white matter and gray matter regions. Previous work from Montagne et al.
suggests higher permeability in white matter regions of both humans and mice based
on Ktrans quantification with the small-molecule Magnevist and deposits of extravascular
fibrinogen and hemosiderin [511, 512]. Gray matter however has shown an agedependent increase in permeability in humans that was absent in subcortical white matter
tracts [511]. These previous results, however, were based on the nontargeted, smallmolecule Magnevist. The results presented here suggest the importance of claudin-1 in
determining uptake of C1C2 NPs, which may overcome the effects that governed
permeation in the small-molecule case. The high Ktrans values in the cortex and
hypothalamus with C1C2 NPs, which were unremarkable with the control NPs, may be a
result of the claudin-1 interactions facilitated by the targeting peptide, though further
work should be carried out to investigate regional permeability increases based on
peptide targeting.
The presence of increased claudin-1 on the BBB is correlated with reduced BBB
function, although the specific role of claudin-1 in the normal function of the BBB is still
under investigation. The question of whether increased claudin-1 expression in the brain
endothelium is utilized in BBB repair following injury or disease or if increased claudin1 expression itself leads to increased BBB leakiness requires further investigation.
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Claudin-1 may be required for embryonic development of the BBB and replaced by
claudin-5 upon complete maturation of the BBB, as claudin-1 is involved in neural tube
closure in chick embryos [570]. However, Tran et al. found that β-catenin activates the
claudin-1 promoter and that inducible knockout of β-catenin in mice resulted in reduced
claudin-1 expression and increased BBB leakiness even though claudin-5 mRNA levels
were not affected [571], which suggests claudin-1 may have a role in maintaining BBB
integrity. Nevertheless, these results may be affected by other mechanisms by which βcatenin helps maintain BBB integrity, as Leibner et al. showed that claudin-1 expression
is not under control of Wnt/β-catenin signaling [572]. This idea is bolstered by Sladojevic
et al. that found, following injury to the BBB caused by stroke, increased claudin-1
expression correlated with reduced repair and increased leakiness of the BBB and that
decreasing cell surface expression of claudin-1 resulted in improved BBB repair [527].
The detrimental effects of claudin-1 were thought to be caused by claudin-1-zona
occludin and claudin-1-claudin-5 interactions that reduced claudin-5-mediated TJ
integrity. Conversely, Pfeiffer et al. found that increased claudin-1 expression correlated
with improved BBB integrity following autoimmune encephalomyelitis injury [573]. It is
thought that claudin-1 is stored in intracellular microvessels that quickly traffic to the cell
membrane following injury to promote sealing of the BBB. This claudin-1 would then
eventually be replaced by de novo synthesis of claudin-5 to complete regeneration of the
BBB. Combined, this suggests claudin-1 may act as an initial scaffold for subsequent
complete sealing of the TJ by claudin-5 in the formation of the BBB. In aging or disease,
however, chronic cell surface expression of claudin-1 may be an early event in BBB
disruption and chronic progression of BBB dysfunction by chronically inhibiting normal
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claudin-5 interactions that would completely seal the BBB. Indeed, our Western blot and
Mander’s colocalization coefficient results (Figure 8-7) support these previous findings.
We did not observe a difference in the protein levels of claudin-5 and claudin-1 between
2 month-old and 12 month-old mice. We did, however, observe increased claudin-1
colocalization with CD31 in the brains from 12 month-old mice as compared to 2 monthold mice. Claudin-11 also plays a major role in maintaining BBB integrity and is
downregulated in multiple sclerosis [574], yet it is unclear if claudin-1 and claudin-11
directly interact. Our results in 2 month-old and 12 month-old mice (Figure 8-6, Figure
8-7C and D) suggest abnormal claudin-1 cell surface expression at the BBB is an agerelated event that can be actively targeted by NPs both as a tool to study age-related BBB
dysfunction and as a delivery vehicle for site specific delivery of therapeutics.
We showed attachment of C1C2 to NPs could increase accumulation specifically
in brains with increased C1C2 expression in endothelial cells, but also observed
accumulation in other regions of the body where claudin-1 plays a major role as a tight
junction protein (Figure 8-8), which further supports the utility in C1C2-NPs in targeting
claudin-1. However, future studies utilizing C1C2-NPs for therapeutic delivery must take
into account possible effects of delivered therapeutics into these organs, especially those
where claudin-1 expression is increased during aging [525], such as Bowman’s capsule in
the kidney [568], as we observed higher C1C2-NP accumulation in the kidney in 12
month-old as compared to 2 month-old mice (Figure 8-8).
While our current study does not look at the downstream effects of C1C2-NP
binding to the BBB in 12 month-old mice, C1C2 peptide has been shown to promote
resealing of the BBB[527]. C1C2 binds to the first extracellular loop of claudin-1, which
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weakens trans- and cis-claudin-1 interactions and reduces claudin-1/ZO-1 interactions.
Similarly, we showed C1C2-NP actively bind to both mouse and human claudin-1 in
brain endothelial cells induced to express claudin-1 through ethanol exposure or
exogenously express human claudin-1 through plasmid transfection (Figure 8-4).
Furthermore, the multivalent effect of multiple C1C2 peptides on the surface of the
C1C2-NP resulted in a high binding affinity to claudin-1 with a dissociation constant of
21 μM. Previous reports have indicated that the permeability of the tight junctions in
Caco II and MDCK II cell lines can be changed using C1C2 peptide at ∼200 μM [527,
575]. This corresponds to saturating concentrations of the peptide with respect to the KD.
Therefore, both the multivalency effect as well as the anchoring of the C1C2 peptide to
the surface of a solid NP may help increase the binding affinity toward claudin-1.
Therefore, since claudin-1/claudin-5 are considered incompatible [576], reducing
these claudin-1 interactions at the cell surface may allow the more robust claudin-5
interactions to predominate for tighter BBB sealing. NP-bound C1C2 may further
promote claudin-1 internalization from the increased wrapping energy induced by the NP
core [577-579]. This could then lead to increased cytosolic degradation of claudin-1
[575]. Thus, specific delivery into the endothelial cells with abnormal TJ protein
expression would make for an ideal treatment strategy if the NPs were modified to also
deliver a therapeutic that was shown to normalize TJ protein expression. These
conjectures are highly deserving of future study in the role claudin-1 plays in the early
breakdown of the BBB as well the use of C1C2-NP as a tool to study and interact with
the changes. The fate of NP after binding to claudin-1 (e.g., internalized, transcytosed,
surface bound, etc.) will be an important consideration in future utility of our reported
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delivery strategy. Our results strongly support claudin-1-specific binding of the C1C2NPs with higher NP binding in mice with higher claudin-1 colocalizion with brain
endothelial cells (Figure 8-6).

8.6

Conclusions
BBB integrity is central to maintaining brain health, and aging-induced alterations

in TJ protein expression can lead to chronic leakiness of the BBB, which is directly
correlated with cognitive impairment. With the eventual goal of establishing a targeting
method for promoting NP delivery specifically to regions of the brain with altered
function, we developed a claudin-1 targeted NP (C1C2-NP) to target this TJ protein that
appears to be involved in the chronic impairment of BBB integrity. We find that C1C2NP has high accumulation and retention in the brain vasculature of aged mice.
Furthermore, C1C2-NP accumulation and retention are observed in regions of high
claudin-1 expression on the brain endothelium. Overall, our findings support the idea of
increased claudin-1 expression in brain endothelial cells during normal aging and that
these regions of altered expression can be targeted with a NP. Therefore, these C1C2-NPs
offer utility as a tool to monitor alterations in TJ protein expression that may cause BBB
leakiness through noninvasive MR imaging as well as a targeted delivery vehicle to
improve site-specific target engagement of delivered therapeutics.
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CHAPTER 9: DISSERTATION OVERALL DISCUSSION AND
FUTURE DIRECTIONS
9.1

Dissertation Conclusions
In this dissertation, my work focused on assessing the various antioxidant

activities and functional groups of antioxidant NPs, and their effects on secondary injury
biomarkers that are directly affected by excess reactive oxygen species (ROS), such as
ROS and lipid peroxidation products (LPOx), as well as biomarkers that are indirectly
affected by ROS, such as cell death and neuroinflammation.
Chapter 2 reviews the current knowledge of TBI, animal models of TBI, roles of
oxidative stress in TBI, and promising treatments for TBI. We found that BBB disruption
was an important factor in drug delivery for TBI treatment. We also found that
antioxidant treatments showed promising results in the preclinical and clinical trials, but
did not show success in the Phase III trials, which might be due to the lack of target
engagement of small molecule antioxidants in the injured brain.
Chapter 3 reviews the current knowledge of NPs for TBI treatment, some of the
limitations of NPs, and various antioxidant and imaging NPs studied for TBI. We found
accumulation and retention of NPs with sizes of 10-800 nm in the injured brain. The
accumulation of NPs in the injured brain were also found when administered up to 3 d
post-injury. Antioxidant NPs (ANPs) showed reduction in secondary injury biomarkers in
the preclinical studies. Thus, we expected that higher accumulation and retention of NPs
would translate to higher efficacy of ANPs in treating TBI compared to small molecule
antioxidants.
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Chapter 4 introduces the use of a thioether core-cross-linked NP (NP1). We found
that NP1 reduced ROS in the acute phase of injury, which might lead to the reduction in
LPOx in the ipsilateral cortex and hippocampus, as well as neuroinflammation in the
contralateral hippocampus, in the chronic phase of injury with NP1 treatment. We did not
find any adverse effect of NP1 treatment. However, the optimum concentration of NP1
treatment and the accumulation of NP1 with delayed administration were not studied.
Chapter 5 introduces the treatment and therapeutic windows of SOD and catalase
encapsulated PLGA NPs (Pro-NP™). Pro-NP™ reduced oxidative stress markers,
delayed the elevation of LPOx in the brain, and delayed the elevation of necrosis in the
contralateral hemisphere. However, the BSA in Pro-NP™ might have induced
cytoskeletal degradation in male mice and acrolein production in the chronic phase of
injury. The large size of Pro-NP™ may cause significant reduction in the accumulation in
the brain lesion when administered at later time points. Therefore, Pro-NP™ may not be
the ideal treatment for TBI, but Pro-NP™ with targeting ligands and without BSA may
become a more ideal treatment for TBI.
Chapter 6 introduces the treatment and therapeutic windows of thiol copolymer
NPs (NPC3), and the reduction in oxidative stress markers with NPC3 treatment. The
small size of NPC3 and the longer blood circulation half-life with PEG may extend the
treatment window of NPC3 to 3 h post-injury. NPC3 also delayed the elevation of LPOx
in the brain, and necrosis in the contralateral hemisphere. We did not find any adverse
effects of NPC3 treatment. However, NPC3 treatment was more effective in males than
females and did not completely inhibit the progression of secondary injury. Therefore,
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multiple administrations of NPC3 might be needed to significantly reduce the secondary
injury biomarkers in the subacute phase of injury.
Chapter 7 reviews the current use of active targeting NPs for drug delivery and
their limitations. Active targeting NPs could improve accumulation and target specificity
in the desired tissues. Active targeting NPs are usually studied for cancer therapy, and
rarely studied for brain injuries and other neurodegenerative diseases. Therefore, more
studies are needed in the future for improving the accumulation of NPs into the brain
with minimally disrupted BBB.
Chapter 8 introduces a ligand that targets leaky BBB, which commonly occurs in
an aging brain and other neurodegenerative diseases. We found an increase in claudin-1
colocalization on the brain endothelial cells. We also found a higher accumulation of
C1C2-targeting NP in the 12 month old mice compared to non-targeting NP. Thus,
claudin-1 might be a promising target to improve the accumulation of NPs and the
delivery of drugs in neurodegenerative diseases and brain injuries with minimally
disrupted BBB.

9.2

Dissertation Overall Discussion
Overall, the findings in this work suggested that 1) smaller size ANPs were

preferred for TBI treatment since we found similar accumulation in both males and
females, as well as a longer treatment window. Females had a significantly lower
accumulation trend with the large size NPs, such as the 200 nm Pro-NP™, while females
tended to have a higher accumulation of small size NPs, such as the 9 nm NPC3, at 0 and
1 h post-injury. However, we did not find a significant difference in the accumulation of
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9 and 200 nm NPs between males and females at 24 h post-injury, as found in a previous
study [131], which might be caused by the difference in the methods for measuring
accumulation. Unfortunately, in this work, treatment window of polysorbate-80-coated
NP1 was not perform as the accumulation of polysorbate-80-coated NPs into the brain
was higher than the accumulation of PEG-coated NPs when administered immediately
and 2 weeks post-injury [580].In the future, polysorbate 80 coating and targeting ligands
might be needed to extend the accumulation of NPs beyond 3 h post-injury, which is the
current treatment window for small molecule drugs.
2) The highest reduction in oxidative stress was found by thioether core-crosslinked NP treatment, followed by thiol copolymer NP and encapsulated antioxidant
enzymes. Multiple free radicals scavenging activity of thiol groups may increase the
effectiveness in reducing the oxidative stress compared to ROS-only scavenging activity
of thioether bonds, as seen by NPC3 were able to give similar therapeutics effect with
much less ROS scavenging capacity than NP1. The extended period of antioxidant
bioavailability was also not needed in reducing the ROS in the acute phase of injury
when administered immediately following an injury, as burst and sustained release of
antioxidant enzymes from Pro-NP™ did not reduce oxidative stress better than NP1 and
NPC3. However, thiol group NPs showed toxicity on neuronal cell in vitro [204], which
may not be caused by the free radicals scavenging of the thiol group NPs. Thus, toxicity
may limit the administration dose of thiol group NPs. On the other hand, the limiting
dose of Pro-NP™ might be the excess SOD and O2●- scavenging [229, 280-288].
3) Thiol group and antioxidant enzyme treatments reduced carbonyl stress in the
ipsilateral hemisphere in both sexes and delayed the spread of carbonyl stress into the

195
contralateral hemisphere in the acute phase of injury in male CCI mice. The reduction in
carbonyl stress at 1 d post-injury was also seen in other antioxidant treatments for TBI
[229, 285, 287]. At 3 d post-injury, NPC3 showed some reduction in LPOx bilaterally in
the hippocampus of both sexes, but Pro-NP™ only showed some reduction of LPOx in
females. The ability of NPC3 to reduce carbonyl stress in males at 3 d post-injury may
suggest that NPC3 is better than Pro-NP™ in reducing the oxidative stress and the
activation of astrocytes and microglia [97]. This finding is in contrary to the expectation
that some Pro-NP™ are retained in the brain lesion, and releasing some antioxidant
enzymes, at 3 d post-injury [222, 267, 268]. However, carbonyl stress in contralateral
hemisphere and female mice are rarely studied in evaluating antioxidants for TBI
treatments since previous studies did not find a significant increase in carbonyl stress in
the contralateral hemisphere [293, 294, 581]. The difference between our and previous
studies were that we used a more severe CCI on mice than rats. The larger brain size of
rats and the milder CCI employed in the previous studies might inhibit the spread of
LPOx into the contralateral hemisphere.
4) ANPs did not substantial reduce SBDPs, which correlates with cell death, in
the ipsilateral hemisphere in both sexes. In the contralateral hemisphere, NPC3 reduced
necrosis at 1 d post-injury in both sexes, while Pro-NP™ only reduced necrosis in males.
The CCI employed in the study might be too severe that the necrosis in the ipsilateral
hemisphere cannot be prevented by ANP treatments. However, SBDPs in contralateral
hemisphere and female mice are rarely studied in evaluating antioxidants for TBI
treatments since previous studies did not find a significant increase in the elevation of
SBDPs in the contralateral hemisphere [309-312], as well as female mice with weight
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drop injury [341]. The difference between our and previous studies were that we used a
more severe CCI on mice than rats. The larger brain size of rats and the milder CCI might
inhibit the spread of SBDPs into the contralateral hemisphere. Higher activation of
endogenous enzyme activities in female mice might also reduce the SBDPs from a mild
TBI.
5) ANP treatments might also reduce the spread of neuroinflammation into the
contralateral hemisphere starting at 7 d post-injury, as seen in the trending reduction of
acrolein with NPC3 treatment at 7 d post-injury in the contralateral cortex in both sexes.
The reduction in neuroinflammation was observed in the NP1 treated female CCI mice at
1 month post-injury. However, Pro-NP™ treatment may induce inflammation starting at
1 d post-injury in male mice and 7 d post-injury female mice. At 1 d post-injury, the
increase in 150 kDa SBDP in Pro-NP™ treated male CCI mice suggesting an increase in
the intracranial pressure, which may occur in the event of edema, one of the markers of
neuroinflammation. At 3 d post-injury, there was no reduction in acrolein with Pro-NP™
treatment compared to the untreated male CCI mice, as seen with NPC3 treatment. At 7 d
post-injury, there was an increase in acrolein at 7 d post-injury in males and females.
6) In general, the results suggested that ANP treatments were more effective in
males than females in reducing the oxidative stress and the spread of injury in the acute
phase of injury. In addition to ANP treatments in CCI mice, the results suggested that
males were more susceptible to the spread of carbonyl stress and necrosis into the
contralateral hemisphere, although the untreated female mice had a higher oxidative
stress following a severe CCI mouse model of TBI. The ANPs treatment in male mice
seems to mimic the higher endogenous antioxidant enzyme activities in the female CCI
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mice. In the future, employing ANPs with higher dose safety may allow higher dose
administration, which may lead to greater oxidative stress and secondary injury
biomarkers reduction, especially in female mice since female mice might need higher
dose of ANPs to observe improvement in the TBI outcome.
7) We also found that NP1 and NPC3, which were fully oxidized between hours
and minutes, respectively, gave similar reduction in oxidative stress, carbonyl stress, and
cell death, as well as better reduction in neuroinflammation, compared to the Pro-NP™
with greater retention in the brain parenchyma and sustained released of antioxidant
enzymes for more than 24 h post-administration. These findings may help to understand
why small molecule drugs with less retention and target engagement showed success in
the preclinical studies when administered immediately following an injury. However,
unlike small molecule drugs, ANPs can be adjusted with targeting ligands to increase the
target engagement for delayed administrations and less disrupted BBBs.
In conclusion (Table 9-1), the results suggested that smaller size ANPs were
preferred for TBI treatment since we found similar accumulation in both males and
females, as well as a longer administration window. The highest reduction in oxidative
stress was found by thioether core-cross-linked NP treatment, followed by thiol
copolymer NP and encapsulated antioxidant enzymes. However, based on scavenging
capacity, thiol groups ANPs reduce oxidative stress more effectively than thioether bond
ANPs. ANP treatments also reduced carbonyl stress in the ipsilateral hemisphere and
delayed the spread of carbonyl stress and necrosis into the contralateral hemisphere in the
acute phase of injury in male CCI mice. ANP treatments might also have reduced the
spread of neuroinflammation into the contralateral hemisphere starting at 7 d post-injury,
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but not with Pro-NP™ treatment. In general, the results suggested minimal benefit from
longer retention and scavenging activity when antioxidants are administered immediately
following an injury. The results also suggested that ANP treatments were more effective
in males than females in reducing the oxidative stress and the spread of injury in the acute
phase of injury. In addition to ANP treatments in CCI mice, the results suggested that
males were more susceptible to the spread of carbonyl stress and necrosis into the
contralateral hemisphere, although the untreated female mice had higher oxidative stress
following a severe CCI mouse model of TBI. In the future, active targeting ANPs may
improve the accumulation of ANPs into the injured brain for delayed administration of
ANPs.

Table 9-1. Comparing the characterizations and the therapeutics of ANPs in TBI.

Comparison\ANPs

NP1 [112, 203]

Pro-NP™ [267,

NPC3 [204]

268]
Scavenging groups

Thioether bonds

SOD

Thiol groups

Catalase
Scavenging activity

9.93 µmol ROS/mg O2●- + H2O2

0.25 µmol ROS/mg

NP

NP
0.07 µmol
LPOx/mg NP

Scavenging

Within 1.5 hours

More than 4 days

minutes

duration
Size

Within a few

16 nm

~200 nm

9 nm
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Surface modifier

Polysorbate 80

Polyvinyl alcohol

PEG

Clearance half-life

N/A

~2 days [222]

~14 hours [5]

Treatment time-

N/A

Significant

Significant

reduction in

reduction in

accumulation

accumulation

starting at 1 h post-

starting at 3 h post-

injury in both

injury in both

sexes.

sexes.

The trend of

Females tended to

accumulation was

have higher

significantly lower

accumulation early

in females.

on.

56.2% in males

~68% in males

54.56% in females

~58% in females

9,000 U SOD/kg

8 mg/kg

window study

Maximum oxidative

68% in females

stress reduction
Therapeutic dose

4 mg/kg

9,800 U CAT/kg

employed
Carbonyl stress

↓ in the ipsilateral

↓ 4-HNE at 1 d

↓ 4-HNE at 1 d

cortex at 1 month

post-injury

post-injury in the

post-injury

bilaterally in the

ipsilateral cortex of

hippocampus of

both sexes

both sexes

↓ at 1 d post-injury

↓ at 3 d post-injury

bilaterally in the

bilaterally in the
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hippocampus of

hippocampus of

females

males

↑ acrolein

↓ at 3 d post-injury

bilaterally in the

bilaterally in the

cortex and

hippocampus of

hippocampus of

both sexes

both sexes at 7 d
post-injury
Α-II-spectrin

N/A

↑ 150 kDa SBDP in ↓ necrosis at 1 d

breakdown

males at 1, 3, 7 d

post-injury in the

products (SBDPs)

post-injury

contralateral

↓ necrosis in males

hemisphere of both

at 1 d post-injury in sexes and
the ipsilateral

ipsilateral cortex of

cortex,

males

contralateral
cortex, and
contralateral
hippocampus
Neuroinflammation

↓ in the

May ↑ at 7 d post-

May ↓ in the

contralateral

injury

contralateral cortex

hippocampus at 1
month post-injury

at 7 d post-injury
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9.3
9.3.1

Future directions
Animal models of TBI
In this dissertation, the CCI mouse model of TBI was used. However, as

mentioned in Chapter 2, CCI may not be the best representation of TBI in the clinical
situation, since CCI induces a more severe injury compared to most clinical situations [7,
53]. There is no model that can fit every TBI situation, but the CCI mouse model of TBI
is a great model for testing antioxidant NPs therapy because of injury severity,
repeatability, and reproducibility [45]. Moving forward, utilizing other models of TBI
will allow us to test if the NPs are able to accumulate in the brain and give therapeutic
effects in the clinic with various causes of brain injuries.

9.3.2

Correlation between ROS, LPOx, cell death, and behavioral outcome
A reduction in the secondary injury biomarkers may not correlate with

improvement in the behavioral outcome following TBI. However, in this dissertation, I
did not look at the behavioral outcome following TBI with ANPs, which may be a more
important and sought-after outcome in the clinical setting. Therefore, moving forward,
behavioral studies can be an excellent measurement of the outcome of NPs treatments in
TBI, especially when significant reductions in the secondary injury biomarkers with the
NPs are found.
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9.3.3

Treatment window
In one study, around 50% of TBI patients arrived at the hospital longer than 4

hours post-injury, and 30% of TBI patients arrived longer than 12 hours post-injury
[339]. However, as reviewed in Chapter 2, most of the clinical trials showed positive
outcomes when the drugs were administered below 4 hours post-injury for moderate to
severe TBI patients, which might be caused by BBB permeability starting to stabilize at 4
hours post-injury [4]. Therefore, there is a need to increase the treatment window. NPs
are a promising candidate for delivering TBI treatments as NPs can accumulate in the
injured brain up to 72 hours post-injury [131], which may not be achievable with small
molecule drugs. In Chapters 5 and 6, we studied the ANPs accumulation when
administered at various time-points following TBI. In the future, improving the
accumulation and studying the outcomes of ANPs with delayed administration will
accelerate the translation of the ANPs into clinical use.

9.3.4

Active targeting nanoparticles for disrupted BBB
One way to improve the accumulation of ANP is through active targeting, as

reviewed in Chapter 7 and studied in Chapter 8. We looked at the claudin-1 expression in
the severe CCI and mild TBI injury at 3 d post-injury (Figure 9-1). We found that
claudin-1 colocalized with CD31 (i.e., marker of the endothelial cell) in the severe and
mild CCI mouse model of TBI at 3 days post-injury, but not in the control mice. In the
mild TBI, we also observed some colocalization between claudin-1 and CD31, but not as
pronounced as the claudin-1 in the severe CCI. Further study is needed on the
accumulation of C1C2-targeting ANPs with delayed administration following TBI.
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Figure 9-1. Colocalization of claudin-1 and CD31 in the ipsilateral hemisphere of control, severe
CCI, and a mild mouse model of TBI at 3 days post-injury as taken by confocal microscopy. Red
represents claudin-1, green represents CD31, and blue represents DAPI. Yellow represents the
colocalization of claudin-1 and CD31. The scale bar is 50 µm.

9.3.5

Multiple administration of ANPs
Successful accumulation of ANPs in the brain with delayed administration may

also be promising for multiple administration of ANPs. As seen in Chapter 5 and 6,
immediate administration of ANPs following injury reduced LPOx, as well as necrosis in
the contralateral hemisphere, at 1 d post-injury in male mice, but LPOx and necrosis went
up at 3 d post-injury. Therefore, multiple administration of ANPs might be needed to
keep LPOx, as well as necrosis in the contralateral hemisphere, close to baseline at 3 d
post-injury in males and females.

9.3.6

Combination of thioether-thiol group ANP
1 mg of NP1 has 40 times higher ROS scavenging capacity than 1 mg of NPC3.

We found that NP1 reduced oxidative stress more than NPC3. On the other hand, the
thiol group of NPC3 can scavenge ROS and LPOx, compared to the thioether bond of
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NP1 that only scavenge ROS. Therefore, studying the combination of the thioether-thiol
groups in reducing oxidative and carbonyl stress may improve the therapeutics of ANP in
the secondary injury of TBI.
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